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II.   Abstract 
 The work in this dissertation examined the biological characteristics of different HIV-1 
Vpu subtypes, with an emphasis on subtypes B and C, and the potential impact of these proteins 
on SHIV pathogenesis.  Different Vpu subtypes exhibited distinct biological properties that 
potentially could affect HIV-1 pathogenesis and/or transmission efficiency, including 
intracellular localization, efficiency in down-modulating CD4 surface expression, and the ability 
to enhance virion release in HeLa cells.  We show for the first time that the subtype B and C Vpu 
proteins partitioned into detergent resistant membranes (DRMs), a property characteristic of lipid 
raft association.  We also identified two mutants, IVV19-21AAA and W22A, that prevented this 
association.  Additionally, we found a correlation between the ability of Vpu to stably associate 
with DRMs and the ability to enhance virion release in HeLa cells.  Analysis of different Vpu 
proteins from clinical isolates identified a membrane proximal tyrosine motif (YXX ) that is 
highly conserved among all Vpu subtypes and an overlapping dileucine motif ([D/E]xxxL[L/I]) 
that is conserved among subtype C Vpu proteins.  Substitution of the tyrosine residue in the 
YXX  motif with an alanine (Y35A) significantly inhibited SHIV replication while substitution 
of the primary leucine residue with a glycine (L39G) in the overlapping [D/E]xxxL[L/I] motif 
significantly increased the amount of virus released from C8166 cells and the mean number of 
viral particles per cell compared to cells inoculated with the parental SHIVSCVpu.  Recently, the 
enhanced virion release function of Vpu has been attributed to the antagonism of bone marrow 
stromal antigen 2 (BST-2) protein.  This has been shown to involve the transmembrane domains 
(TMD) of both proteins.  Our results indicate that the length of the BST-2 TMD is more 
important than the primary sequence both for the function and sensitivity of the protein.  
Additionally, we showed that the BST-2 protein expressed in pig-tailed macaques is not 
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antagonized by HIV-1 Vpu, but rather by SIV Nef, thus indicating a species-specific basis for 
this antagonism.  Based on these results we continued our analyses by examining the biological 
characteristics of SHIV expressing either a subtype B (SHIVKU-1bMC33) or C (SHIVSCVpu) Vpu 
protein.  SHIVSCVpu caused a more gradual rate of CD4
+
 T cell loss and lower peak viral loads in 
infected pig-tailed macaques compared to macaques inoculated with SHIVKU-1bMC33.   The 
identification of the TMD and the putative sorting signals proximal to the membrane as key 
determinants in Vpu-mediated enhanced virion release prompted the hypothesis that these two 
regions may dictate these differences in pathogenesis.  Therefore, we constructed chimeric Vpu 
proteins in which the N-terminus/TMD regions of the subtype B and C Vpu proteins were 
exchanged (VpuBC and VpuCB).  Inoculation of pig-tailed macaques with SHIVVpuCB resulted 
in a more gradual loss of circulating CD4
+
 T cells compared to SHIVVpuBC-inoculated macaques, 
but more rapid than resulted in macaques inoculated with parental SHIVSCVpu.  Since both of 
these proteins down-modulated CD4 surface expression similar to the unmodified VpuSCEGFP1 
protein, our results indicate that the differences observed in CD4 surface down-modulation in 
vitro are most likely not physiologically relevant.  Finally, as pig-tailed macaques express a 
BST-2 protein that is not affected by the HIV-1 Vpu protein, our results suggest that the 
enhanced virion release function of different Vpu subtypes as observed during an intravenous 
inoculation may be dependent upon a different factor(s).  The work presented here demonstrates 
a clear potential for differential signaling and functional efficiency among all HIV-1 Vpu 
subtypes with the ability to modify pathogenesis.  Additionally, our analyses identified the TMD 
and membrane proximal regions as crucial components to Vpu enhancement of pathogenesis 
providing novel information essential for anti-retroviral therapeutic development. 
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VIII.   Introduction 
Goals of the Study 
 There are 9 different subtypes of HIV-1 Group M viruses responsible for the current 
HIV/AIDS global pandemic.  Epidemiological studies have established a disproportionate global 
distribution of these different subtypes proposing the possibility that these different subtypes 
exhibit distinct virological properties that have evolved in order to promote virus spread among 
diverse populations.  While highly active anti-retroviral therapy (HAART) has provided a 
reprieve in the morbidity and mortality ratios of infected patients, drug resistance and the 
continued spread of these viruses remain a substantial issue.  More studies are needed to 
determine the specific genetic contributions of different HIV-1 subtypes involved in the 
continued propogation of these viruses.  Hence, this study focused on identifying specific 
molecular determinants of the HIV-1 accessory protein, Vpu, involved in the enhancement of 
pathogenesis. 
Human immunodeficiency virus type 1 (HIV-1) and several simian immunodeficiency 
viruses (SIV) encode for a transmembrane protein known as Viral Protein U (Vpu).  While one 
of the smallest of the HIV-1 encoded proteins, it has two important functions within virus-
infected cells.  The first of these functions is the down-regulation of the CD4 receptor to prevent 
its interaction with the HIV-1 envelope glycoprotein.  Vpu interacts with the CD4 receptor in the 
rough endoplasmic reticulum (RER), resulting in its re-translocation across the RER and 
subsequent degradation via the proteasomal pathway.  The second major function of the Vpu 
protein is to facilitate release of virus from infected cells.  Previous studies have shown that virus 
release is cell-type specific, suggesting that certain cells may express a restriction factor that 
inhibits virus release in the absence of Vpu.  The exact mechanism of Vpu-mediated enhanced 
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virion release is still under investigation, however it has recently been attributed to the 
antagonism of a cellular protein known as bone marrow stromal antigen 2 (BST-2) (Neil et al., 
2008; Van Damme et al., 2008). 
 Our laboratory has used chimeric simian-human immunodeficiency viruses (SHIV) 
extensively as a model for analyzing the role of the Vpu protein in viral pathogenesis.  With the 
recent discovery of BST-2 as a restriction factor for HIV-1, we initiated our studies by 
examining the BST-2-mediated restriction of SHIVKU-2MC4 and the ability of the Vpu protein to 
overcome this restriction.  We also analyzed the role of specific amino acids within the 
transmembrane domain (TMD) of BST-2 in establishing Vpu susceptibility by sequentially 
humanizing the TMD of the pig-tailed BST-2, which is normally not sensitive to HIV-1 Vpu.  
Our results show that human and pig-tailed BST-2 (hBST-2 and ptBST-2) restrict SHIV release 
and are susceptible to the encoded Vpu (HIV-1 derived) and Nef (SIV derived) proteins, similar 
to results reported for HIV-1 and SIV, respectively.  These results substantiate our continued use 
of the SHIV/macaque model as a tool for studying the effects of HIV-1 Vpu on pathogenesis.  
We also found that sequential “humanization” of the ptBST-2 TMD resulted in a fluctuation in 
sensitivity to HIV-1 Vpu, suggesting that the topology of the TMD rather than the specific amino 
acid identity is responsible for the interaction with Vpu.  Finally, we show that the length of the 
TMD in human and ptBST-2 proteins is important for BST-2 restriction and susceptibility to 
HIV-1 Vpu.  Based on our previous in vivo studies in which Vpu was clearly demonstrated to 
play a significant role in SHIV pathogenesis in the absence of a BST-2 protein that was sensitive 
to the Vpu protein, these studies suggest that the HIV-1 Vpu TMD may have additional functions 
in vivo unrelated to BST-2 antagonism (Hout et al., 2006b; Hout et al., 2005; McCormick-Davis 
et al., 2000a; Singh et al., 2001; Stephens et al., 2002). 
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 Based on evolutionary results that have identified a variety of genotypic differences 
among HIV-1 subtypes including divergence in the vpu genes, we hypothesized that different 
Vpu proteins exhibit distinct molecular determinants that dictate differential function of Vpu in 
HIV-1 pathogenesis.  Therefore, the second study presented herein examined the biological 
properties of several different HIV-1 Vpu protein subtypes including each protein’s intracellular 
localization, ability to down-modulate CD4 from the cell surface, and the ability to enhance 
SHIV virion release in the presence of high levels of hBST-2.  Our results show that Vpu protein 
subtypes A, A2 and C are transported to the cell surface more efficiently than Vpu proteins from 
subtypes B, D, F, and H, which are predominately localized within intracellular compartments.  
We also show that all of the proteins maintained the ability to down-modulate CD4 from the 
surface, even though subtypes A2 and C were significantly less efficient.  We also found that the 
subtype F Vpu protein was the only protein unable to enhance SHIV particle release in HeLa 
cells, which express high levels of hBST-2.  This study provided evidence in support of distinct 
biological determinants of Vpu function among different subtypes that may affect the ability of 
Vpu to enhance pathogenesis. 
 In light of these results we focused our analysis on the molecular differences between 
subtype B and subtype C Vpu proteins.  Our third study further analyzed the biological 
properties of these two Vpu subtypes with an emphasis on their ability to modify pathogenesis 
using a SHIV/macaque model for disease.  We consistently found that subtype C Vpu proteins 
were less efficient than the subtype B Vpu protein at down-modulating CD4 from the cell 
surface using four different subtype C Vpu proteins.  We also found that a SHIV expressing a 
subtype C Vpu protein (SHIVSCVpu) replicated with decreased kinetics compared to a SHIV 
expressing a subtype B Vpu protein (SHIVKU-1bMC33), even though the Env and Gag proteins 
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were synthesized and processed similarly.  We inoculated three pig-tailed macaques with 
SHIVSCVpu and monitored disease progression by analyzing the circulating CD4
+
 T cell levels 
and plasma viral burdens in each macaque for up to 44 weeks.  Our results show that SHIVSCVpu 
caused a more gradual rate of CD4
+
 T cell loss and lower viral loads in pig-tailed macaques 
compared to those inoculated with SHIVKU-1bMC33.  This study provided evidence in support of 
differential modification of pathogenesis by different HIV-1 Vpu proteins and show for the first 
time that different Vpu proteins can influence the rate of CD4
+
 T cell loss in the SHIV/macaque 
model of disease. 
 In order to understand the mechanisms associated with differential modification of 
pathogenesis by different Vpu proteins, we concentrated on identifying conserved or unique 
elements of each protein that govern the structural and functional features of either the subtype B 
or the subtype C Vpu protein.  Our fourth study therefore focused on the role of the 
transmembrane domain in Vpu membrane association, stability and function.  Since Vpu is 
membrane bound and known to interact with lipid raft proteins (i.e. CD4 and BST-2), we 
hypothesized that Vpu would also associate with lipid rafts and that specific amino acids within 
the TMD would dictate this association.  Using biochemical and morphological techniques we 
demonstrated that both subtype B and subtype C Vpu proteins associate with membrane rafts in a 
cholesterol dependent manner.  We also demonstrate a correlation between membrane raft 
association and the enhanced virion release function of Vpu by analyzing Vpu proteins with 
combinatorial substitutions within the TMD.  Raft association-deficient TMD mutants were 
impaired in the enhanced release function in HeLa cells, but still maintained the ability to down-
modulate CD4 surface expression.  These results demonstrate that the two functions of Vpu 
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require distinct membrane localization patterns and implicate regions of the TMD as targets for 
inhibiting Vpu enhanced virion release function. 
 The fifth study presented, examined the role of two overlapping putative sorting signals 
in the membrane proximal region of the subtype C Vpu in intracellular transport, CD4 surface 
down-modulation, and virus release from the cell surface.  The first is a tyrosine-based (YxxΦ) 
motif that is highly conserved among different Vpu subtypes and the second is a dileucine-based 
([D/E]xxxL[L/I]) motif that is only highly conserved among subtype C Vpu proteins.  Our 
results indicated that neither of these motifs is required for CD4 surface down-modulation, 
although elimination of both motifs together reduced the ability of the protein to down-modulate 
CD4 from the cell surface.  In contrast, the dileucine motif significantly affected the intracellular 
transport of the protein.  Disruption of this motif through mutagenesis resulted in a protein that 
was expressed at the surface at significantly reduced levels compared to the unmodified 
VpuSCEGFP1 protein.  Examination of SHIVs expressing subtype C Vpu proteins with mutations 
in the tyrosine (SHIVSCVpuY35A), dileucine (SHIVSCVpuL39G), or both motifs (SHIVSCVpuYL35,39AG) 
identified the tyrosine-based sorting motif as an essential component for efficient virus release.  
These analyses also indicate that the dileucine-based sorting motif not only affects intracellular 
trafficking, but particle release as well.  Taken together, these results identify the membrane 
proximal region and these putative sorting signals as potential targets for anti-virals directed 
against Vpu. 
 Finally, we concluded our analysis by determining the contributions of the N-
terminus/TMD and cytoplasmic domain of subtype B and subtype C Vpu proteins to the 
differences observed in SHIV pathogenesis in pig-tailed macaques.  Chimeric Vpu proteins in 
which the N-terminus/TMD regions of the subtype B and subtype C Vpu proteins were 
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exchanged allowed us to identify the cytoplasmic domain as the determinant for localization.  
Since both of these proteins down-modulated CD4 surface expression similar to the unmodified 
VpuSCEGFP1 protein, our in vivo analyses allowed us to address the physiological relevance of 
the differential efficiencies observed among the subtype B and subtype C Vpu proteins for this 
function.  Since we observed different rates of CD4
+
 T cell loss in macaques inoculated with 
SHIV expressing either of these two chimeric proteins, the differences observed in CD4 surface 
down-modulation in vitro are most likely not physiologically relevant.  SHIV expressing these 
two chimeric proteins, replicated in C8166 cells with intermediate kinetics compared to the 
parental SHIVs (SHIVKU-1bMC33 and SHIVSCVpu).  However, the SHIV expressing the Vpu 
protein with the subtype B N-terminus/TMD (SHIVVpuBC) replicated at a faster rate than the 
SHIV expressing the subtype C N-terminus/TMD (SHIVVpuCB).  When inoculated into pig-tailed 
macaques SHIVVpuBC resulted in a rapid loss of circulating CD4
+
 T cells and high viral loads 
similar to results in macaques inoculated with SHIVKU-1bMC33.  Inoculation of three pig-tailed 
macaques with SHIVVpuCB resulted in a more gradual loss of circulating CD4
+
 T cells than 
observed in SHIVVpuBC-inoculated macaques, however more rapid than resulted in macaques 
inoculated with parental SHIVSCVpu.  These results demonstrate the impact of both domains of 
the Vpu protein on protein function and pathogenesis. 
 
Epidemiology  
Human immunodeficiency virus type 1 (HIV-1) is the causative agent of acquired 
immune deficiency syndrome (AIDS) (Barre-Sinoussi et al., 1983; Gallo et al., 1984).  Following 
its discovery in 1983, HIV-1 has caused a worldwide pandemic resulting in more than 25 million 
deaths and the current estimate of 33 million people living with HIV-1 infections (Global 
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distribution of HIV-1 infections shown in Figure 1; Statistics provided by the Joint United 
Nations Program on HIV/AIDS (UNAIDS) and the World Health Organization (WHO)).  
According to the 2008 UNAIDS/WHO report on the global AIDS epidemic, there are 
approximately 2.7 million new infections and 2 million AIDS-related deaths per year.  There is 
no known cure for HIV-1 infection and while the introduction of highly active anti-retroviral 
therapy (HAART) has led to a global stabilization of the epidemic, the levels of current and new 
infections are still alarmingly high.  The genetic diversity of HIV-1, increasing rates of 
acquisition of drug resistance in treated patients and the insufficient availability of affordable 
treatments remain unaddressed threats posed to the regression of the epidemic and eradication of 
this virus.  Disregard of these issues and many others will inevitably lead to the reestablishment 
of a growing pandemic and therefore the continued expansion of our understanding of HIV-1 
molecular determinants associated with the progression of disease is critical for development of 
more effective treatments and vaccines. 
  
Classification 
 Simian and human immunodeficiency viruses (SIV and HIV) are genetically related 
members of the Lentivirus genus of the Family Retroviridae.  In addition to HIV-1, HIV-2 and 
SIV, the Genus Lentivirus also includes bovine immunodeficiency virus (BIV), feline 
immunodeficiency virus (FIV), visna, caprine arthritis-encephalitis virus (CAEV) and equine 
infectious anemia virus (EIAV) (Narayan et al., 1988).  Distinct SIVs have been isolated from a 
multitude of primate species that include African green monkeys (SIVAGM), chimpanzees 
(SIVCPZ), mandrills (SIVMND), sykes (SIVSYK), and sooty mangabeys (SIVSMM).  While these 
particular isolates cause non- or mildly-pathogenic infections in their primary hosts, several SIVs 
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Figure 1.  Global distribution of HIV-1 infections according to the UNAIDS/WHO 2008 
Report on the Global AIDS Epidemic. 
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have been isolated that cause AIDS-like disease from macaques that are not normally natural 
hosts.  These include viruses isolated from Asian macaque species macaca mulatta (rhesus 
macaques, SIVMAC) and macaca nemestrina (pig-tailed macaques, SIVMNE).  These isolates arose 
from an initial infection of a rhesus macaque that was being housed with an infected sooty 
mangabey.  The majority of HIV isolates are classified into two groups, HIV-1 and HIV-2.  HIV-
1 infections are responsible for the AIDS epidemic, while HIV-2 infections are isolated to 
regions within Western and Central Africa.  The origin of these viruses is still under 
investigation; however, compelling evidence exists for a zoonotic transmission between non-
human and human primates.  Genomic analysis of HIV-1 revealed a high percent of homology to 
an SIV isolated from chimpanzees (SIVCPZ), while HIV-2 was more closely related to a strain 
isolated from sooty mangabeys (SIVSMM) (Clavel et al., 1986; Gao et al., 1999; Reeves and 
Doms, 2002; Sharp et al., 1995).  It is therefore thought that a recombinant virus formed within 
these two hosts that was biologically fit to transfer and replicate within a human host.  Evidence 
supporting this theory was obtained when a specific isolate YBF30 was identified as a 
recombinant between HIV-1 and SIVCPZ strains (Gao et al., 1999). 
 HIV-1 isolates are categorized into three groups, the major (M) group, the outlier (O) 
group, and the non-M/O (N) group.  Group M isolates are responsible for more than 90% of the 
HIV/AIDS cases worldwide while viruses from groups O and N are primarily found in 
Cameroon and West Central Africa (Jaffe and Schochetman, 1998; Simon et al., 1998a; Zekeng 
et al., 1994).  Group M contains nine different subtypes (A-D, F-H, J and K) and although this 
classification was originally based on env sequences, it applies to all regions of the genome.  
Some subtypes can also be further divided into sub-subtypes, including subtypes A, B and F (A1 
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and A2, B and B’, F1 and F2).  These group M viruses frequently recombine and these 
intersubtype recombinants are classified as either circulating recombinant forms (CRF) or unique 
recombinant forms (URF).  Circulating recombinant forms are defined as fully sequenced viruses 
that have regions of genes from different subtypes within their genomes and identified in at least 
three epidemiologically unlinked individuals (Liner et al., 2007; Robertson et al., 2000).  To 
date, 19 CRFs have been identified and several have played a significant role in the 
establishment of certain regional epidemics, including CRF01_AE and CRF02_AG (Casado et 
al., 2005).  Unique recombinant forms have multiple combinations between different subtypes, 
are only found within specific individuals and are thought to be recombinations of CRFs (Liner 
et al., 2007; McCutchan, 2006).  Finally, HIV-2 is divided into subtypes A, B and C-G 
(Kandathil et al., 2005).  Phylogenetic representation of all HIV isolates is depicted in Figure 2. 
 
Geographic Distribution  
 The original cross-species transmission of all HIV-1 groups is thought to have occurred 
in West Central Africa (Gao et al., 1999).  Essentially all strains of HIV-1 including all group M 
subtypes, group N, group O and HIV-2 are found within this region.  However, during 
progression of the epidemic, the stabilization of specific populations with certain subtypes 
predominating over others has occurred.  The regional distributions of each major group subtype 
according to data collected in the WHO/UNAIDS report titled “Global and regional distribution 
of HIV-1 genetic subtypes and recombinants in 2004” (Hemelaar et al., 2006) is presented in 
Figure 2.  This data suggests that subtypes A and B are major contributing factors to the growing 
pandemic accounting for 12% and 10% of worldwide infections, respectively.  Subtype A is 
predominately found in West, Central and East Africa, Eastern Europe and Central Asia. 
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Figure 2.  Phylogenetic representation and globabl/regional distribution of all HIV-1 
genetic subtypes and recombinants.  Data depicted according to Arien et al., 2007 and 
Hemelaar et al., 2006. 
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Subtype B is responsible for 98% of HIV-1 infections in the United States and the majority of 
current HIV research focuses on this particular subtype.  Subtype B is also prevalent in the rest 
of North America, Latin America, Western Europe and East Asia.  Subtype C accounts for more 
than 50% of HIV-1 infections worldwide and is the major contributing factor to the current 
AIDS epidemic.  The majority of subtype C infections are located in southern Africa and India.  
Subtype D is found mainly within North, East and Central Africa and the middle East.  Subtype 
G infections occur mainly within West and Central Africa.  Subtypes F, H, J and K only account 
for ~0.94% of the total number of infections worldwide.  Subtype F infections are predominately 
found in Latin America and Central Africa while H, J and K are exclusively in Sub-Saharan 
Africa.  The two major CRFs CRF01_AE and CRF02_AG cause infections mainly found within 
South/South-East Asia and West Africa, respectively.  Finally, the remaining CRFs are most 
prevalent in East Asia, West and East Africa.  CRFs account for ~18% of HIV-1 infections 
globally (Hemelaar et al., 2006). 
 
Genome Structure of Lentiviruses 
 HIV-1, similar to all replication competent retroviruses, encodes for structural and 
enzymatic proteins Gag (group-specific antigen), Pol (polymerase) and Env (envelope).  HIV-1 
also encodes for two regulatory proteins, Tat (transcriptional activator) and Rev (regulator of 
virion), and 4 auxiliary proteins including the Vif (virion infectivity factor), Vpr, Vpu (viral 
protein U) and Nef (negative factor) (Frankel and Young, 1998).  Unlike HIV-1, HIV-2 and the 
majority of SIVs do not express a vpu gene.  Besides HIV-1, only SIVs isolated from 
chimpanzees (SIVCPZ) and from select monkeys in the genus Ceropithecus express a Vpu 
homologue (Barlow et al., 2003; Cohen et al., 1988; Courgnaud et al., 2002; Dazza et al., 2005; 
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Huet et al., 1990; Maldarelli et al., 1993; McCormick-Davis et al., 2000b; Strebel et al., 1988).  
Also of note, is that some strains of SIV and HIV-2 express a vpx gene that has been shown to be 
related to the vpr gene.  Although vpx was originally thought to represent an evolutionarily 
derived duplication of the vpr more recent evidence establishes divergence both in targeted 
substrates and functional significance (Ayinde et al., 2010; Tristem et al., 1992; Tristem et al., 
1990; Tristem et al., 1998).  The genomic structures of the members of the Lentivirinae 
subfamily are shown in Figure 3. 
 
Viral Replication Cycle and Current HIV-1 Therapeutic Targets 
 HIV-1 infection is initiated by recognition and binding of the envelope glycoprotein, 
gp120, to the CD4 receptor and a respective co-receptor.  CD4 is a 58 kDa monomeric 
glycoprotein expressed on the surface of ~60% of T-lymphocytes, T-cell precursors within the 
bone marrow and thymus, monocytes, macrophages, eosinophils, dendritic cells and microglial 
cells.  Binding of gp120 to CD4 induces conformational changes in the V3 loop of gp120 that 
allow a more efficient interaction with the appropriate co-receptor.  While 12 different 
membrane proteins have been identified as co-receptors for HIV-1, chemokine receptors CCR5 
and CXCR4 have been identified as the prinicipal co-receptors for T-cell line tropic (T-tropic) 
and macrophage tropic (M-tropic) HIV-1 isolates, respectively (Berger et al., 1999; Deng et al., 
1996; Deng et al., 1997; Doranz et al., 1996; Dragic et al., 1998; Feng et al., 1996; Liao et al., 
1997).  Some viruses undergo a transformation in co-receptor recognition from CCR5 to a dual-
tropic phenotype (R5/X4) and finally to using the CXCR4 receptor.  This adaptation is most 
likely due to the fact that the virus will encounter macrophages and dendritic cells (CCR5 
expressing) initially during infection and T-lymphocytes (CXCR4 expressing) during the later 
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Figure 3.  Schematic representation of several members of the Lentivirinae subfamily 
including HIV-1, SIVCPZ, HIV-2, SIVSMM, and SIVMAC. 
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stages of infection once the virus has spread to the pheripheral lymph nodes (Coffin, 1996; 
Doms, 2004).  Binding of gp120 to the co-receptor again induces a conformational change in 
gp41 exposing the fusion domain which in turn inserts into the host cell membrane.  C-heptad 
repeat (CHR) peptides interact with N-heptad repeat (NHR) trimers to form a six-helix bundle 
that bring the viral envelope and target cell membrane into close proximity and eventually form a 
pore in the membrane (Melikyan et al., 2000; Ryser and Fluckiger, 2005).  Currently there are 
two anti-retrovirals available for inhibiting viral entry: enfuvirtide (T20), an inhibitor of gp41 
core formation, and maraviroc, an inhibitor of CCR5 (De Clercq, 2009).  
The fusion of the viral and host cell membrane allows for the release of the viral 
nucleocapsid into the cytoplasm of the host cell.  The viral core is then uncoated and the reverse 
transcriptase (RT) synthesizes a double stranded DNA copy of the viral genome.  The uncoating 
and reverse transcription of the HIV-1 RNA is inhibited in lymphocytes isolated from rhesus 
macaques and Owl monkeys by a cellular factor known as TRIM5α, however, human TRIM5α 
does not inhibit HIV-1 replication as efficiently as the rhesus equivalent (Nisole et al., 2005; 
Towers, 2007).  This cellular factor represents a potential restriction factor and studies are 
currently ongoing to further elucidate its biological significance.  The majority of anti-retrovirals 
currently available target the reverse transcriptase.  There are 11 reverse transcriptase inhibitors 
approved for clinical use in the treatment of HIV-1: seven nucleoside reverse transcriptase 
inhibitors (NRTIs): zidovudine, didanosine, stavudine, lamivudine, abacavir and emtricitabine; 
one nucleotide reverse transcriptase inhibitor (NtRTI): tenofovir; and four non-nucleoside 
reverse transcriptase inhibitors (NNRTIs): nevirapine, delavirdine, efavirenz and etravirine (De 
Clercq, 2009). 
19 
 
Following reverse transcription, a preintegration complex (PIC) is formed to facilitate 
viral DNA integration into the host chromosome.  The PIC complex is around 56nm in diameter 
and consists of reverse transcribed viral genomic DNA, viral integrase (IN), viral protein R 
(Vpr), matrix protein (MA), and cellular factors that assist in translocation of the complex to the 
nucleus (Fouchier and Malim, 1999; Sherman et al., 2002; Sherman and Greene, 2002).  The 
nuclear pore complex (NPC) forms an aqueous channel and when active transport occurs 
between the cytoplasm and nucleoplasm, macromolecules up to 25 nm in diameter are allowed to 
pass bidirectionally through the pore.  Translocation into the nucleus is regulated by a class of 
proteins known as importins and exportins.  Classical and non-classical nuclear import signals 
have been identified in the IN, MA and Vpr proteins (Bouyac-Bertoia et al., 2001; Bukrinsky et 
al., 1993; Jenkins et al., 1998).  The exact mechanism and roles for all PIC-associated proteins in 
nuclear translocation and passage through the NPC are still unknown, however, at present the IN 
is thought to play the primary role in nuclear import with the remaining proteins providing 
support for the docking and transport processes (Sherman et al., 2002; Sherman and Greene, 
2002).  Once in the nucleoplasm, the integrase cleaves the viral and host DNA and ligates the 
linear viral DNA into the host genome through a reaction known as strand transfer.  The IN 
protein binds a short sequence in the LTR and removes a dinucleotide adjacent from the highly 
conserved CA dinucleotide in the 3’ strand of the U3 and U5 LTR domains.  While there is no 
consensus site for host DNA integration, several lines of evidence support a non-random 
integration with preferential integration in transcription units for HIV-1 using symmetrical 
sequences (Grandgenett, 2005; Holman and Coffin, 2005; Marshall et al., 2007; Wu et al., 2005).  
Host cellular repair enzymes fill in the gaps between the integrated viral DNA and the host 
chromosomal DNA left by the integrase-mediated cleavage (Van Maele and Debyser, 2005).  
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Currently only one integrase inhibitor, raltegravir, is approved for clinical use and targets the 
strand transfer reaction rather than the 3’ DNA processing event (De Clercq, 2009). 
Initial transcription of the viral genome is regulated by the host cell RNA polymerase II 
and the basal levels of transcription are relatively low.  Long terminal repeat (LTR) regions flank 
the viral DNA and the 3’LTR contains three distinct regions, the unique 3’ end (U3), the 
repeated domain (R), and the unique 5’ end (U5).  The U3 domain allows for direct binding of 
the RNA polymerase II and contains several elements that promote transcription.  These 
elements include a TATA box to which the transcription factor IID binds, three Sp1 sites, two 
NF- B sites, and a “modulatory region” with binding sites for transcription factors: LEF, Ets and 
USF (Freed, 2001; Ross et al., 1991).  The early mRNA products are doubly spliced and encode 
the regulatory proteins, Tat and Rev, and the accessory protein, Nef.  The production of the Tat 
protein increases viral mRNA transcription levels by two logs and is essential for a productive 
infection (Dayton et al., 1986; Fisher et al., 1986).  The accumulation of these early proteins 
promotes the transcription of the late mRNA products which encode for the structural and 
enzymatic components of the virion (Gag, Pol, Env) as well as the non-structural accessory 
proteins that facilitate viral replication and assembly, promote genomic stability and enhance 
virion release (Vif, Vpr, Vpu).  The envelope glycoprotein precursor, gp160, is synthesized on 
the endoplasmic reticulum (ER) and is processed in the Golgi apparatus where it is cleaved by 
the host cellular protease furin, resulting in the surface glycoprotein gp120 and the 
transmembrane/fusion glycoprotein gp41.  The structural and non-structural polyprotein 
precursors, the gp120/gp41 envelope complex, and two full-length copies of viral RNA are 
transported to the plasma membrane for assembly into virion particles (Briggs et al., 2003; 
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Zimmerman et al., 2002).  There are currently no available anti-retrovirals targeted towards the 
transcriptional elements involved in HIV-1 replication. 
The Gag polyprotein precursor Pr55
Gag
 is essential for particle assembly as it contains the 
components necessary for targeting and binding the plasma membrane, promoting interactions 
between the virion structural components, encapsidating the viral RNA genome copies, 
associating with the Env glycoproteins and stimulating particle budding.  Pr55
Gag
 uses the 
cellular Endosomal Sorting Complex Required for Transport I (ESCRT-1), specifically the 
TSG101 and ALIX proteins, for targeting to the cellular surface and for release from the cell 
(Martin-Serrano et al., 2003; Stuchell et al., 2004; von Schwedler et al., 2003).  The HIV-1 Gag 
p6 protein recruits Tsg101 and ALIX with PTAP and YPLTSL late assembly domains, 
respectively (Bieniasz, 2006; McDonald and Martin-Serrano, 2009; Morita and Sundquist, 
2004).  ALIX directly activates ESCRT-III by recruiting and activating the Snf7 subunit 
(McCullough et al., 2008).  ESCRT-III is directly involved in the scission of the membrane neck 
that connects the virion to the plasma membrane.  Once all of the viral particle components have 
been recruited to the site of assembly the immature virion buds from the plasma membrane with 
the host cell lipid bilayer as its outer envelope (Freed, 2002; Ono and Freed, 2001).  Previously, 
HIV-1 assembly in T-cells was thought to occur at the plasma membrane while assembly in 
macrophages occurred within multi-vesicular bodies (MVB) or late endosomes (LE).  However, 
this notion has recently come into question with increasing evidence that assembly may occur 
within large invaginations of the plasma membrane in macrophages that resemble MVB/LE.  
While more studies are necessary to fully elucidate the site of assembly in macrophages, HIV-1 
assembly occurs exclusively at the plasma membrane in T-cells (Gelderblom, 1991; Ono, 2009; 
Orenstein et al., 1988). 
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The HIV-1 envelope is known to be enriched in cholesterol and both the Gag and Env 
proteins have been isolated in detergent resistant membrane (DRM) fractions (Aloia et al., 1993; 
Brugger et al., 2006; Nguyen and Hildreth, 2000).  These investigators found that 
glycophosphatidylinositol (GPI)-anchored proteins such as Thy1, CD59, and GM-1 ganglioside 
were present in DRMs but that a non-raft protein, CD45, was largely absent from viral particles.  
It was subsequently shown that membrane rafts were critical for virus assembly and release (Ono 
and Freed, 2001).  These investigators found that the myristylated N-terminal domain of Gag and 
the I domain of the NC protein were critical for raft association and that the cholesterol depleting 
compound, methyl-β-cyclodextrin (M-β-CD), reduced the efficiency of virus release.  The 
palmitoylation of the gp41 envelope glycoprotein was initially shown to be important for raft 
targeting and infectivity but later studies showed that substitution of the cysteines at positions 
764 and 837 in the cytoplasmic domain of gp41 (thus resulting in no palmitoylation) only 
partially affected infectivity or had no effect (Bhattacharya et al., 2004; Chan et al., 2005; 
Rousso et al., 2000).  It was later shown that mutations in the Gag p17 protein would prevent 
Env incorporation into rafts and virions, suggesting that Gag regulates Env incorporation into 
rafts (Bhattacharya et al., 2006; Patil et al., 2010). Other investigators have shown that the HIV-1 
Env has a cholesterol recognition/interaction amino acid consensus (CRAC) domain that is 
responsible for raft association (Epand et al., 2006; Vishwanathan et al., 2008).  There are 
currently no anti-retrovirals targeting virion assembly and egress approved for clinical use in 
HIV-1 treatment. 
Once the immature virion is released from the cell the viral protease (PR) is 
spontaneously activated and cleaves the Pr55
Gag
 and Pol polyprotein precursor (Pr160
Gag-Pol
) to 
yield the mature Gag and Pol proteins.  The virion undergoes a morphological change resulting 
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in a spherical particle with a visibly dense conical core containing the RNA genome copies 
(Ganser et al., 1999; Yeager et al., 1998).  Currently, there are ten protease inhibitors (PI) 
approved for use in HIV-1 treatment: saquinavir, ritonavir, indinavir, nelfinavir, amprenavir, 
lopinavir/ritonavir, atazanavir, fosamprenavir, tipranavir and darunavir.  These compounds are 
all designed to occupy the active site of the HIV-1 PR therefore preventing cleavage of the 
polyprotein precursors and in turn virion maturation (De Clercq, 2009). 
An overview of the replication cycle of HIV-1 and the stages of viral infection that 
therapeutics are currently available is depicted in Figure 4. 
 
Viral Proteins 
 While Gag is the only protein required for formation and release of virion-like particles 
the remaining proteins contribute to the regulation of HIV-1 replication as well as evasion of the 
host immune system by promoting optimal conditions intra- and extra-cellularly.  A 
representation of a mature HIV-1 virion is depicted in Figure 5. 
 
Gag 
 The gag gene of HIV-1 encodes for a polyprotein precursor Pr55 that is cleaved upon 
maturation of a virion into the proteins matrix (MA or p17), capsid (CA or p24), nucleocapsid 
(NC or p7) and p6.  Cleavage by the protease protein (PR) also results in two spacer proteins p1 
and p2.  The MA protein is found at the N-terminal region of the Gag polyprotein and is 131 
residues in length.  It contains the M domain where a myristic acid moiety is attached to the 
penultimate glycine residue allowing for insertion into the host lipid bilayer and a cluster of basic 
residues which are thought to serve as an interface for head groups of acidic phospholipids 
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Figure 4.  An overview of the replication cycle of HIV-1.  Stages of viral infection that 
therapeutics are currently available for are labeled by number. 
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Figure 5.  Diagram of a mature HIV-1 virion. 
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stabilizing the interaction with the negatively charged phosphate backbone of the host 
membrane.  One particular acidic phospholipid that is known to specifically localize to the 
cytoplasmic leaflet of the plasma membrane (PM), PI(4,5)P2, binds specifically to the basic patch 
in the MA.  This interaction is required for assembly and is most likely responsible for the direct 
targeting of Gag to membrane rafts (Chukkapalli et al., 2008; Ono et al., 2004; Saad et al., 2006).  
The myristoylation site is generally sequestered and the ability for Gag to insert this moiety into 
the host cell membrane is regulated by the CA protein.  CA folds into two distinct domains: the 
N-terminal core and the C-terminal dimerization domain (Ono, 2009).  CA multimerization 
causes a conformational change in the Gag protein that unmasks the myristate moiety and allows 
for strong binding of the precursor protein to the membrane (Saad et al., 2006).  The CA protein 
has also been shown to incorporate cyclophilin A (CypA) for optimal infectivity of HIV-1 
particles (Braaten et al., 1996; Franke et al., 1994; Luban et al., 1993; Thali et al., 1994).  The 
incorporation of CypA into the capsid appears to stabilize the structure and may explain why the 
human TRIM5α protein is not as efficient at preventing “uncoating” as its rhesus counterpart 
(Sayah and Luban, 2004; Towers et al., 2003).  The NC region of the Gag polyprotein functions 
to encapsidate viral genomic RNA for efficient packaging into the viral particle.  The packaging 
signal (  site) locating in the viral RNA 5’ to the gag initiation codon is composed of four stem 
loop structures that allow for binding to the NC protein.  NC contains two zinc finger motifs 
(CCHC type) each flanked by basic sequences that directly bind and stabilize the interaction with 
the viral RNA (Ono, 2009).  Finally, the p6 region of the Gag polyprotein contains the Late (L) 
domain and the PTAP motif that allow for recruitment of the host ESCRT-associated complexes 
TSG101 and ALIX that facilitate virus particle budding from the cellular surface (Bieniasz, 
2006; Gottlinger et al., 1991; Huang et al., 1995; Ono and Freed, 2004; Rudner et al., 2005). 
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Pol 
 The Pol protein is also synthesized as a precursor polyprotein in conjunction with the Gag 
protein, known as Pr160
Gag-Pol
.  The synthesis of this protein occurs following a frame-shift event 
during transcription and occurs at 5-10% the levels of the Pr55
Gag
.  This large polyprotein 
precursor is cleaved during maturation to yield the pol encoded enzymes protease (PR), reverse 
transcriptase (RT), and integrase (IN).  A wealth of information on the reverse transcriptase is 
available including the three dimensional structure, mapping of resistance mutations, and its role 
in the virus replication cycle, however, it is beyond the scope of this dissertation and the central 
hypothesis, therefore it will not be discussed in great detail.  The relevant aspects of these 
enzymes in the HIV-1 lifecycle has been discussed in the overview of viral replication.  
 
Vif 
 Vif is a 192 amino acid protein and a potent regulator of HIV-1 infection (Fisher et al., 
1987; Gallo et al., 1988; Strebel et al., 1987).  Vif is critical for virus replication in cells termed 
“non-permissive” and dispensible in “permissive cells” (Gabuzda et al., 1992; von Schwedler et 
al., 1993).  In permissive cells, the Vif protein is incorporated into virions and therefore serves as 
a structural protein.  In non-permissive cells, Vif-deficient viruses complete entry and initiate 
reverse transcription but have reduced or incomplete synthesis of proviral DNA following 
challenge of target cells (i.e. inhibition occurs during the second round of replication) (Courcoul 
et al., 1995; Simon and Malim, 1996; Sova and Volsky, 1993; von Schwedler et al., 1993).   The 
ability of Vif to impact infectivity is species-specific and the fusion of “permissive” and “non-
permissive” cells yields a non-permissive phenotype (Madani and Kabat, 1998; Simon et al., 
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1998b; Simon et al., 1998c).  Building from these discoveries, CEM15 was identified as a 
dominant cellular restriction factor of Vif-deficient HIV-1(Sheehy et al., 2002). 
CEM15 was found to be a member of the human apolipoprotein B mRNA editing 
enzyme catalytic polypeptide-like 3 family of proteins (APOBEC3) and specifically 
APOBEC3G.   This family includes 7 members: APOBEC3A, APOBEC3B, APOBEC3C, 
APOBEC3D, APOBEC3E, APOBEC3F, APOBEC3G, and APOBEC3H (Chiu and Greene, 
2008; Conticello et al., 2005; Jarmuz et al., 2002; Malim, 2009; OhAinle et al., 2006).  These 
proteins are cytidine deaminases and each protein contains either one or two cytidine deaminase 
domains.  Following the identification of APOBEC3G as an HIV-1 restriction factor, multiple 
investigators have examined the anti-HIV-1 properties of the other APOBEC3 proteins.  The 
RNA editing activity of the APOBEC3 family of proteins (A3A-H) involves an active site 
characterized by a conserved zinc-binding motif (Cys/His-Xaa-Glu-Xaa23-28-Pro-Cys-Xaa2-4-
Cys) (Jarmuz et al., 2002).    Human A3B, A3DE, A3F and A3G all exhibit the ability to inhibit 
replication of Vif-deficient HIV-1 isolates, while A3A, A3C and A3H are inactive or weakly 
restrict HIV-1 vif (Bishop et al., 2004; Conticello et al., 2005; Dang et al., 2008; Dang et al., 
2006; Doehle et al., 2005; Jarmuz et al., 2002; Liddament et al., 2004; OhAinle et al., 2006; 
Wiegand et al., 2004; Yang et al., 2007; Zennou and Bieniasz, 2006; Zheng et al., 2004).  The 
actively restricting A3 proteins interact with HIV-1 viral genomic RNA and the Pr55
Gag
 or 
Pr160
Gag-Pol
 and are incorporated into budding virions.  Following infection of a target cell the 
A3 protein interact with the RT complex as well as the viral RNA being reverse 
transcribed(Bogerd and Cullen, 2008; Burnett and Spearman, 2007; Khan et al., 2005; Luo et al., 
2004; Luo et al., 2007; Navarro et al., 2005; Schafer et al., 2004; Svarovskaia et al., 2004; 
Zennou et al., 2004).  During reverse transcription, the A3 protein induces deamination of 
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cytidines to uridines leading to an accumulation of G-to-A transitions in the newly synthesized 
plus strand viral DNA (Chiu and Greene, 2008; Harris et al., 2003; Malim, 2009; Mangeat et al., 
2003; Mariani et al., 2003; Yu et al., 2004).  More recent studies have also revealed deaminase-
independent restriction functions of hA3G and considerable efforts are being made to elucidate 
the precise mechanisms of restriction by the APOBEC3 proteins (Chiu and Greene, 2008; 
Malim, 2009; Navarro et al., 2005; Newman et al., 2005).   
HIV-1 has evolved to counteract the functions of these cellular restriction factors by 
encoding the Vif protein.  Vif binds to the A3G protein as well as the Cullin5, Elongin B/C-
rbx1/E3 ubiquitin ligase and induces the polyubiquitination of the A3G protein and possibly Vif 
itself, which subsequently leads to the proteasomal degradation of both proteins (Conticello et 
al., 2005; Kewalramani and Emerman, 1996; Kobayashi et al., 2005; Marin et al., 2003; Mehle et 
al., 2004a; Mehle et al., 2004b; Sheehy et al., 2003; Yu et al., 2003).  This diminishes the 
cytosolic levels of A3G proteins available for virion incorporation which allows for optimal 
virion infectivity.   
 
Vpx/Vpr 
  Vpr is a 96 amino acid virion incorporated protein expressed in both the HIV-1 and HIV-
2 lineages.  Vpx is a 112 amino acid virion incorporated protein whose expression is specific to 
the HIV-2 and SIVSMM lineages.  Both proteins are incorporated into budding virions through 
association with a dileucine motif (LXXLF) found within the p6 domain of the Pr55
Gag
 precursor 
protein (Accola et al., 1999; Bachand et al., 1999; Cohen et al., 1990; Kewalramani and 
Emerman, 1996; Kondo and Gottlinger, 1996; Paxton et al., 1993; Wu et al., 1994).  This 
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incorporation suggested that these proteins most likely play an important role in the early stages 
of the viral life cycle.   
  The Vpr protein was originally thought to be specifically dedicated to the progressive 
infection of macrophages, however, more recent studies have brought into question the 
biological significance of this protein.  A variety of functions have been attributed to the HIV-1 
Vpr protein including modulation of transcription (Sawaya et al., 2000), induction of apoptosis, 
disruption of cell cycle regulation (Chang et al., 2004), nuclear transport of the PIC (Vodicka et 
al., 1998), facilitation of reverse transcription (Rogel et al., 1995), suppression of immune 
activation (Ramanathan et al., 2002), and reduction of the mutation rate of the HIV-1 genome 
(Jowett et al., 1999).  Vpr is able to interact with or effect a considerable number of cellular 
proteins including proteins involved in anti-inflammatory and immunosuppressive responses 
(including the glucocorticoid receptor), proteins associated with apoptotic regulation pathways 
(including the permeability transition pore complex), protein associated with nuclear 
translocation (including importin-α and several nucleoporins), and ubiquitin ligase associated 
proteins (Cullin 4A and DCAF-1) (Belzile et al., 2007; DeHart et al., 2007; He et al., 1995; 
Hrecka et al., 2007; Jacotot et al., 2001; Le Rouzic et al., 2007; Le Rouzic and Benichou, 2005; 
Schrofelbauer et al., 2007; Schrofelbauer et al., 2005; Tan et al., 2007; Varin et al., 2005; 
Vodicka et al., 1998; Wen et al., 2007; Yedavalli et al., 2005; Zeitler and Weis, 2004).  While the 
potential of Vpr functions in HIV-1 infection is extensive, in vitro studies have defined the 
facilitation of the PIC nuclear translocation and the disruption of cell cycle regulation as the two 
main functions of Vpr.   
  Vpr contains a non-classical nuclear localization signal and interacts with proteins 
associated with the HIV-1 PIC as well as proteins associated with the nuclear pore complex, 
33 
 
including the nucleoporin human CG1, in order to facilitate docking of the PIC to the nuclear 
envelope (Heinzinger et al., 1994; Jenkins et al., 1998; Le Rouzic and Benichou, 2005; Vodicka 
et al., 1998; Zeitler and Weis, 2004).  Vpr is also thought to induce herniations in the nuclear 
envelope that may contribute to the nuclear import of the PIC as well as the induction of G2 
arrest (de Noronha et al., 2001; Le Rouzic et al., 2002).   
  The biological significance of the induction of G2 arrest by Vpr is controversial since 
Vpr was not found to be required for efficient replication in dividing cells such as cell lines and 
primary CD4
+
 T cells and since macrophages do not divide and thus cell cycle regulation is 
irrelevant. However, while the mechanisms and significance associated with the induction of G2 
arrest by Vpr remains elusive, research in recent years has provided a consensus among 
researchers of the proteins involved in this function.  Vpr interacts with DCAF-1 using it as an 
adaptor to engage damaged DNA binding protein 1 (DDB1), which is a component of the Cul4A 
ubiquitin ligase.  Vpr also recruits a yet unidentified protein that is required for entry of the cell 
into mitosis and uses the Cul4A ubiquitin ligase to target this unknown protein for ubiquitination 
and subsequent proteasomal degradation (Ayinde et al., 2010).  The identification of this 
unknown protein is essential for understanding the biological significance of Vpr in HIV-1 
function since the induction of G2 arrest may simply be a by-product of the elimination of this 
protein and not the direct function of Vpr.  Since several HIV-1 accessory proteins have evolved 
to overcome host restriction factors, it is possible that Vpr evolved in a similar response.  It’s 
possible this unknown protein represents another host restriction factor that can be utilized for 
the development of novel anti-retrovirals.  
  In vitro studies have ascribed several functions of Vpr to be required for HIV-1 infection, 
however, in vivo analysis of vpr deleted viruses questions their validity and significance.  These 
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viruses have been shown to replicate and cause disease similar to wild-type (wt) viruses in rhesus 
macaques (Gibbs et al., 1995; Hoch et al., 1995; Kim et al., 2005).  Further investigation is 
required to determine the importance of Vpr either for pathogenicity or evolutionary aspects of 
HIV-1 since it is clear that the vpr gene provides some selective advantage to the virus (Gibbs et 
al., 1995; Lang et al., 1993). 
  In contrast to vpr deleted viruses, vpx deficient SIV display marked attenuation for 
growth in macrophages.  Pig-tailed macaques inoculated with vpx deficient viruses displayed 
delayed kinetics of viral replication and no disease manifestions (Hirsch et al., 1998).  Rhesus 
macaques inoculated with similar viruses did progress to an AIDS-related death although the 
onset of pathogenesis was delayed and virus burdens were significantly lower than macaques 
inoculated with the parental virus (Gibbs et al., 1995).  Also, contrary to previous hypotheses, 
Vpx does not simply mimic the functions of Vpr, and has been shown to be critical for infection 
of non-dividing macrophages, monocytes and monocyte-derived dendritic cells (Gibbs et al., 
1994; Goujon et al., 2008; Goujon et al., 2007; Kawamura et al., 1994; Mahalingam et al., 2001; 
Ueno et al., 2003; Wolfrum et al., 2007; Yu et al., 1991).  However, Vpx does interact with 
DCAF-1 and subsequently the DDB1-Cul4A ubiquitin ligase similar to Vpr (Bergamaschi et al., 
2009; Le Rouzic et al., 2007; Sharova et al., 2008; Srivastava et al., 2008).  This interaction 
allows Vpx to counteract a macrophage-specific restriction factor most likely by utilizing the 
Cul4A-DDB1
DCAF1
 complex for its degradation (Ayinde et al., 2010).  The antagonism of this 
restriction factor promotes accumulation of HIV-2 and SIV reverse transcripts although the 
mechanism of restriction and how Vpx counteracts this restriction factor(s) remains to be 
determined. 
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Tat/Rev 
 Tat is an early transcription transactivation regulatory protein that has a variable length of 
86-104 amino acids and contains two functional domains.  The first domain is an activation 
domain that mediates interactions with host cellular machinery and the second is an arginine-rich 
region that is required for binding to the transactivation responsive element RNA (TAR) (Hwang 
et al., 2003).  Post-integration of the HIV-1 genome into the host chromosome, elements 
including NF- B, p50, and human deacetylase 1 (HDAC1) bind to the latent HIV-1 LTR and 
cause histone deacetylation and repressive changes in the chromatin structure of the LTR that 
causes RNA Polymerase II to initiate synthesis of short mRNAs and the virus remains latent 
(Pagans et al., 2005; Williams et al., 2006).  During a period of stimulation (e.g. TNF-α), these 
complexes are removed and Tat recruits several chromatin and histone modifying complexes 
including the histone acetyltransferase CREB-binding protein (CBP)/p300 complex.  These 
histone acetyltransferases (HATS) acetylate the nucleosomes on the HIV-1 promotor.  Tat binds 
to a stem loop structure (TAR) and interacts with the P-TEFb complex, which 
phosphorylates/activates the RNA polymerase II.  This allows the RNA polymerase II to 
synthesize full length HIV-1 transcripts (Garber et al., 1998; Kim et al., 2002; Williams et al., 
2006). 
 The Tat protein also promotes transcription of the viral genome by inducing the 
phosphorylation of additional transcription factors including Sp1, the alpha subunit of eukaryotic 
initiation factor 2 (eIF2α), and NF- B (Demarchi et al., 1999; Li et al., 2005a; Li et al., 2005b; 
Rossi et al., 2006; Zauli et al., 2001).  The activation of these proteins induces binding to their 
respective sites within the LTR and subsequent facilitation of viral genome transcription.   
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 The regulatory properties of Tat extend to the modulation of cellular gene expression as 
well as the induction and inhibition of apoptosis (Li et al., 2005a; Li et al., 2005b; Romani et al., 
2010; Stettner et al., 2009).  This ability is not limited to the infected cell as Tat is efficiently 
released extracellularly and can enter uninfected cells and induce transcriptional regulation (Ju et 
al., 2009).  This property could provide an explanation for the neurodegenerative effects of HIV-
1 since Tat can transverse an in-tact blood brain barrier and enter cells such as neurons and cause 
apoptosis (Campbell et al., 2004b; Cheng et al., 1998; de Mareuil et al., 2005; Giacca, 2005; 
Giunta et al., 2009; Haughey and Mattson, 2002; Vendeville et al., 2004; Wallace et al., 2006). 
 Transcription from the LTR leads to the generation of three major types of viral RNA 
transcripts: 1) full length unspliced transcripts that give rise to the Pr55
Gag
 and Pr160
GagPol
 
precursors and the full length HIV-1 genomes packaged into virions; 2) singly spliced mRNAs 
which encode the Vif, Vpr, Vpu and Env proteins; and 3) doubly spliced mRNAs that give rise 
to the Rev, Tat and Nef proteins.  Mammalian cells are restrictive to the nuclear export of 
unspliced or partially spliced mRNAs and HIV-1 encodes the Rev protein to overcome this 
barrier.  Rev is a 116 amino acid protein that contains two functional domains: 1) an arginine-
rich domain required for RNA binding; and 2) a leucine-rich region that acts as a nuclear export 
signal (Cullen, 1998).  During the initial stages of infection, full length transcripts are 
synthesized and the multiply spliced gene products are translated in the cytoplasm (Tat, Rev, and 
Nef).  Tat and Rev are then transported back into the nucleus via their nuclear localization 
signals to facilitate viral transcription.  When sufficient levels of Rev are produced, nuclear 
export of unspliced and partially splice transcripts is initiated and translation of the Gag, Pol, Vif, 
Vpr, Vpu, and Env proteins takes place (Freed, 2001; Hope, 1999; Seelamgari et al., 2004).   
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 Rev binds to a highly structured RNA element located in the env gene and therefore 
present within all unspliced or partially spliced viral transcripts, known as the Rev response 
element (RRE).  The RRE folds into a series of five stem-loop structures and a Rev monomer 
initially binds to stem-loop 2 and then multimerizes with additional Rev molecules.  This 
complex then binds to the nuclear export protein Exportin 1 as well as the Ran-GTP nuclear 
protein and allows for efficient export of all viral transcripts from the nucleus.  Once the protein 
has been successfully transported across the nuclear membrane into the cytoplasm, Rev 
dissociates from the complex by converting Ran-GTP to Ran-GDP and is then shuttled back into 
the nucleus (Freed, 2001; Hope, 1999). 
 
Vpu 
The Vpu protein is a small transmembrane protein encoded by HIV-1 but not by HIV-2 
(Cohen et al., 1988; Strebel et al., 1988).  Structural homologues have been detected in SIV from 
chimpanzees (SIVcpz), the mona monkey (Cercopithecus mona; SIVmon), the greater spot-nosed 
monkey (Cercopithecus nictitans; SIVgsn), mustached monkeys (Cercopithecus cephus; SIVmus), 
more recently Dent’s mona monkey (Cercopithecus mona denti; SIVden) and gorillas (Gorilla 
gorilla; SIVgor) (Barlow et al., 2003; Courgnaud et al., 2002; Dazza et al., 2005; Van 
Heuverswyn et al., 2006).  Sequence analysis has shown that the vpu from SIVcpz is most closely 
related to the vpu from HIV-1 both in amino acid sequence and CD4 down-modulation function 
(Gomez et al., 2005; McCormick-Davis et al., 2000b).  While one of the smallest of the HIV-1 
proteins, it has two important functions within virus-infected cells, which will be discussed in 
detail in a later section.   The first of these functions is the down-regulation of the CD4 receptor 
to prevent its interaction with the HIV-1 envelope glycoprotein.  Vpu interacts with the CD4 
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receptor in the rough endoplasmic reticulum (RER), resulting in its re-translocation across the 
RER and subsequent degradation via the proteasomal pathway (Schubert et al., 1998; Schubert et 
al., 1996a; Vincent et al., 1993; Willey et al., 1992a).  The second major function of the Vpu 
protein is to facilitate release of virus from infected cells.  Previous studies have shown that virus 
release is cell type specific, suggesting that certain cells may express a restriction factor that 
inhibits virus release in the absence of Vpu.  Recently, bone marrow stromal antigen 2 (BST-
2/HM1.24/CD317/tetherin) has been identified as this factor (Neil et al., 2008; Van Damme et 
al., 2008). 
The Vpu protein is 77-86 amino acids in length and is comprised of a short N-terminal 
region, a transmembrane domain (TMD), and a longer cytoplasmic domain (CD) (Figure 6).   
Vpu is translated on the rough endoplasmic reticulum (RER) with the TMD also serving as an 
uncleaved leader sequence.  The signal sequence is bound by the signal recognition particle 
(SRP) which subsequently binds to the SRP receptor on the RER.  The nascent Vpu protein is 
inserted into the RER membrane and synthesis of the remainder of the protein is completed.  The 
CD of Vpu has two predicted α-helical domains separated by a hinge region characterized by two 
canonical casein kinase II sites (S/T-X-X-E/D) (Maldarelli et al., 1993; Schubert et al., 1992).   
The most variable regions of the protein are the N-terminal region (including parts of the 
transmembrane domain) and the far C-terminal region of the protein (McCormick-Davis et al., 
2000b).   However, there are several highly conserved amino acids and domains among most vpu 
species.  The most highly conserved region is the hinge region, which reflects its importance in 
Vpu function and will be discussed later. There are several invariant amino acids found in the 
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Figure 6.  Schematic diagram of the membrane orientation of the consensus subtype B 
Vpu protein (strain HXB2 with a correct methionine at the N-terminus).  The amino 
acids within the hexagons represent amino acids that were found to be invariant among 
all vpu subtypes (Chen et al., 1993).  
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transmembrane region and the cytoplasmic domain.  The first is the invariant tryptophan at 
position 23 of the corrected HXB2 Vpu protein (position 22 in the uncorrected protein).  This 
amino acid with its ring structure is probably involved in stabilizing the TMD within the lipid 
bilayer (Park and Opella, 2005).  There is also an invariant glutamine at position 35 within the 
first α-helical domain and an invariant leucine at position 63 within the second α-helical domain.  
The function of G35 is unknown and the L63 will be discussed in a later section.  The second 
highly conserved domain is the tyrosine-based motif YXX  (where  is a hydrophobic amino 
acid) located at the TMD/CD interface.  Unlike the other transmembrane glycoprotein of HIV-1, 
gp120/gp41, Vpu has no predicted N-linked glycosylation sites.    
While the three-dimensional structure of the entire Vpu protein has yet to be solved, the 
structure of the TMD has been determined by nuclear magnetic resonance (NMR) spectroscopy 
in micelle and bilayer samples (Park et al., 2003).  These investigators used the peptide Vpu2–30+, 
which was a 36-residue polypeptide that consists of residues 2–30 from the N terminus of Vpu 
and a six-residue “solubility tag” at its C terminus.  They found that the Vpu2–30+ has a TM α-
helix spanning residues 8–25 with an average tilt of 13o.  They found that the helix was kinked 
slightly at the isoleucine at position 17, which results in tilts of 12
o
 for residues 8–16 and 15o for 
residues 17–25.  These investigators subsequently showed that the tilt angle of the helix was 
inversely proportional to hydrophobic thickness of the lipid bilayer (Park and Opella, 2005). 
 
Env 
 Similar to Gag and Pol, the Env protein is synthesized as a polyprotein (gp160).  The 
envelope protein is synthesized on the RER similar to the Vpu protein except that the signal 
sequence of Env is cleaved by signal peptidase.  The function of the Env protein is to recognize 
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and bind to the CD4 molecule for viral entry, it is not surprising that this event also occurs in the 
RER between nascent CD4 and gp160 molecules leading to the formation of gp160-CD4 
complexes.  This interaction sequesters both proteins in the RER preventing processing and 
transport to the cell surface leading to their eventual transport to lysosomes for destruction 
(Piguet et al., 1999b).  This does down-regulate CD4 from the cell surface which has been shown 
to be beneficial for viral replication.  This interaction has been shown to be relieved by the Vpu 
protein as described above by permitting transport, cleavage into gp120/gp41 subunits, and 
addition and processing of N-glycans. 
 The gp160 precursor protein is transported to the Golgi where it oligomerizes and 
undergoes heavy glycosylation modification mainly involving N-linked high-mannose-type 
oligosaccharides.  These N-linked glycans are processed as the protein is transported to different 
compartments of the Golgi.  These glycans allow for proper folding and conformational stability 
of the glycoproteins and ultimately provide a host-derived “mask” of carbohydrates that aide in 
the evasion of immune recognition and neutralization of viral infectivity by host antibody and 
cellular immune responses (Pantophlet and Burton, 2006; Poignard et al., 2001; Wyatt et al., 
1998).  The resulting glycoprotein is cleaved by host encoded proteases resulting in two mature 
heterodimers consisting of the surface glycoprotein, gp120, and the transmembrane or fusion 
glycoprotein, gp41 (Deng et al., 1996; Wyatt et al., 1998).  The two glycoproteins remain 
associated through weak noncovalent interactions and are transported to the surface for 
incorporation into budding virions (Wyatt et al., 1998).  The expression of the gp120/gp41 
complexes on the surface of infected cells can cause fusion of two or more cells leading to the 
formation of multinucleated giant cells known as syncitia (Yao et al., 1993).   
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 The gp120 protein consists of five variable regions (V1-V5) and five constant regions 
(C1-C5).  The functional domains of this protein are responsible for recognition and binding of 
the HIV-1 receptor, CD4 (achieved by residues within a hydrophobic pocket surrounding a 
phenylalanine at position 43 (Phe43) formed mainly by segments within the C2, C3 and C4 
domains), and the co-receptor, generally either CCR5 or CXCR4 (associated with V3 loop) 
(Deng et al., 1996; Krambovitis and Spandidos, 2006; Pantophlet and Burton, 2006; Wyatt and 
Sodroski, 1998).  The interaction of the gp120 with CD4 causes a conformational change in the 
variable loop regions V1, V2 and V3.  This allows the V3 loop to bind to the coreceptor which is 
mediated by charge-charge interactions.  The CXCR4 and CCR5 coreceptors have regions of 
either strong negative or strong positive charge, respectively, that interacts with differential 
regions of the V3 loop that possess an opposing charge (Doms and Peiper, 1997; Kwong et al., 
2000; Moulard et al., 2000; Sullivan et al., 1998).  The interaction of the V3 loop with a co-
receptor causes further conformational changes that allow for dissociation of the gp41 from 
gp120.  The gp41 protein consists of three separate domains, the ectodomain, the transmembrane 
domain and the cytoplasmic domain.  This protein anchors the envelope complex (gp120/gp41) 
in the viral membrane and catalyzes the fusion (via insertion of a hydrophobic fusion peptide 
into the host cell membrane) of the viral and host cell lipid bilayers during virus entry (Chen et 
al., 1995; Lu et al., 1995; Weissenhorn et al., 1997).   
 
Nef 
 Nef is a small myristoylated early protein in HIV-1 infection that is polymorphic in 
length (200-215 amino acids).  A myristic acid moiety is attached to the N-terminal region of 
Nef during protein processing and is required for membrane association.  Nef is mainly localized 
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in the perinuclear region and less abundantly at the plasma membrane.  While Nef is dispensable 
for viral replication, it has been established as a major determinant of pathogenicity.  Several in 
vivo studies have demonstrated that nef-deficient viruses caused lower virus burdens and severity 
of disease both in humans and rhesus macaques (Foster and Garcia, 2008).  Nef appears to serve 
as an adaptor protein that redirects specific host cellular proteins to atypical pathways in order to 
promote viral replication.  Four major functions of Nef have been demonstrated in vitro 
including the: 1) down-regulation of CD4 from surface of infected cells; 2) down-regulation of 
major histocompatibility complex class 1 (MHC-1); 3) regulation of cellular signaling and 
activation; and 4) enhancement of virion infectivity (Aiken, 1997; Aiken et al., 1996; Anderson 
et al., 1994; Arora et al., 2000; Atkins et al., 2008; Campbell et al., 2004a; Chowers et al., 1994; 
Garcia and Miller, 1991; Greenberg et al., 1998b; Lundquist et al., 2002; Luo et al., 1997; 
Mangasarian et al., 1997; Miller et al., 1994; Noviello et al., 2008; Pizzato et al., 2007; Renkema 
et al., 1999; Schwartz et al., 1996; Simmons et al., 2001; Wei et al., 2005; Wonderlich et al., 
2008). 
 The down-modulation of CD4 from the surface of infected cells is the most extensively 
studied functions of the Nef protein and appears to be the major factor in Nef modification of 
viral pathogenesis.  Nef interacts with and accumulates CD4 molecules into clathrin coated pits 
at the cellular surface by the membrane proximal region of the cytoplasmic tail of CD4 
(Anderson et al., 1994; Garcia and Miller, 1991; Grzesiek et al., 1996; Hua and Cullen, 1997).   
Nef contains a canonical dileucine motif (
160
EXXXLL
165
) and a diacidic motif (
174
[E/D]D
175
) that 
are required for binding adaptor protein 2 (AP-2) and down-regulation of the CD4 molecule 
(Chaudhuri et al., 2007; Coleman et al., 2005; Craig et al., 1998; Greenberg et al., 1998a; 
Lindwasser et al., 2008).  The vacuolar membrane ATPase (V-ATPase) appears to bind both the 
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C-terminal region of Nef and the µ2 subunit of AP-2 connecting the the CD4/Nef/AP-2 complex 
to the endocytic pathway (Geyer et al., 2002).  This combination of events increases the 
internalization rate of CD4 and diverts the molecule from being recycled to being degraded via 
the lysosome. 
 Nef also down-regulates MHC-I from the cellular surface by interacting with an adaptor 
protein (AP-1) (Roeth et al., 2004).  The main function of AP-1 is to direct proteins at the trans-
Golgi network (TGN) to the endolysosomal pathways (Robinson and Bonifacino, 2001).  The 
exact mechanism by which Nef down-regulates MHC-I is still under investigation, however, it 
has been suggested that Nef serves as an adaptor between AP-1 and newly synthesized MHC-I 
molecules.  This data is supported by the discovery of a ternary complex between Nef, the 
cytoplasmic tail of MHC-I and AP-1 (Noviello et al., 2008; Wonderlich et al., 2008).  Normally, 
newly synthesized MHC-I molecules would become phosphorylated and transported to the 
plasma membrane for antigen presentation, however in the presence of Nef, these 
hypophosphorylated molecules are prevented from becoming phosphorylated and through the 
interaction with AP-1 are redirected to the lysosomes for degradation (Kasper et al., 2005; Roeth 
et al., 2004).  Nef has also been shown to increase the rate of endocytosis of MHC-I molecules 
on the surface through the recruitment of phosphofurin acidic cluster sorting protein 1 and/or 2 
(PACS1/2).  This allows for activation of the endocytic pathway and through a yet unknown 
mechanism Nef is able to prevent the recycling of the MHC-I containing vesicles to the plasma 
membrane and rather deliver the MHC-I molecules to the lysosome for degradation 
(Blagoveshchenskaya et al., 2002; Foster and Garcia, 2008; Swann et al., 2001). 
 Finally, Nef has been demonstrated to impact infectivity of viral particles released from 
an infected cell and is thought to occur through several different mechanisms (Chowers et al., 
46 
 
1994; Miller et al., 1994).  Campbell et al. demonstrated that disruption of the actin cytoskeleton 
was able to overcome the defect observed in nef-deficient viruses suggesting that Nef is able to 
somehow counteract the barrier presented by the actin cytoskeleton (Campbell et al., 2004a).  
Pizzato et al. provided another possible mechanism suggesting that a yet unknown protein 
distinct from CD4 inhibits the function of HIV-1 Env and that Nef down-regulates this protein 
through a Dynamin 2/clathrin-mediated mechanism thereby counteracting its effects on the Env 
protein (Pizzato et al., 2007).  Finally, additional studies have suggested that Nef may protect the 
viral core from post-fusion degradation (Qi and Aiken, 2007, 2008). 
 
LTR 
 The HIV-1 genome is flanked by two long terminal repeat (LTR) regions.  These regions 
allow for integration into the host cellular DNA and do not encode for any viral proteins.  The 
5’LTR contains the transactivation-response elements (TAR) where the Tat protein binds and the 
promoter enhancer binding sites and allows for the recruitment of host cellular transcriptional 
machinery to promote viral replication as described above in the overview of viral replication. 
 
Pathogenesis 
 HIV-1 is characterized by the progressive depletion of the CD4
+
 subset of the T cell 
population resulting in severe immunosuppression and ultimately the development of AIDS and 
increased susceptibility to opportunistic infections.  The exact mechanism for the depletion of the 
CD4
+
 T cell population remains unknown, however it is generally thought to be associated both 
with the cytopathic effects of the virus as well as the over activation of the immune system. 
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 HIV-1 can be transmitted through sexual intercourse, intravenously (most likely through 
contaminated needles (healthcare workers or drug users) or transfusion of blood products), or 
vertically from mother to child.  During the primary or acute phase of infection viral loads are 
high in the peripheral blood and the virus disseminates throughout the host especially localizing 
to the primary and secondary lymphoid organs.  This phase is generally accompanied by a short 
flu-like illness (Hirsch and Curran, 1996).  There are three general patterns of disease 
progression that occur following infection: 1) typical progressor; 2) rapid progressor; and 3) 
long-term non-progressor.  After several weeks, a typical progressor will enter into a clinically 
asymptomatic or latent stage of infection, which has a mean time of 10 years in untreated 
patients.  This stage is accompanied by steady levels of viral replication and slow continual 
depletion of CD4
+
 T cells.  The continuous damage of the immune system eventually results in 
an increase in viral loads and progression to a symptomatic stage of infection followed by 
advancement into the AIDS stage which is characterized by severe clinical symptoms and/or 
opportunistic infections (Hirsch and Curran, 1996).  Clinical AIDS is established when an 
infected individuals circulating CD4
+
 T cell levels drop below 200 cells/µl or if they exhibit one 
of the AIDS defining clinical conditions as defined by the Center for Disease Control and 
Prevention (CDC).  Around 5-10% of individuals infected with HIV-1 are rapid progressors and 
generally develop AIDS within 3-4 years.  These individuals do not mount a stage of clinical 
latency, but rather continually exhibit high viral loads and a rapid decrease in circulating CD4
+
 T 
cell levels (Arens et al., 1993; Bollinger et al., 1996; Demarest et al., 2001).  Finally, around 5% 
of HIV-1 patients are termed long-term non-progressors (LTNP).  These individuals initially 
exhibit high viral loads during the acute phase of infection and then continually present with low 
virus burdens for an extended period of infection.  The circulating CD4
+
 T cell levels of LTNPs 
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remain stable at or above 600 cells/µl and are devoid of clinical symptoms (Rinaldo et al., 1995).  
Several studies have suggested a correlation between deletions or premature truncations of 
accessory proteins especially the nef gene and long-term nonprogressive infections (Deacon et 
al., 1995; Kirchhoff et al., 1995; Kondo et al., 2005; Salvi et al., 1998; Yamada and Iwamoto, 
2000). 
 In addition to severe lymphoid depletion, HIV-1 is also known to cause HIV-1 associated 
nephropathy (HIVAN) and HIV-1 associated dementia (HAD) during the late stages of infection.  
Relatively 10% of HIV-1 infected individuals develop HIVAN and 90% of these patients are 
African American (Winston and Klotman, 1996).  HIVAN is characterized by focal segmental 
glomerulosclerosis (FSGS), elevated serum nitrogen levels, and microproteinuria (Rao, 1991; 
Szczech, 2001).  Patients progressively lose renal function and ultimately develop end stage 
renal disease which has a mortality rate of ~50% within one year post-initiation of dialysis 
(Szczech, 2001).  Approximately 15-25% of HIV-1 infected patients develop HAD without anti-
retroviral treatment.  HIV-1 invades the central nervous system (CNS) early after infection and 
while the exact mechanisms by which HIV-1 traverses the blood brain barrier are still unknown, 
it is most likely attributed to infiltration by infected macrophages (microglia) and/or lymphocytes 
and neuronal injury caused by release of neurotoxic factors (Cunningham et al., 1997; Gartner, 
2000; Kaul et al., 2001; Li et al., 1992; Smit et al., 2001; Williams et al., 2001). 
 
SHIV Macaque Models of HIV-1 Infection 
 As Vpu is only expressed in HIV-1 and some SIVCPZ strains, examination of the role of 
Vpu in viral pathogenesis is limited by the lack of a relevant animal model.  Chimeric viruses 
composed of HIV-1 tat, rev, vpu, and env genes in a genetic background of SIVMAC239, known 
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as SHIVs, have permitted extensive research on the role of HIV-1-specific genes products in a 
pathogenic macaque model (Figure 7).  These viruses provide an alternative non-human primate 
model of HIV-1 disease that allows for examination of unique biological motifs within the HIV-
1 gp160 as well as the biological role of the HIV-1 vpu.  The initial SHIV constructed (SHIV-4) 
was able to infect rhesus and pig-tailed macaques and cause a persistent infection, however no 
loss of CD4
+
 T cells nor development of an AIDS-like disease was observed (Li et al., 1992).  
This virus was subsequently passaged through a series of rhesus and pig-tailed macaques to yield 
pathogenic variants that replicate to extremely high titers, cause rapid CD4
+
 T cell loss and the 
development of AIDS within six months to one year post-inoculation.  Several of these SHIVs 
could cause end-stage renal and neurological disease similar to disease observed within HIV-1 
infected human hosts and also use CXCR4 as a coreceptor for virus entry into cells, which is not 
observed in SIV infections (Chen et al., 1997; Choe, 1998; Edinger et al., 1997; Joag et al., 1996; 
Joag et al., 1998a; Karlsson et al., 1997; Kimata et al., 1999; Liu et al., 1999; Narayan et al., 
1999; Raghavan et al., 1997; Reeves et al., 1999; Shibata et al., 1997; Stephens et al., 1997; 
Stephens et al., 2000).  The two main pathogenic variants used within our laboratory are 
SHIVKU-1bMC33 and SHIVKU-2MC4.  Both variants contain the US.HXB2 laboratory adapted 
subtype B vpu gene and have both been shown to cause rapid CD4
+
 T cell loss and development 
of AIDS (Liu et al., 1999; McCormick-Davis et al., 2000a).   
 During the derivation and selection of these viruses our laboratory provided evidence 
indicating that the Vpu protein plays an important role in the modification of SHIV pathogenesis.  
The initial indication was observed during the sequential characterization of the pathogenic 
SHIVKU-1 virus (an uncloned virus isolated from the cerebrospinal fluid of a pig-tailed macaque).  
This study demonstrated an association between the reversion of the vpu to an open reading 
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Figure 7.  Schematic representation of chimeric simian-human immunodeficiency 
viruses (SHIVs).  SIV encoded genes are shown in blue.  HIV-1 encoded genes are shown 
in yellow. 
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frame (start codon changed from ACG (SHIV-4) to ATG (SHIVKU-1)) and the selection of virus 
variants that caused a second phase of CD4
+
 T cell loss and the development of AIDS 
(McCormick-Davis et al., 1998).  This study also identified consensus mutations within the env 
and nef genes that correlated with the reversion of the vpu to an open reading frame (Joag et al., 
1997; McCormick-Davis et al., 1998).  The construction of the pathogenic molecular clone 
SHIVKU-1bMC33 that contained these consensus mutations in tat, rev, vpu, env, and nef was 
completed in order to create a reproducibly pathogenic virus clone (Stephens et al., 2002).  
Similarily, a reproducibly pathogenic clone of the SHIVKU-2 cell-free virus stock (an uncloned 
virus isolated from the CSF of a rhesus macaque), SHIVKU-2MC4, was constructed.  Of note is the 
ability of SHIVKU-2MC4 to cause severe glumerulosclerosis of the kidney and lentiviral 
encephalitis (Liu et al., 1999). 
 The role of Vpu in pathogenesis was indicated further with the construction of two 
separate deletion mutants.  In the first study, a mutant in which 42 of the total 82 amino acids of 
Vpu were deleted (Singh et al., 2001).  The Vpu protein expressed by this virus was truncated 
and non-membrane and the virus was designated vpuSHIVKU-1bMC33.  The inoculation of this 
virus into four separate macaques caused a moderate to no decline in CD4
+
 T cells in three 
macaques and a rapid decrease in CD4
+
 T cells and neurological disease in the final macaque 
(50O).  The severe CD4
+
 T cell loss and neurological disorder of macaque 50O was attributed to 
significant amino acid substitutions and deletions within the Nef and Env proteins.  Also, 
inoculation of a virus isolated from the lymph node of macaque 50O into four additional 
macaques demonstrated reproducible development of severe CD4
+
 T cell loss and development 
of AIDS (Singh et al., 2001).  These results taken to together support the conclusion that Vpu 
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does increase pathogenicity of SHIV however, individual macaques can select for compensating 
mutations within other genes, especially env and nef.   
 Finally, an additional study was completed to confirm the role of Vpu in pathogenesis 
with a virus where the entire coding region of vpu upstream of env gene was deleted 
(novpuSHIVKU-1bMC33).  Three macaques were inoculated with this virus and none developed a 
significant drop in CD4
+
 T cells or any disease manifestations (Stephens et al., 2002).  Taken 
together, these studies demonstrate that the HIV-1 Vpu protein plays a significant role in the 
pathogenesis of SHIV in macaques. 
 These SHIV viruses have allowed our laboratory to conduct extensive in vivo studies 
examining the role of specific amino acids and motifs within the Vpu protein in SHIV 
pathogenesis.  Of note are our studies involving the transmembrane domain (TMD) and hinge 
region of Vpu that contains the two casein kinase II phosphorylation sites.  Inoculation of 
macaques with a SHIV expressing a Vpu with a scrambled TMD (SHIVTM) that presumably 
disrupted ion channel function resulted in no CD4
+
 T cell loss and no development of any other 
disease manifestations (Hout et al., 2005).  Additional analysis of the role of the potential role of 
the ion channel function of Vpu was conducted using a SHIV expressing a Vpu in which the 
TMD was exchanged with that of the M2 protein of the Influenze A virus, a known viroporin 
(SHIVM2).  Macaques inoculated with SHIVM2 exhibited high viral loads, rapid CD4
+
 T cell loss 
and histological lesions consistent with lymphoid depletion similar to macaques inoculated with 
the parental SHIVKU-1bMC33 (Hout et al., 2006b).  Taken together, these results indicate that the 
TMD of Vpu is important for Vpu-mediated modification of SHIV pathogenesis and may 
potentially be associated with the ion channel properties of Vpu.     
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As mentioned, our laboratory also confirmed the role of the hinge region casein kinase II 
phosphorylated serine residues in Vpu modification of viral pathogenesis using a SHIV 
expressing a Vpu protein in which the two serine residues at positions 52 and 56 were substituted 
with glycines (SHIVS52,56G).  Of the four pig-tailed macaques inoculated with this SHIV, one 
exhibited rapid CD4
+
 T cell loss and histological lesions consistent with inoculation with a 
parental SHIV, while the others developed no or gradual CD4
+
 T cell loss.  It was later 
confirmed that the virus isolated from the macaque that developed rapid CD4
+
 T cell loss had 
reverted the glycine residues back to serines (Singh et al., 2003).  At the time this study was 
conducted, it was assumed that these phosphorylation sites were only required for Vpu-mediated 
down-modulation of CD4 from the cell surface, leading to the conclusion that this was an 
essential function of Vpu in enhancing pathogenesis in vivo.  However, more recent studies, 
which will be discussed later, have suggested a role for these residues in the enhancement of 
virion release function of Vpu as well as CD4 down-modulation and therefore indicates that the 
specific contributions of each of the functions of Vpu in modifying pathogenesis still remain 
unknown. 
 
Is Vpu an Ion Channel Protein? 
Several studies suggest that Vpu may have ion channel activity.   In the early descriptions 
of the Vpu protein, its structure was compared to the M2 protein of influenza as it had: a) a 
similar topology in the membrane having a short N-terminal region; b) an uncleaved 
leader/transmembrane domain and longer cytoplasmic domain; and c) a similar length and two 
casein kinase II phosphorylation sites.  The H
+
 ion channel of M2 has been extensively 
characterized and is considered the prototypical “viroporin.”  It is the best characterized of this 
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class of viral proteins, which also includes the 6K protein of Sindbis virus (SV), and the 2B 
protein of poliovirus, to name a few (Gonzalez and Carrasco, 2003).  The initial evidence that 
Vpu could form an ion channel arose from studies showing that expression of Vpu in frog 
oocytes results in a conductance that is weakly selective for cations (Ewart et al., 1996; Schubert 
et al., 1996b).  Modeling studies have suggested that a pentameric structure for the Vpu TMD 
would be optimal for the formation of such a channel (Cordes et al., 2001; Grice et al., 1997; 
Lopez et al., 2002; Sansom et al., 1998; Wray et al., 1999).   These same investigators later 
showed that two derivatives of the Na
+
/K
+
 antiporter amiloride, dimethyl amiloride (DMA) and 
hexamethylene amiloride (HMA), inhibited Vpu-mediated virion release and replication in 
monocyte-derived macrophage cultures (Ewart et al., 2002; Ewart et al., 2004).  However, we 
have found that these compounds affected the cell cycle regulation when T-cells were treated 
with concentrations required to inhibit viral replication (unpublished data). 
Previous studies of the M2 protein have shown that the H-X-X-X-W motif within the 
TMD was essential for ion channel activity with the histidine being the proton sensor and the 
tryptophan being the actual pore (Okada et al., 2001; Takeuchi et al., 2003; Tang et al., 2002).  
The drugs amantadine and rimantadine are known as M2 ion channel blockers (Okada et al., 
2001; Takeuchi et al., 2003; Tang et al., 2002).  Substitution of the M2 TMD histidine residue 
with an alanine resulted in a constitutively open channel, indicating its importance to channel 
activation (Holsinger and Lamb, 1991; Holsinger et al., 1994; Pinto et al., 1992; Tang et al., 
2002).  As previously mentioned our laboratory constructed a SHIV in which the TMD of Vpu 
was exchanged with the TMD of M2 (Hout et al., 2006b).  This virus, SHIVM2, was capable of 
causing a severe loss of CD4
+
 T cells and AIDS when inoculated into macaques.  In addition, we 
found that unlike the parental SHIVKU-1bMC33, replication of the SHIVM2 virus was sensitive to an 
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M2 ion channel blocker, rimantadine.  This study showed that drugs targeting the TMD of Vpu 
(in this case a chimeric Vpu with the TMD of the M2 protein) could reduce virus release from 
infected cells.  If one compares the sequence of the Vpu and M2 TMDs, the subtype B Vpu 
contains the sequence A-X-X-X-W in approximately the same position as M2 with the 
tryptophan being invariant in Vpu (McCormick-Davis et al., 2000b).   We subsequently showed 
that substitution of the alanine in this motif with a histidine residue resulted in a SHIV 
(SHIVVpuA19H) that became more sensitive to rimantadine than the SHIVM2 virus (Hout et al., 
2006a).   These results indicate that a single amino acid substitution within the TMD of the Vpu 
protein converts a rimantadine-resistant SHIV to a rimantadine-sensitive SHIV.  In a subsequent 
study, Park and Opella used NMR spectroscopy to analyze the structure of the TMD with the 
alanine to histidine substitution They showed that in C14 phospholipid bicelles, the unmodified 
TMD has a tilt angle of 30
o
 but that the A18H had a tilt angle of 41
o
, indicating that the 
introduced histidine altered the structure of the helix in the bicelle. These investigators also 
showed that the isoleucine at position 15 and the tryptophan at position 22 of A18H but not the 
unmodified TMD were perturbed by the presence of rimantadine. Finally, they showed that the 
rotation angle of H18 and W22 in A18H were almost identical to H37 and W41 of the M2 
protein (A18H, 41
o
, M2, 38
o
).  Taken together, these studies indicate that the TMD of Vpu can 
be designed to bind the influenza antiviral rimantadine.  Whether the ion channel activity of Vpu 
is functionally required for the virus release function is still controversial.  However, these 
studies do provide “proof of concept” that Vpu could be a target for novel antiviral drugs.  
 
 
 
57 
 
The Role of Vpu in CD4 Surface Down-Modulation  
During virus entry, the HIV-1 Env glycoprotein binds to the CD4 receptor and 
subsequently with a chemokine co-receptor, normally CCR5 on macrophages and CXCR4 on T 
helper cells. Thus, expression of CD4 molecules on the surface of cells is essential to HIV-1 
infection, however, once infection has occurred, expression of CD4 poses several problems in 
the virus replication cycle.  Newly synthesized CD4 molecules are capable of forming complexes 
with the Env precursor gp160 in the endoplasmic reticulum (ER) preventing transport and 
processing of the two cleavage products, gp120 and gp41, to the site of assembly (Crise et al., 
1990; Jabbar and Nayak, 1990; Levesque et al., 2003; Stevenson et al., 1988; Willey et al., 
1992b).  High CD4 surface expression can lead to the retention of nascent virions at the plasma 
membrane and/or superinfection of cells by cell-free or cell-associated virus (Klimkait et al., 
1990; Schubert et al., 1996a; Vincent et al., 1993; Wildum et al., 2006; Yao et al., 1993).  
Finally, CD4 surface expression has been shown to decrease viral infectivity by incorporating 
CD4 molecules and inactive CD4-gp120 complexes into the virion (Cortes et al., 2002; Levesque 
et al., 2003; Tanaka et al., 2003).  While the physiological significance of each of these potential 
complications is still under investigation, there is a clear indication that CD4 degradation is 
important for HIV-1 replication. HIV-1 has developed several mechanisms to down-modulate 
both intracellular and surface expression of CD4 molecules promoting productive virion 
assembly and release.  These mechanisms are mediated by two accessory proteins encoded for 
by HIV-1: Nef and Vpu.  These two proteins regulate CD4 expression at different cellular 
compartments and by distinct mechanisms.  HIV-1 Nef functions by acting on mature CD4 
molecules present at the plasma membrane or in late endosomes.  Nef accelerates clathrin-
mediated endocytosis of CD4 molecules from the cell plasma membrane and targets them to the 
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lysosomes for destruction (Garcia and Miller, 1991; Piguet et al., 1998; Piguet et al., 1999a).   
HIV-1 Vpu is expressed from the same mRNA as Env and is responsible for counteracting the 
effects of CD4 molecules early within the biosynthetic pathway.  The general mechanism by 
which HIV-1 Vpu counteracts the problems presented by CD4 molecules has been well studied.  
Research conducted over the past several years has focused on the characterization of specific 
molecular components involved in this process and the consequences that this CD4 down-
modulation has on pathogenesis and cellular homeostasis in vitro and in vivo (Figure 8). 
Following synthesis of Vpu in the ER, it binds to a specific motif, LSEKKT, within the 
cytoplasmic domain of CD4 between residues 414 and 419 (Bour et al., 1995; Chen et al., 1993; 
Lenburg and Landau, 1993; Vincent et al., 1993).  Binding of the CD4 molecule by Vpu is 
required for its subsequent degradation; however, it is not sufficient (Bour et al., 1995; 
Buonocore et al., 1994; Schubert et al., 1994; Tiganos et al., 1997).  Previous studies have shown 
that both α-helical domains within the CD of HIV-1 Vpu are structurally important for CD4 
down-modulation from the cell surface with only the first α-helix being required for binding 
(Tiganos et al., 1997).  These investigators showed that disruption of the predicted secondary 
structure of the two cytoplasmic α-helical domains eliminates Vpu-mediated CD4 surface down-
modulation (Tiganos et al., 1997).  These investigators showed that expression of a Vpu protein 
with amino acid substitutions in the first α-helical domain but not in the second α-helical domain 
affected binding to CD4.  Also, deletion of the C terminal 23 residues within HIV-1 Vpu strain 
HXB2 or substitution of residues V65 thru M71 with the amino acid sequence ALGMAL, 
eliminates Vpu-mediated CD4 surface down-regulation, but not CD4 binding (Pacyniak et al., 
2005; Tiganos et al., 1997).  Taken together, these studies indicate that primary and secondary 
structures are important for Vpu-mediated CD4 surface down-regulation and that the first α- 
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Figure 8.  Down-modulation of cell surface CD4 expression by Vpu.  In the rough 
endoplasmic reticulum, Vpu binds CD4 through an interaction between the first α-helix 
within the cytoplasmic domain of Vpu and a specific motif within the cytoplasmic 
domain of CD4 (LSEKKT).  Vpu is phosphorylated by several different isoforms of 
casein kinase II.  This phosphorylation recruits and binds the cellular F-box protein β-
TrCP.  CD4 is then ubiquitinated via the SCF
β-TrCP
 E3 Ub ligase complex after which it 
is shunted to the proteasome for degradation through an unknown mechanism.   
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helical region of the cytoplasmic domain of Vpu appears to be involved in the interaction with 
CD4.  We recently completed a study that systematically analyzed the importance of each amino 
acid in the predicted second α-helical domain (Hill et al., 2010).  In this study, each amino acid 
was substituted with an alanine residue.   We identified an additional amino acid, L63 within the 
second α-helix of HIV-1 Vpu strain HXB2 that is required for CD4 surface down-modulation 
(Hill et al., 2010).  In this study, we also identified a second amino acid, V68, which is necessary 
but is not sufficient for complete CD4 surface down-regulation.  The L63 residue is conserved 
among all HIV-1 Vpu subtypes.  While Tiganos and colleagues showed that substitution of this 
residue with a proline did disrupt Vpu-mediated CD4 degradation, a proline substitution 
eliminated the ability to distinguish between a primary role of the hydrophobic amino acid 
residue at this position and its structural role in the predicted second α-helical domain (Tiganos 
et al., 1997).  Substitution of this residue with alanine or valine, which maintains the predicted 
secondary structure, did not disrupt binding to CD4 or β-TrCP, but did eliminate CD4 surface 
down-modulation.  Interestingly, substitution of this residue with either an isoleucine or a 
glycine resulted in partial function in CD4 down-modulation, suggesting that the length of the 
side chain is important.  Similar results were obtained for mutant Vpu with similar substitutions 
of the valine at position 68 although to a lesser extent.  These mutants will be useful in 
determining the specific role of the second α-helix in the process of CD4 degradation. 
The Vpu protein is phosphorylated at residues S52 and S56 (positions from HIVNL4-3 
clone) present within two highly conserved casein kinase II phosphorylation sites (S/T-XX-D/E) 
(Schubert et al., 1994).  This phosphorylation is required for CD4 degradation, but not CD4 
binding (Bour et al., 1995; Paul and Jabbar, 1997).  The phosphorylated Vpu protein recruits and 
binds the cellular F-box protein β-TrCP generating a CD4-Vpu-β-TrCP ternary complex (Binette 
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et al., 2007; Margottin et al., 1998).  The signal for recognition of ligands, including HIV-1 Vpu, 
by β-TrCP is the phosphorylation of one or two serine residues present within a conserved motif, 
DS
P
GxxS
P
.  Both phosphoserines have distinct orientations within the protein complex that allow 
them to make specific contacts with the WD-repeat β-propeller domain of β-TrCP (Coadou et al., 
2003; Evrard-Todeschi et al., 2006; Megy et al., 2005; Wu et al., 2003).  Biochemical analyses 
of the HIV-1 Vpu protein showed that the first phosphoserine interacts with the binding pocket 
of the β-TrCP WD-repeat domain (residues Y271, R285, S309 and S325). The second 
phosphoserine interacts with a basic patch in the β-TrCP WD-repeat domain centered around 
residue K365.  The hydrophobic amino acids surrounding the DS
P
GxxS
P
 motif also strengthen 
the interaction of Vpu with the β-TrCP by forming electrostatic, hydrogen and van der Waals 
bonds with specific residues within the binding pocket (Coadou et al., 2003; Evrard-Todeschi et 
al., 2006; Megy et al., 2005; Wu et al., 2003).     
The F-box protein β-TrCP recruits the other components of the E3 ubiquitin ligase 
complex (Skp1 and Cullin1) and mediates the ubiquitination of the CD4 molecule in trans.  A 
homologue of β-TrCP known as β-TrCP2 or HOS was shown to be sufficient for Vpu-mediated 
CD4 down-modulation (Besnard-Guerin et al., 2004; Butticaz et al., 2007).  Silencing of both 
homologues with siRNA was required for the inhibition of Vpu-mediated CD4 surface down-
regulation (Butticaz et al., 2007).  The process by which Vpu mediates CD4 down-regulation 
resembles the ER-associated protein degradation process (ERAD); however, the exact 
mechanism by which CD4 is poly-ubiquitinated and transported to the cytosol for degradation is 
not completely understood.  Meusser and Sommer reconstituted HIV-1 Vpu-mediated CD4 
degradation in Saccharomyces cerevisiae to determine the role of ERAD proteins in this process 
(Meusser and Sommer, 2004).  In this system, CD4 was translocated across the ER membrane 
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but, unlike human cells where CD4 is stable the CD4 was rapidly degraded in the absence of 
Vpu and depended on the presence of the yeast ERAD proteins and a functional proteasome.  
The rapid degradation of CD4 was eliminated in yeast defective in ERAD-dependent 
ubiquitination ligases, but could be restored by the expression of Vpu and human β-TrCP.  Also, 
in the ERAD-defective yeast CD4 was shown to be ubiquitinated in the presence of 
phosphorylated Vpu and β-TrCP providing evidence supporting the trans-polyubiquitination of 
the CD4 by the SCF
β-TrCP
 E3 Ub ligase complex.  The degradation of CD4 was shown to be 
dependent on the presence of four lysine residues within the cytosolic tail of CD4 (Meusser and 
Sommer, 2004).  Similar results were obtained for the polyubiquitination of the CD4 cytoplasmic 
domain mediated by the SCF
β-TrCP
 E3 Ub ligase complex in human cells (Binette et al., 2007).  
However, CD4 down-regulation was not completely dependent on ubiquitination of the four 
cytoplasmic lysine residues suggesting a role for other serine or threonine residues present within 
the CD4 cytoplasmic tail.  This study also provided evidence for the involvement of an ERAD 
protein, the AAA ATPase (ATPases Associated with diverse cellular Activities) Cdc4/p97 by 
showing disruption of Vpu-mediated CD4 down-regulation through the expression of a 
transdominant negative mutant of this ATPase.  This protein is involved in dislocation of ERAD 
substrates and this group also provides evidence for dislocation of the CD4 molecule that is 
dependent on its poly-ubiquitination.  These data provide a better understanding of the specific 
mechanism by which Vpu mediates CD4 degradation and continued studies are needed to 
determine all proteins involved in the process and possible targets for therapeutics. 
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The HIV-1 Vpu protein has been found to escape degradation during the process of CD4 
down-regulation and degradation (Margottin et al., 1998; Schubert et al., 1994).  In a recent 
study Vpu degradation was shown to occur in cells arrested in early mitosis by a proteasome-
mediated process (Estrabaud et al., 2007).  The Vpu protein was shown to become 
phosphorylated at a downstream phosphoserine residue (S61 in HIVHXB2) inducing recruitment 
of an unknown E3 ubiquitin ligase complex for ultimate degradation (Estrabaud et al., 2007).  
Mutation of this residue resulted in the accumulation of HIV-1 Vpu within cells and increased 
release of HIV-1 particles from HeLa cells in comparison to HeLa cells infected with wild-type 
virus.  Vpu-mediated CD4 degradation was not affected by mutation of this serine residue.   
These investigators indicated that phosphorylation of this residue was involved in regulating Vpu 
degradation.  We previously analyzed the Vpu sequences from over 100 strains of HIV-1 group 
M with representation of all different subtypes (McCormick-Davis et al., 2000b).  Our results 
indicate that a serine residue at this position is a relatively rare occurrence (BRU, HXB2 strains) 
and extrapolation to Vpu proteins from “clinical isolates” may not be possible.  Whether the 
serine present at position 64 in the majority of HIV-1 Vpu proteins is phosphorylated and can 
substitute for the serine at position 61 remains to be elucidated.  While our results are in 
agreement regarding serine 61 and degradation of Vpu, substitution of residues L63 and V68 
with alanines also resulted in slower turnover of HXB2 Vpu in transfected cells (Hill et al., 
2010).   Taken together, these results indicate that other amino acids within the second α-helical 
domain also contribute to the regulation of Vpu degradation.  
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The Role of Vpu in Enhanced Virion Release 
The ability of Vpu to enhance the release of virions from infected cells exemplifies viral 
antagonism of an intrinsic host defense mechanism.  The interferon-induced transmembrane 
protein BST-2 (CD317, HM1.24 or tetherin) restricts the release of nascent virions from the cell 
surface, while the Vpu protein relieves this restriction.  Although the mechanisms involved in 
this process are not fully elucidated, current data suggest that BST-2 blocks release by directly 
retaining mature, nascent HIV-1 virions on the cell surface, while Vpu counteracts BST-2 by 
removing it from sites of virion assembly and budding at the plasma membrane.  These 
relationships allow Vpu to be considered an antagonist of the innate, interferon-induced, immune 
response to enveloped viruses. 
BST-2 is an interferon-induced, lipid raft-associated, type II integral membrane protein 
with an unusual topology.  It contains a short cytoplasmic N-terminus followed by a 
transmembrane domain, a central extracellular domain predicted to form a coiled-coil that 
contains two N-linked glycosylation sites, and a C-terminal cleavage site predicted to form a 
glycosyl-phosphatidylinositol (GPI) anchor (Ishikawa et al., 1995; Kupzig et al., 2003).  This 
unusual membrane topology in which BST-2 interacts with the lipid bilayer twice, has suggested 
a membrane-spanning model of tethering in which one end of BST-2 is embedded in the 
membrane of the host cell and the other in the membrane of the budded virion.  As a GPI-
anchored protein, BST-2 is found within the cholesterol-enriched lipid domains from which 
HIV-1 (and other enveloped viruses) bud (Kupzig et al., 2003; Nguyen and Hildreth, 2000; Ono 
et al., 2004; Ono and Freed, 2001).  The protein is found on the plasma membrane and within the 
endosomal system, including the trans-Golgi network (Dube et al., 2009; Kupzig et al., 2003; 
Neil et al., 2008; Van Damme et al., 2008).  BST-2 co-localizes with HIV-1 Gag in a punctate 
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distribution along the plasma membrane of cells expressing HIV-1, consistent with a direct 
tethering mechanism (Jouvenet et al., 2009; Mitchell et al., 2009; Neil et al., 2008; Van Damme 
et al., 2008).  This mechanism appears to involve the incorporation of BST-2 into nascent virions 
(Perez-Caballero et al., 2009).  So far, the molecular requirements for virion-tethering within 
BST-2 include the cytoplasmic domain, the predicted coiled-coil ectodomain, and the GPI 
anchor (Goffinet et al., 2009; Neil et al., 2008).  BST-2 forms disulfide linked dimers and is 
heterogeneously glycosylated (Andrew et al., 2009; Barlow et al., 2003; Kaletsky et al., 2009; 
Perez-Caballero et al., 2009).  However, the importance of dimerization and glycosylation in 
BST-2 function is not completely understood.  Kaletsky and colleagues treated 293T cells 
expressing the HIV Gag-Pol and human BST-2 with DTT (dithiothreitol) and showed that it had 
no ability to elute restricted HIV from the cell surface, suggesting that cysteine-mediated 
dimerization alone does not mediate the restriction of virion release (Kaletsky et al., 2009).  
However, the exact role of glycosylation and dimerization in conjunction with other protein-
protein interactions in the tethering process remain unknown.  The ability of BST-2 to restrict the 
release of virus like particles (VLPs) derived from viral proteins from members of diverse viral 
families including all retroviruses tested, filoviruses, and an arenavirus (Lassa), suggests that it 
does not interact with any specific viral component, but rather the viral lipid envelope, an 
unknown receptor, or itself (Jouvenet et al., 2009).  In the latter scenario, cell-associated BST-2 
would interact with virion-associated BST-2, potentially via the protein’s coiled-coil 
extracellular domain.  A recent study by Andrew and colleagues provided further insight into the 
mechanism by which BST-2 restricts HIV-1 release (Andrew et al., 2009).  Disruption of 
individual intermolecular disulfide bonds by point and 2 or 3 mutations of three cysteine residues 
within the extracellular domain (C53A, C63A, or C91A) revealed that no individual cysteine was 
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sufficient to abolish dimerization or antiviral activity of the BST-2 protein.  However, mutation 
of all three cysteine residues abrogated both dimer formation and antiviral activity of the protein 
against Vpu deficient HIV-1.  Further analysis of the triple cysteine mutant provided evidence 
that the lack of antiviral activity was not due to a mislocalization of the protein.  This group also 
used point mutational analysis to investigate the role of glycosylation in BST-2 function.  The 
two asparagines residues potentially involved in glycosylation (N65 and 92) were mutated in 
combination to glutamine and the ability of the mutant to inhibit HIV-1 release was analyzed.  
The results indicated that the mutant inhibited Vpu deficient HIV-1 release to a similar extent as 
a wild-type BST-2 protein suggesting that glycosylation is not required for the antiviral activity 
of BST-2.  Also of note, is that neither the triple-cysteine mutant nor the glycosylation deficient 
mutant affected Vpu sensitivity (Andrew et al., 2009). 
Another study by Perez-Caballero and colleagues also analyzed the role of cysteine-
mediated dimerization and glycosylation in BST-2 antiviral activity (Perez-Caballero et al., 
2009).  This study used a series of point mutations, deletions and domain exchanges within the 
BST-2 protein in order to elucidate the importance of these residues and domains for antiviral 
activities.  Similar to the Andrew’s study, this group also determined that any of the three 
cysteine residues could mediate dimerization, and that mutation of all three residues completely 
abolished dimer formation.  In slight contrast to the previous study this group found that while 
mutation of all three cysteines significantly decreased the antiviral activity of the protein, a weak 
phenotype was still observed.  The effects of glycosylation on the antiviral activities of BST-2 
were also evaluated through mutagenesis of the two asparagine residues within the extracellular 
domain (N65A and N92A).  They found that N92A but not N65A markedly impaired the 
antiviral properties of BST-2.  In stark contrast to the Andrew’s study, amino acid substitutions 
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at both positions essentially inactivated the protein.  This group evaluated the biological 
properties of these mutant proteins along with a secreted protein that lacked both the N-terminal 
transmembrane domain as well as the putative GPI anchor.  These results revealed that 
glycosylation was essential for secretion and localization to the plasma membrane, suggesting a 
role in proper folding and transport and potentially not for direct tethering of virions.  Deletion of 
the majority of the coiled-coil domain inhibited BST-2 function, but allowed for localization to 
the plasma membrane and formation of disulfide linked homodimers.  Deletion of either the N-
terminal transmembrane domain or the GPI anchor signal completely abolished the block of 
particle release, however both of these mutants were incorporated into budding virions as dimers.  
This group further analyzed the potential orientation of the BST-2 protein within the cellular and 
viral membranes by using these two mutants.  Interestingly, the delTM mutant was able to be 
completely digested with subtilisin treatment of purified virions suggesting that this protein was 
anchored in the viral membrane by only the GPI anchor.  This group also analyzed BST-2 
incorporation into virions using gold immunolabeling and backscatter electron detection 
providing further evidence for virion incorporation.  These experiments revealed that the delGPI 
mutant BST-2 preferentially localized to sites of particle budding while the WT and delTM BST-
2 proteins were associated with budding particles but were not enriched at sites of assembly.  
This group suggests that the N-terminal transmembrane domain is essential for localization to 
these sites.  The importance of the specific amino acids within the BST-2 protein for interaction 
with viral proteins is still under analysis, however this group developed an artificial BST-2 
protein (art-tetherin) to test the role of the domains in antiviral activity.  This protein consisted of 
the N-terminal region of the transferrin receptor (TfR), the 75 residue coiled-coil from the 
cytoplasmic dimeric protein, dystrophia myotonica protein kinase (DMPK), an HA-tag following 
69 
 
the coiled-coil domain, and the C-terminal region of the urokinase plasminogen activator 
receptor (uPAR).  This artificial protein inhibited the release of both HIV-1 and Ebola virion 
like-particles, however did not display a susceptibility to the HIV-1 Vpu protein that has been 
previously reported (Perez-Caballero et al., 2009).  The construction and analysis of this artificial 
protein provides a significant advance in the development of potential therapeutics.  While this 
study provides evidence for a direct mechanism of tethering for the BST-2 protein it does not 
completely eliminate the possibility for other indirect mechanisms of action.   
Vpu relieves the restriction of virion release imposed by BST-2.  This relationship 
accounts for the long observed vpu phenotype of enhanced efficiency of viral release, and it 
explains why certain cell types such as HEK293 do not support this phenotype as they do not 
express BST-2 constitutively.  To counteract BST-2, Vpu appears to remove the protein from 
sites of virion assembly along the plasma membrane (Jouvenet et al., 2009; Mitchell et al., 2009; 
Van Damme et al., 2008).  In cells expressing Vpu, the overall level of BST-2 at the cell surface 
is reduced (Bartee et al., 2006; Gupta et al., 2009a; Mitchell et al., 2009).  This reduction occurs 
rapidly, within sixteen hours of viral gene expression, consistent with the time frame in which 
progeny virions begin to bud from infected cells.  The molecular mechanisms by which Vpu 
modulates BST-2 likely involves an interaction between the two proteins and the recruitment of a 
specific SCF E3 ubiquitin ligase complex containing the substrate adaptor β-TrCP to BST-2 by 
Vpu (Gupta et al., 2009a; Mitchell et al., 2009).  In support of an interaction between Vpu and 
BST-2, the proteins co-localize microscopically in endosomal vesicles and can be co-
immunoprecipitated from cellular lysates (Douglas et al., 2009; Neil et al., 2008; Van Damme et 
al., 2008).  Though not yet formally shown, the transmembrane domains (TMDs) of Vpu and 
BST-2 likely mediate this interaction within the lipid bilayer.  Conversely, BST-2 orthologues of 
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non-human primates are neither virologically counteracted nor removed from the cell surface by 
Vpu (Gupta et al., 2009a; McNatt et al., 2009; Rong et al., 2009).  This resistance to Vpu maps to 
the BST-2 TMD (Gupta et al., 2009a; McNatt et al., 2009; Rong et al., 2009).  McNatt and 
colleagues constructed plasmids expressing human bst-2 genes with point mutations within the 
TMD that correlated with residues found in the TMD of the rhesus BST-2 protein (McNatt et al., 
2009).  This group concluded that no single change in the human BST-2 TMD abolished Vpu 
sensitivity.  However, several combinatorial mutations elicited an increase in resistance 
including delGI,T45I (where residues G25 and I26 were deleted and residue T45 was substituted 
with an isoleucine) and delGI,I33V,I36L (where residues G25 and I26 were deleted, residue I33 
was substituted with a valine and residue I36 was mutated to a leucine).  McNatt also noted that 
residues V30 and P40 impart a distinct contribution to Vpu sensitivity.  Exchange of the TMDs 
from human and rhesus BST-2 conferred complete resistance of human BST-2 and sensitivity of 
the rhesus BST-2 protein to HIV-1 Vpu (McNatt et al., 2009).  Gupta also emphasized the 
importance of residue T45 in the human BST-2 protein, concluding that mutation of this residue 
to an isoleucine substantially reduces the sensitivity of human BST-2 to HIV-1 Vpu, without 
affecting antiviral activity.  These investigators also noted that substitution of this residue 
abrogates the Vpu mediated depletion of cellular steady state levels of BST-2, providing 
additional evidence in favor of the importance of BST-2 degradation for the virus to overcome 
its antiviral effects (Gupta et al., 2009a).  Both groups, as well as that of Rong and colleagues, 
agree that the TMD of human BST-2 is not only necessary but is also sufficient for the species 
specificity of Vpu-responsiveness (Gupta et al., 2009a; McNatt et al., 2009; Rong et al., 2009).  
These data support a model in which the TMDs of the two proteins interact, potentially directly, 
although the structural basis of this interaction remains to be elucidated.  The study by Perez-
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Caballero and colleagues provided further evidence for the interaction of HIV-1 Vpu with the 
transmembrane domain of BST-2 and the incorporation of BST-2 into virions (Perez-Caballero 
et al., 2009).  This group hypothesized that if the incorporation of BST-2 into virions was 
important for the restriction of particle release, then the HIV-1 Vpu protein should prevent 
incorporation of the delGPI mutant BST-2 but have no affect on the delTM mutant 
incorporation.  Analysis of virions from 293T cells stably expressing these mutant proteins in the 
presence and absence of HIV-1 Vpu provided evidence in favor of this hypothesis (Perez-
Caballero et al., 2009).  
 The importance of Vpu-mediated surface down-regulation and the intracellular depletion 
of BST-2 with respect to the virologic effect of Vpu in spreading infections is not without 
controversy.  Several groups have shown that HIV-1 Vpu causes intracellular depletion and 
surface down-regulation of human BST-2 in cell lines including HeLa, HEK 293T (exogenously 
expressed), and A3.01 CD4-positive T lymphoid cells, and these effects correlate with the 
enhancement of virion release (Bartee et al., 2006; Douglas et al., 2009; Goffinet et al., 2009; 
Gupta et al., 2009a; Mitchell et al., 2009; Van Damme et al., 2008).  However, Miyagi and 
colleagues further investigated the roles of HIV-1 Vpu and the surface down-regulation and 
intracellular depletion of BST-2 on the kinetics of viral replication during spreading infections 
(Miyagi et al., 2009).  This group observed minimal changes in the surface expression of BST-2 
during the course of infection of CEMx174 and H9 cells, while vpu clearly contributed to the net 
production of cell-free virions.  The authors concluded that Vpu enhances virus release in the 
absence of either surface down-regulation or intracellular depletion of BST-2.  This conclusion 
relies on the assumptions that the accumulation of cell-free virions during spreading infections is 
a simple correlate of the efficiency of virion release from infected cells and that no other 
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functions of Vpu are relevant to the rate of viral spread.  These assumptions may not be correct: 
the absence of vpu enhances the rate of cell-to-cell viral spread (Gummuluru et al., 2000) and the 
down-regulation of CD4 by Vpu may affect viral propagation, as reviewed above.  In contrast to 
the conclusions of Miyagi et al., Rong and colleagues showed that BST-2 specifically decreased 
the replication rate of vpu-negative HIV-1 in a dose-dependent manner (Rong et al., 2009). 
These investigators used an inducible system to express BST-2 in the CD4-positive T cell line 
SupT1, which lacks endogenous BST-2. The ability of Vpu to counteract BST-2 in this system 
directly correlated with the depletion of BST-2 levels.  
Several questions regarding the mechanism of down-regulation of BST-2 by Vpu remain 
to be answered. In addition to interacting with BST-2, Vpu recruits to BST-2 a β-TrCP-
containing E3 ubiquitin ligase complex to modulate the protein either directly or indirectly via 
ubiquitination (Douglas et al., 2009; Mangeat et al., 2009; Mitchell et al., 2009).  As discussed 
above, the cytoplasmic domain of Vpu contains the sequence DS
p
GxxS
P
 which recognizes the 
cellular proteins β-TrCP-1 and -2, which are F-box proteins and substrate adaptors for SCF E3 
ubiquitin-ligase complexes.  The interaction of Vpu with β-TrCP was first described as the basis 
for the down-regulation of CD4 by Vpu, however, evidence that a related process occurs in the 
case of BST-2 include the observations that: 1) the DS
P
GxxS
P
 sequence in Vpu is required both 
for optimal virion release and the down-regulation of BST-2, and 2) expression of a dominant-
negative β-TrCP or knockdown of endogenous β-TrCP inhibits both the Vpu-mediated 
enhancement of virion release and the down-regulation of BST-2.  Although a consensus is now 
emerging regarding a key role of β-TrCP as a Vpu co-factor in counteracting BST-2, a number of 
questions remain.  First, is BST-2 ubiquitinated in response to Vpu?  Second, what is the 
consequence of such Vpu-mediated ubiquitination?  Evidence has been presented in support of 
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various outcomes: proteasomal degradation of BST-2, lysosomal degradation of BST-2, and/or 
post-endocytic endosomal trapping with partial lysosomal degradation (Douglas et al., 2009; 
Goffinet et al., 2009; Gupta et al., 2009a; Gupta et al., 2009b; Iwabu et al., 2009; Mitchell et al., 
2009).  In support of the latter, the plasma membrane clathrin adaptor AP-2 and endosomal 
acidification are required for optimal down-regulation of BST-2 from the cell surface by Vpu 
(Mitchell et al., 2009).  The K5 protein of the Kaposi Sarcoma Virus has also been identified as 
an antagonist of human BST-2, and the data supporting this inhibition parallel to some extent the 
results reported for the Vpu protein (Mansouri et al., 2009).  The observation that lysines in the 
short amino-terminal domain of BST-2 are ubiquitinated by the K5 protein resulting in the rapid 
degradation of BST-2 provides increased incentive for determining if and how BST-2 is 
ubiquitinated in response to Vpu.  Such information would provide a better understanding of the 
fate of BST-2 following its interaction with Vpu, and it might embrace multiple mechanisms for 
the down-regulation and degradation of BST-2, some of which could be cell-type specific.  
Notably, cell type differences and/or experimental formats (transient expression of exogenous 
BST-2 versus constitutive expression of endogenous protein) could contribute to the different 
mechanisms proposed thus far for the counteraction of BST-2 by Vpu.  Nevertheless, a model is 
now apparent in which the transmembrane and cytoplasmic domains of Vpu each contribute to 
the counteraction of BST-2: the transmembrane domain via an interaction with BST-2 and the 
cytoplasmic domain via recruitment of an E3 ubiquitin ligase complex to cellular membranes 
containing BST-2.  The effect of these interactions is the altered localization of BST-2 within the 
cell and the counteraction of restricted virion release (See Figure 9 for potential model). 
As is a caveat of all in vitro studies, the importance and validity of these conclusions will 
not be fully substantiated until observed within a physiologically relevant in vivo host system. 
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Figure 9.  Possible mechanisms by which Vpu enhances virion release from cells.  Vpu 
allows efficient transport of Env proteins to the site of virion assembly.  Vpu is 
synthesized on the rough endoplasmic reticulum and binds CD4 releasing gp160 for 
processing and cleavage into gp120/gp41 which may be transported to the site of 
assembly.  Vpu may function as a viroporin.  Vpu resides within the rough endoplasmic 
reticulum, trans-Golgi network and at the cell surface.  It is unknown whether the ability 
of Vpu to serve as an ion channel functions to enhance virion release at any of these 
intracellular locations.  Vpu removes BST-2 from the site of virion assembly.  In the 
absence of Vpu, BST-2 is expressed at the cell surface.  The orientation used by BST-2 to 
“tether” virions to the surface remains unknown, however, the GPI anchor resides 
within lipid rafts where HIV-1 virions assemble and bud.  This potentiates a model 
where the N-terminal transmembrane remains anchored within the cell membrane 
while the C-terminal GPI anchor is embedded in the virion membrane.  BST-2 is 
internalized from lipid rafts on the cell surface by clathrin-mediated endocytosis.  Two 
tyrosine residues within the N-terminal cytoplasmic tail are required for an interaction 
with a α-adaptin of the AP-2 complex (Masuyama et al., 2009).  It is possible that in the 
presence of Vpu the targeting of endocytosed BST-2 containing vesicles is altered for 
endo-lysosomal degradation.  Vpu may also potentially interact with BST-2 in trans-
Golgi network and target it for lysosomal or proteasomal degradation.    
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Pig-tailed (pt) and rhesus (rh) macaque BST-2 proteins have been shown to have antiviral effects 
on HIV-1 replication that are not Vpu sensitive (McNatt et al., 2009).  However, recent studies 
have determined that SIV Nef is an inhibitor of these orthologues (Jia et al., 2009; Zhang et al., 
2009).  More research is needed to increase our understanding of the mechanisms by which BST-
2 restricts virion release and how Vpu and Nef antagonize this restriction. This will allow us to 
establish the most effective way to study the role of these interactions in vivo and to determine 
the potential of BST-2 as an antiviral therapeutic.  Further research is also needed to determine if 
specific interactions (indirect or direct) exist between the Vpu and/or the Nef proteins and 
pt/rhBST-2 proteins that could be used to study the effects of BST-2 in vivo.  The 
SHIV/macaque model of disease is an excellent tool for studying the in vitro and in vivo effects 
of human and non-human primate BST-2 proteins, because it expresses both the HIV-1 Vpu 
protein and the SIVmac239 Nef gene.  SHIVs could potentially be engineered to express Vpu or 
Nef proteins with mutations that abrogate specific interactions without affecting other functions 
of both proteins.  The intrinsic antiviral defenses encoded by human and non-human primate 
hosts now includes the TRIM family, APOBEC3 and BST-2 proteins, providing multiple 
avenues to the development of approaches to the design of novel therapies.  The analysis of these 
endogenous antiviral agents also provides evidence of evolutionary pressure for multiple families 
of viruses to acquire new or positively selected genes that contribute to species tropism and the 
barriers to cross-species transmission. 
A recent study by a collaborative group analyzed the role of BST-2 in the adaption of 
Vpu and Nef proteins as well as the potential effects of BST-2 on the evolution of pandemic and 
non-pandemic HIV-1 strains (Sauter et al., 2009).  This group analyzed a panel of vpu constructs 
representing nearly all primate lentiviruses that encode this gene including, HIV-1 groups M, N 
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and O; SIVcpz; SIVgor; SIVgsn; SIVmon; and SIVmus.  The salient results of this study were a 
selection of the Vpu proteins as a BST-2 antagonist following the transmission of SIVcpz  to 
humans and the differences in the HIV-1 groups both in CD4 down-regulation and BST-2 
antagonism.  The strains representing the HIV-1 group M both degraded CD4 and used Vpu to 
antagonize BST-2 rather than Nef of SIVcpz.  In contrast, the strains that represent HIV-1 group 
N antagonize BST-2 but do not degrade CD4, while HIV-1 group O strains down-modulate CD4 
but do not antagonize BST-2.  This combination of functions may have contributed significantly 
to the ability of HIV-1 group M strains but not groups N and O to cause the current HIV-1 
pandemic.  This group observed similar conserved features in all the primate lentivirus Vpus as 
previously reported by our group (Gomez et al., 2005; Sauter et al., 2009) including a 
hydrophobic N-terminal transmembrane domain; a putative central α-helical region containing 
one or two serine residues known to be phosphorylated and required for CD4 down-regulation 
(Paul and Jabbar, 1997; Schubert and Strebel, 1994); and an acidic C-terminal region.  All Vpu 
proteins except those representative of the HIV-1 group N strains induced CD4 degradation to 
varying degrees.  These results provide evidence for the importance of CD4 degradation in 
causing disease since the HIV-1 group O strains are able to cause disease in humans, even 
though this group of viruses has not caused a pandemic.  The Vpu proteins isolated from SIVcpz, 
SIVgor and HIV-1 group O were not efficient at antagonizing BST-2 derived from their 
respective hosts or those from other species.  Only HIV-1 Vpus (group M and N) were capable 
of counteracting BST-2 proteins derived from humans, chimpanzees and gorillas.  The Vpu 
homologs from SIVgsn, SIVmon and SIVmus were able to antagonize BST-2 proteins both from 
their respective hosts as well as from other monkey species.  Due to the inability of SIVcpz, 
SIVgor and HIV-1 group O Vpus to counteract BST-2 proteins, this group analyzed the 
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antagonistic abilities of their respective Nef proteins.  The Nef proteins from SIVcpz and SIVgor 
were shown to effectively counteract the BST-2 proteins derived from their respective hosts but 
not human BST-2.   The sensitivity of these BST-2 proteins was mapped to the same five amino 
acid region identified by others in the N terminal cytoplasmic domain (Jia et al., 2009; Sauter et 
al., 2009; Zhang et al., 2009).  This group identified trends among all species of viruses and 
BST-2 proteins with a few exceptions.  These few exceptions underline the importance of 
understanding the role of specific amino acids within both the restriction factor proteins as well 
as those of the viral proteins for the development of potential therapeutics.  This study provides 
multiple lines of evidence for the facilitation of cross-species transmission by evolutionary 
pressure imposed by endogenous restriction factors.  These adaptations may be key in 
understanding the ability of specific strains to cause a pandemic and the possible development of 
therapeutics targeting these regions.  
 
The Role of BST-2 in Release of Primate Lentiviruses Lacking a Vpu Protein 
Recent studies have addressed the question of how retroviruses that lack a vpu gene, 
including multiple primate lentiviruses, are efficiently released from cells that express BST-2.  
Two reports have investigated the ability of SIVmac239 Env and Nef proteins to counteract 
multiple primate BST-2 proteins (Jia et al., 2009; Zhang et al., 2009).  While SIVmac239 Env was 
found to possess no antagonistic abilities towards either rhesus or pig-tailed BST-2 (rhBST-2; 
ptBST-2) proteins, the SIVmac239 Nef protein did.  The ability of several different Nef proteins 
from different primate lentiviruses to counteract various primate BST-2 proteins revealed a 
species-specific bias towards antagonism (Zhang et al., 2009).  Both groups showed that the 
release of SIVΔNef could be inhibited by several primate BST-2 proteins.  Both groups 
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investigated the potential for specific regions or amino acids within the BST-2 proteins that 
conferred susceptibility to the SIV Nef protein, and both identified an amino acid motif that 
included residues D/GDIW14-17, which is present within the cytoplasmic domain of pig-tailed and 
rhesus BST-2 but absent in human BST-2.  Their results also revealed that this region could be 
inserted into the human BST-2 protein and impart susceptibility to the SIV Nef protein (Jia et al., 
2009; Zhang et al., 2009).  Mutation of either the myristoylation site within the N-terminal 
region of SIV Nef or residues that affect the down-regulation of CD4 completely abolished the 
ability to counteract BST-2 whereas mutation of a site specifically involved in the down-
regulation of MHC-I had no effect (Zhang et al., 2009).  SIVmac239 Nef down-regulated surface 
BST-2 in 293T cells stably expressing HA-tagged rhesus BST-2, similar to the results obtained 
for cell surface down-regulation of human BST-2 by Vpu (Jia et al., 2009).  Thus, it appears that 
SIVmac239 Nef functions similarly to HIV-1 Vpu in the counteraction of BST-2 proteins in a 
species-specific manner. 
 
Unanswered Questions of the Vpu Protein in Viral Pathogenesis 
The new exciting data from the last several years has brought some clarity to the role of 
Vpu in the virus replication cycle and its role in virus pathogenesis.  One question that needs to 
be addressed is whether CD4 down-modulation is more important in vivo than the release of 
infectious virus from cells.  Unfortunately, the macaque models do not express a BST-2 protein 
that is susceptible to HIV-1 Vpu.  Thus, macaque models may be able to assess the role of CD4 
down-modulation in virus pathogenesis but not virus release.  Several studies have shown that a 
mutant Vpu with either asparagine or glycine substitutions at positions 52 and 56 (Vpu2/6) 
abolishes Vpu binding to β-TrCP and subsequently CD4 surface down-modulation (Margottin et 
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al., 1998; Schubert et al., 1994; Singh et al., 2003).  Previous studies suggested that the TMD and 
CD of Vpu were specifically responsible for virus release and CD4 down-modulation, 
respectively(Schubert et al., 1996a).  However, several studies have since provided evidence for 
contributions of both domains in all of the biological activities of Vpu (Douglas et al., 2009; 
Hout et al., 2005; Mitchell et al., 2009; Tiganos et al., 1998).  Our laboratory has used a simian-
human immunodeficiency virus (SHIV) macaque model to study the specific contributions of the 
HIV-1 Vpu protein to pathogenesis.  Using this model our laboratory showed that macaques 
inoculated with SHIV expressing a Vpu protein with the two serines of the CK-II sites changed 
to glycines did not lose circulating CD4
+
 T cells and maintained significantly lower viral loads 
than macaques inoculated with parental SHIV (Singh et al., 2003).  This study suggested that the 
ability of Vpu to down-modulate CD4
 
expression directly correlates to the progression of disease 
in macaques.  More recent studies have presented data for the requirement of Vpu binding to β-
TrCP for BST-2 surface down-regulation and subsequent release of virions from the cell surface, 
suggesting that CD4 down-modulation and virus release may involve a common cellular cofactor 
(Douglas et al., 2009; Mitchell et al., 2009).   Thus, elimination of the CK-II sites may have 
pleiotropic effects on different Vpu functions.   These results extend the still unanswered 
question of “What is the specific contribution of Vpu mediated CD4 degradation to disease 
progression in vivo?”  Therefore, the isolation of mutants that affect one function but not the 
other are needed to definitely address each function in its role in disease progression.  It will be 
interesting to use the macaque model to study the pathogenesis of SHIVs expressing a Vpu 
protein that binds CD4 and β-TrCP, but is deficient in CD4 surface down-modulation (such as 
the VpuL63A and VpuV68A).  
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As discussed above, two recent studies have shown that SIV Nef proteins can counteract 
the BST-2 proteins of non-human primates; pointing to a new role for Nef in lentiviral 
pathogenesis (Jia et al., 2009; Zhang et al., 2009).  However, these studies raise an interesting 
question about how hBST-2 affects the replication of SIVmac239 in CEMx174 cells.  This human 
B-T hybrid cell line expresses copious amounts of hBST-2, and hBST-2 inhibits the release of 
SIVmac239 derived virions (Jia et al., 2009; Miyagi et al., 2009; Zhang et al., 2009).  This is 
somewhat surprising, as many researchers have grown SIVmac239 and SIVmac239ΔNef stock 
viruses in this cell line (Hammes et al., 1989; Joag et al., 1994; Kestler et al., 1991; Stephens et 
al., 1998; Yoon et al., 1998).  This apparent paradox again raises the question of the extent to 
which BST-2 restricts the rate of viral replication during multi-cycle, spreading infection.    
Perhaps the key question is how the enhancement of virion release by Vpu relates to 
pathogenesis in the host.   During HIV-1 infection of humans or SIV infection of macaques the 
depletion of CD4+ T cells in the secondary lymphoid organs ultimately results in AIDS, not the 
depletion of circulating CD4+ T cells.  Since CD4+ T cells in these organs are generally in close 
proximity to one another (e.g., in the paracortical region of the lymph nodes, the periarterial 
lymphatic sheath of the spleen, and the lymphoid aggregates and Peyer’s patches of the gut 
associated lymphoid tissue), and tethered particles may be infectious, the efficient spread of virus 
by cell-to-cell transmission may occur even in the absence of Vpu.  On the other hand, the 
observation that three lentiviral proteins, HIV-1 Vpu, SIV-Nef and HIV-2 Env, each counteract 
BST-2 to enhance virion release, weighs in favor of a key role for this phenotype in the 
replication of these viruses.  Finally, few Vpu proteins from strains other than laboratory-adapted 
subtype B viruses have been studied.  Subtype B HIV-1 isolates account for only 5-10% of the 
total HIV-1 infections worldwide. Future studies will determine if the counteraction of BST-2 
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and the enhancement of virion release are common to most or all HIV-1 subtypes and non-
human primate lentiviruses that encode the Vpu protein, or if it is instead a phenotype of only a 
subset of vpu genes. 
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VII.   Chapter 2: BST-2 mediated restriction of simian-human immunodeficiency virus 
 
Abstract 
Pathogenic simian–human immunodeficiency viruses (SHIV) contain HIV-1 Vpu and 
SIV Nef, both shown to counteract BST-2 (HM1.24; CD317; tetherin) inhibition of virus release 
in a species-specific manner. We show that human and pig-tailed BST-2 (hBST-2 and ptBST-2) 
restrict SHIV particle release and are susceptible to the encoded Vpu and Nef proteins, 
identifying SHIVKU-2MC4 as a beneficial tool for studying mechanisms of BST-2 mediated viral 
restriction. We also found that sequential “humanization” of the transmembrane domain (TMD) 
of the ptBST-2 protein resulted in a fluctuation in sensitivity to HIV-1 Vpu. Finally, we show 
that the length of the transmembrane domain in human and ptBST-2 proteins is important for 
BST-2 restriction and susceptibility to Vpu. Taken together, our results emphasize the 
importance of tertiary structure in BST-2 antagonism and suggest that the HIV-1 Vpu 
transmembrane domain may have additional functions in vivo unrelated to BST-2 antagonism. 
 
Introduction 
Human bone marrow stromal cell antigen 2 (BST-2; HM1.24; CD317 or tetherin) was 
recently identified as a potent inhibitor of the release of multiple enveloped viruses including 
HIV-1 and SIV (Jouvenet et al., 2009; Kaletsky et al., 2009; Neil et al., 2008; Van Damme et al., 
2008).  While the exact cellular function of human BST-2 (hBST-2) in the human host is unclear, 
it has been shown to play a role in regulating the growth and development of B cells, to be 
involved in the organization of the subapical actin cytoskeleton in polarized epithelial cells 
(Rollason et al., 2009), and most recently to function as a ligand for ILT7, a receptor that inhibits 
IFN production from plasmacytoid dendritic cells (Cao et al., 2009). BST-2 is an interferon-
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induced, lipid raft-associated, type II integral membrane protein with an unusual topology that is 
similar in membrane orientation to a neuro-pathogenic form of the prion protein (PrP) (Kupzig et 
al., 2003). It contains a short cytoplasmic N-terminus followed by a transmembrane domain 
(TMD), a central extracellular domain predicted to form a coiled-coil structure, and a C-terminal 
cleavage site predicted to form a glycosyl-phosphatidylinositol (GPI) anchor (Ishikawa et al., 
1995; Kupzig et al., 2003). This topology supports membrane-spanning models of restriction of 
virion release, in which the protein would form dimers providing a physical, protease-sensitive 
link between the cellular and viral membranes (Perez-Caballero et al., 2009).  This model is 
supported by evidence that hBST-2 is incorporated into nascent virions and that the formation of 
cysteine-linked dimers is required for hBST-2 restriction of HIV-1 virion release (Ali et al., 
2010; Andrew et al., 2009; Fitzpatrick et al., 2010; Habermann et al., 2010; Perez-Caballero et 
al., 2009).  Several studies have provided evidence that viruses including HIV-1 and SIV have 
evolved to acquire activity against the anti-viral properties of BST-2. The HIV-1 group M Vpu 
proteins counteract specifically the restriction of human, chimpanzee and gorilla BST-2 proteins, 
with the exception of Vpu from strains JR-CSF and YU-2, which also antagonized BST-2 
proteins derived from Greater-spot nosed and African green monkeys (Jouvenet et al., 2009; Neil 
et al., 2008; Sauter et al., 2009; Van Damme et al., 2008). The Nef proteins isolated from 
SIVMAC, SIVCPZ, SIVGOR, and SIVAGM also antagonize the effects of certain non-human primate 
BST-2 proteins, including those isolated from rhesus (rhBST-2) and pig-tailed (ptBST-2) 
macaques (Jia et al., 2009; Sauter et al., 2009; Zhang et al., 2009). Similar to other known 
intrinsic viral restriction factors such as the APOBEC3 and TRIM families of proteins, the ability 
of specific viral proteins to counteract BST-2 restriction is species-specific (Gupta et al., 2009a; 
Jia et al., 2009; McNatt et al., 2009; Zhang et al., 2009). Specific domains and amino acids 
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within these proteins mediate this specificity, allowing small evolutionary changes to confer 
susceptibility to cross-species infection (Gupta et al., 2009a; Jia et al., 2009; McNatt et al., 2009; 
Yap et al., 2005; Zhang et al., 2009).  The interaction of Vpu with hBST-2 involves the TMDs of 
both proteins (Douglas et al., 2009; McNatt et al., 2009; Rong et al., 2009).  Several studies have 
identified amino acids within the human, rhesus and tantalus monkey BST-2 proteins required 
for Vpu sensitivity/resistance.  These studies found several combinations of substitutions within 
the transmembrane domain of hBST-2 that reduced susceptibility to Vpu, including delGI,T45I 
(where glycine and isoleucine residues at positions 25 and 26 were deleted in combination with 
the substitution of a threonine at position 45 with an isoleucine) and delGI, I33V, I36L (where 
the glycine and isoleucine residues at positions 25 and 26 were deleted in combination with the 
substitution of the isoleucine at position 33 with a valine and mutation of the isoleucine at 
position 36 to a leucine). These studies also noted the importance of the proline residue at 
position 40 in sensitivity to Vpu (McNatt et al., 2009).  More recent studies focused on the 
specific role of amino acids within the BST-2 proteins from non-human primates in the 
susceptibility and resistance to SIVMAC Nef proteins. Several groups obtained similar results that 
identified an amino acid motif that is present within the cytoplasmic domain (D/GIWK14–17) of 
pig-tailed and rhBST-2 as important for SIV Nef susceptibility. These investigators showed that 
this motif could be inserted into the hBST-2 protein and impart susceptibility to the SIV Nef 
protein (Jia et al., 2009; Zhang et al., 2009). 
Simian–human immunodeficiency viruses (SHIVs) have been used extensively for in 
vivo studies to understand the role of HIV-1 Vpu and Env proteins as well as other SIV proteins 
in viral pathogenesis. These chimeric viruses express both the HIV-1 Vpu and SIVMAC Nef 
proteins shown to counteract BST-2 orthologues from human and non-human primates and 
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possibly represent a useful virus to study these interactions.  However, during the selection of 
pathogenic clones of these viruses, consensus mutations were introduced into several of the 
encoded genes, especially in the env and nef genes (Liu et al., 1999; McCormick-Davis et al., 
1998).  While studies have established that Vpu does not interact with or require other HIV-1 
proteins in order to counteract the hBST-2 protein, it is unknown whether the antagonistic 
abilities of Vpu would be altered in the context of a SHIV.  It is also unknown whether the 
mutations introduced into the other viral proteins encoded within the pathogenic molecular 
clones of SHIV, specifically Env and Nef, would result in an altered ability to counteract BST-2 
proteins expressed by different species (specifically pig-tailed and rhesus macaque BST-2 
proteins).  In this study, we examined the ability of the pathogenic molecular clone SHIVKU-2MC4 
to counteract both hBST-2 and ptBST-2, with specific emphasis on the Vpu and Nef proteins.  
We also assess the characteristics and anti-viral activities of hBST-2 and ptBST-2 proteins with 
specific amino acid exchanges in the context of SHIVs lacking the HIV-1 vpu gene, the SIV nef 
gene, or both. Our results indicate that SHIVKU-2MC4 can serve as a model for studying the anti-
viral properties of BST-2 proteins and the antagonistic mechanism(s) associated with the Vpu 
and Nef proteins.  We also demonstrate that the transmembrane domain of the BST-2 protein is a 
determinant of HIV-1 Vpu susceptibility, however, the length of the domain may play more of a 
role in this rather than specific amino acids and or combinations of residues. 
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Results 
Comparison of the sequence of pig-tailed and rhesus bst-2 genes 
We amplified and sequenced the bst-2 genes from five rhesus macaques (CX54, AH64, 
AS05, AS34 and AS89) and seven pig-tailed macaques (CC8X, W004, W005, W006, W007, 
W013, and W018).  The genes isolated from the rhesus macaques exhibited considerable 
variability compared to genes isolated from pig-tailed macaques, most notably in the N-terminal 
regions (Figure 10).  We observed a 50:50 distribution of arginine and cysteine at position 9, a 
60:40 ratio of aspartic acid to glycine at position 14, a 70:30 distribution of valine to isoleucine 
at position 29 and finally an 80:20 ratio of leucine to proline at position 43.  In contrast the pig-
tailed sequences did not show significant variability with the exception of one sequence that had 
a leucine instead of a methionine at position 13.  Based on the sequence analysis, we cloned the 
ptbst-2 gene for expression studies. 
 
Analysis of human and ptBST-2 mutants 
We constructed a series of mutations in the human and pig-tailed bst-2 genes.  These are 
presented in Figure 11.  We first examined the expression of each mutant BST-2 protein by 
transfection of 293 cells with vectors expressing each mutant protein and subsequent Western 
blot analysis of the cell lysates (Figure 12).  Substitution of the leucine and glycine residues at 
positions 24 and 25 in hBST-2 with alanines or isoleucines (hBST-2-LG/AA or hBST-2-LG/II) 
consistently resulted in higher levels of expression, suggesting that these mutations may increase 
the half-life of these proteins.  The only other protein with altered expression was the ptBST-2-
(ΔDDWIK/+LG).  This amino acid substitution resulted in decreased protein expression, which 
could be due to altered stability of the protein and was not further studied. 
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Figure 10.  Sequence analysis of bst-2 genes amplified from rhesus (A) and pig-tailed (B) 
macaques. RNA was isolated from either spleen tissue or PBMC from five rhesus 
macaques and seven pig-tailed macaques. The bst-2 gene was amplified from each of 
these samples and bulk sequenced. The sequences obtained from the rhesus macaques 
are presented along with the sequences of rhBST-2 from the genomic database. The 
BST-2 proteins used in this study for both rhesus and pig-tailed macaques were used as 
references and the dashes represent similar identity. 
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Figure 11.  The amino acid sequence of the N-terminal region of human and pig-tailed 
BST-2 proteins, and the BST-2 mutants analyzed in this study. 
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Figure 12.  Expression of parental and mutant BST-2 proteins analyzed in this study. 
293 cells were transfected with vectors expressing each of the BST-2 proteins. At 48 
hours, cell lysates were collected and the nuclei were removed through centrifugation. 
The lysates were boiled in sample reducing buffer and protein expression was examined 
through Western blot analysis using a rabbit polyclonal anti-BST-2 antibody (NIH). 
Panel A. 293 cells transfected with vectors expressing human parental and mutant BST-
2 proteins. Panel B. 293 cells transfected with vectors expressing pig-tailed parental and 
mutant BST-2 proteins. 
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SHIV can serve as models for studying BST-2 mediated restriction 
In order to examine the ability of the wild-type hBST-2 and ptBST-2 proteins to restrict 
virus release, we used parental SHIVKU-2MC4 to construct three SHIVs that did not express either 
HIV-1 Vpu (SHIVΔVpu), SIV Nef (SHIVΔNef) or both proteins (SHIVΔVpu/ΔNef).  HEK 293 cells 
were co-transfected with plasmids expressing one of the four SHIVs and each of the BST-2 
constructs.  At 48 hours post-transfection, the supernatants were collected and cleared by 
centrifugation, the cells were lysed and the nuclei and cellular debris cleared by centrifugation.  
The supernatants and cell lysates were used to quantify the percent p27 antigen release from cells 
and the supernatants were also evaluated for 50% tissue culture infectious doses (TCID50) 
(Figure 13).  The percent release of p27 in the context of each SHIV in the presence and absence 
of each BST-2 protein is shown in Figure 13A.  All samples were normalized to their respective 
SHIV empty vector controls.  Significance in the restriction of p27 release for the SHIVKU-2MC4 
samples was determined with respect to the parental SHIVKU-2MC4 empty vector control using a 
Student's t-test (▲).  Significance in the restriction of p27 release for the SHIVΔVpu, SHIVΔNef, 
and SHIVΔVpu/ΔNef samples was calculated with respect to the SHIVKU-2MC4 in the presence of 
each respective BST-2 using a Student's t-test (*).  The level of infectious virus released was 
determined using TZM-bl indicator cells (Figure 13B).  The results are represented as the 
average log10 infectious units.  Significance in the restriction of infectious units released was 
determined with respect to the appropriate empty vector control (•) since Nef has significant 
effects on virion infectivity that are not associated with BST-2 incorporation (Aiken and Trono, 
1995; Chowers et al., 1994).  All four SHIVs exhibited similar p27 release in the absence of any 
BST-2 protein.  In the presence of hBST-2, SHIVΔVpu and SHIVΔVpu/ΔNef viruses exhibited a 
significant decrease in p27 release from cells while SHIVΔNef had no decrease in p27 release. 
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Figure 13.  BST-2 dependent down-regulation of SHIV virion release from cells 
transfected with hBST-2 and ptBST-2.  Panel A. p27 release assay.  293 cells were co-
transfected with vectors expressing proviral DNA from one of four SHIVs (SHIVKU-2MC4, 
SHIVΔVpu, SHIVΔNef or SHIVΔVpu/ΔNef) and a vector expressing either the hBST-2 or 
ptBST-2 protein.  At 48 hours post-transfection, the supernatants and cell lysates were 
collected and cleared of cellular debris and nuclei by centrifugation.  The p27 content of 
both the supernatant and cell lysate from each sample was quantified using a p27 
antigen capture assay (Zeptometrix) and the percent p27 release calculated.  All 
conditions were run at least three separate times, normalized to their respective SHIV 
empty vector controls, and the average percent p27 release and standard error 
calculated.  Significance in the restriction of p27 release for the SHIVKU-2MC4 samples 
was determined with respect to the parental SHIVKU-2MC4 empty vector control using a 
Student's t-test (▲).  Significance in the restriction of p27 release for the SHIVΔVpu, 
SHIVΔNef, and SHIVΔVpu/ΔNef samples was calculated with respect to the SHIVKU-2MC4 in 
the presence of each respective BST-2 using a Student's t-test (*).  Panel B. Infectious 
units assay using TZM-bl indicator cells.  Supernatants from transfections described 
above were added to the TZM-bl cells and serially diluted. At 48 hours post-infection, 
cells were washed, fixed, and stained for 2 hours. The TCID50 for each supernatant was 
calculated based on wells containing cells expressing β-galactosidase.  All conditions 
were run at least three times and the TCID50 calculated.  The average TCID50 and 
standard error were calculated.  Significance in the restriction of infectivity was 
determined with respect to the parental SHIV empty vector control using a Student's t-
test with p ≤ 0.05 considered significant (•). 
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Similar results were observed in the infectious units assay.  In the presence of ptBST-2 protein, 
only SHIVΔNef and SHIVΔVpu/ΔNef showed a decrease in p27 release as well as infectious units 
released.  These results are in congruence with those published by other investigators that found 
that hBST-2 is susceptible to HIV-1 Vpu and ptBST-2 is sensitive to the SIV Nef (Neil et al., 
2008; Van Damme et al., 2008; Zhang et al., 2009), indicating that these SHIVs can serve as 
models for studying the individual and additive effects of different BST-2 proteins.  
 
Mutant ptBST-2 antagonism of SHIV release  
Previous studies showed that the transmembrane domain of the hBST-2 protein dictates 
its interaction with and susceptibility to HIV-1 Vpu (Gupta et al., 2009a; McNatt et al., 2009; 
Rong et al., 2009).  We determined if cumulative consecutive amino acid substitutions in the 
transmembrane domain of the ptBST-2 would result in a gradual increase in sensitivity to Vpu.  
We generated a library of ptBST-2 constructs with successive “humanizing” amino acid 
substitutions starting from the amino terminal end of the TMD with an insertion of two amino 
acids, a leucine and a glycine, at positions 29 and 30.  We transfected each construct into 293 
cells in conjunction with one of four different simian–human immunodeficiency virus expressing 
plasmids.  The supernatants and cell lysates were used to quantify the percent p27 antigen release 
from cells and the supernatants were also evaluated for the number of infectious doses (TCID50) 
(Figure 14).  The percent release of p27 in the context of each SHIV in the presence and absence 
of each BST-2 protein is shown in Figure 14A.  Results and significance are expressed and 
calculated similar to Figure 13A.  The level of infectious virus released was determined using 
TZM-bl indicator cells (Figure 14B).  Again, the results and significance are expressed and 
calculated as described for Figure 13B.  Surprisingly, a gradual increase in sensitivity to Vpu 
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Figure 14.  BST-2 dependent down-regulation of SHIV virion release from cells 
transfected with vectors expressing ptBST-2 mutants.  Panel A. p27 release assay.  293 
cells were cotransfected with vectors expressing proviral DNA from one of four SHIVs 
(SHIVKU-2MC4, SHIVΔVpu, SHIVΔNef or SHIVΔVpu/ΔNef) and a vector expressing either the 
hBST-2 or ptBST-2 protein.  At 48 hours post-transfection, the supernatants and cell 
lysates were collected and cleared of cellular debris and nuclei by centrifugation. The 
p27 content of both the supernatant and cell lysate from each sample was quantified 
using a p27 antigen capture assay (Zeptometrix) and the percent p27 release calculated.  
All conditions were run at least three separate times, normalized to their respective 
SHIV empty vector controls, and the average percent p27 release and standard error 
calculated.  Significance in the restriction of p27 release for the SHIVKU-2MC4 samples 
was determined with respect to the parental SHIVKU-2MC4 empty vector control using a 
Student's t-test (▲).  Significance in the restriction of p27 release for the SHIVΔVpu, 
SHIVΔNef, and SHIVΔVpu/ΔNef samples was calculated with respect to the SHIVKU-2MC4 in 
the presence of each respective BST-2 using a Student's t-test (*).  Panel B. Infectious 
units assay using TZM-bl indicator cells.  Supernatants from transfections described 
above were added to the TZM-bl cells and serially diluted.  At 48 hours post-infection, 
cells were washed, fixed, and stained for 2 hours.  The TCID50 for each supernatant was 
calculated based on wells containing cells expressing β-galactosidase.  All conditions 
were run at least three times and the average TCID50 and standard error were 
calculated.  Significance in the restriction of infectivity was determined with respect to 
the parental SHIV empty vector control using a Student's t-test with p ≤ 0.05 considered 
significant (•). 
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was not observed.  We observed that most mutations resulted in BST-2 sensitivity to HIV-1 Vpu 
but the level was random in distribution.  Mutations that significantly increased sensitivity to 
Vpu, including substitution of the leucine at position 41 with an isoleucine, did not retain this 
phenotype with additional “humanizing” amino acid substitutions.  This indicates that the 
substitutions were not sufficient for the interaction with and antagonism by HIV-1 Vpu and 
suggests that their effect on the spatial orientation of the TMD within the membrane is also 
important. 
 
The length of the transmembrane domain is important for hBST-2 susceptibility to Vpu 
Our results shown in Figure 14 indicated that insertion of the two residues in the 
transmembrane domain of ptBST-2 alone significantly increased the susceptibility to HIV-1 
Vpu.  These results were confirmed by quantifying the level of infectious virus released using 
TZM-bl indicator cells (Figure 14B). These results suggested that the length of the 
transmembrane domain may be important for Vpu antagonism.  To test this hypothesis, we 
generated additional hBST-2 constructs with different amino acid substitutions in the 
transmembrane domain.  These constructs included hBST-2 proteins in which the TMD was 
replaced with the TMD from ptBST-2 (hBST-2-PT-TMD), the leucine and glycine residues at 
positions 24 and 25 were substituted with alanines (hBST-2-LG/AA), the residues at positions 24 
and 25 were substituted with hydrophobic, isoleucine residues (hBST-2-LG/II), or the two 
residues were deleted (hBST-2-ΔLG).  These plasmids were used in the same virion release 
assay described above to determine the percent virion release (Figure 15A).  The hBST-2-PT-
TMD protein was no longer susceptible to any viral protein, similar to results that have been 
published previously (Douglas et al., 2009; McNatt et al., 2009).  The hBST-2-ΔLG protein 
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exhibited similar results to hBST-2-PT-TMD, while the hBST-2-LG/AA and hBST-2-LG/II 
proteins produced results similar to the wild-type protein.  These data suggest that alteration of 
the length of the transmembrane domain and not necessarily the hydrophobic nature of the amino 
acid residues at these positions contributed to the resistance to HIV-1 Vpu.  These results were 
confirmed by quantifying the levels of infectious virus released using TZM-bl indicator cells 
(Figure 15B). The results and significance for both assays are expressed and calculated as 
described for Figure 13.  
 
Deletion of residues 13–17 in the ptBST-2 decreases sensitivity to SHIV Nef  
In order to study the susceptibility of the ptBST-2 mutants to the SIVMAC Nef protein 
encoded in our SHIVs, we generated a construct that expressed a protein with a deletion in the 
region previously shown to be sufficient for antagonism by Nef.  Deletion of residues 13–17 
within this region (ptBST-2-ΔDDIWK) decreased susceptibility of the protein to SIVMAC Nef 
and resulted in a decrease in p27 released from cells transfected with all four SHIV constructs 
(Figure 14A).  These results are in accordancewith those published previously that residues 14–
17within the rhesus BST-2 protein determine susceptibility to SIVMAC Nef. Again, these results 
were confirmed using TZM-bl cell assays that indicated a similar level of infectious virus (Figure 
14B).  
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Figure 15.  BST-2 dependent down-regulation of SHIV virion release from cells 
transfected with vectors expressing hBST-2 mutants.  Panel A. p27 release assay.  293 
cells were co-transfected with vectors expressing proviral DNA from one of four SHIVs 
(SHIVKU-2MC4, SHIVΔVpu, SHIVΔNef or SHIVΔVpu/ΔNef) and a vector expressing either the 
hBST-2 or ptBST-2 protein.  At 48 hours post-transfection, the supernatants and cell 
lysates were collected and cleared of cellular debris and nuclei by centrifugation.  The 
p27 content of both the supernatant and cell lysate from each sample was quantified 
using a p27 antigen capture assay (Zeptometrix) and the percent p27 release calculated.  
All conditions were run at least three separate times, normalized to their respective 
SHIV empty vector controls, and the average percent p27 release and standard error 
calculated.  Significance in the restriction of p27 release for the SHIVKU-2MC4 samples 
was determined with respect to the parental SHIVKU-2MC4 empty vector control using a 
Student's t-test (▲).  Significance in the restriction of p27 release for the SHIVΔVpu, 
SHIVΔNef, and SHIVΔVpu/ΔNef samples was calculated with respect to the SHIVKU-2MC4 in 
the presence of each respective BST-2 using a Student's t-test (*).  Panel B. Infectious 
units assay using TZM-bl indicator cells.  Supernatants from transfections described 
above were added to the TZM-bl cells and serially diluted.  At 48 hours post-infection, 
cells were washed, fixed, and stained for 2 hours.  The TCID50 for each supernatant was 
calculated based on wells containing cells expressing β-galactosidase.  All conditions 
were run at least three times and the average TCID50 and standard error were 
calculated.  Significance in the restriction of infectivity was determined with respect to 
the parental SHIV empty vector control using a Student's t-test with p ≤ 0.05 considered 
significant (•). 
 
103 
 
  
104 
 
Discussion 
Previous studies have shown that BST-2 restricts HIV-1 and SIVMAC in a species-specific 
manner with these effects being counteracted by HIV-1 Vpu and SIV Nef (Jia et al., 2009; 
McNatt et al., 2009; Neil et al., 2008; Van Damme et al., 2008; Zhang et al., 2009).  SHIVs that 
express both of these proteins have been used extensively to study the effects of these and other 
viral proteins in vivo.  Thus, one goal of these studies was to determine if SHIVs would counter 
human and pig-tailed BST-2 proteins and if specific mutations in these primate BST-2 proteins 
would increase or decrease sensitivity to Vpu and Nef.  We approached this by characterizing 
BST-2-mediated restriction of the unmodified SHIVKU-2MC4 and three additional SHIVs that did 
not express Vpu, Nef or both proteins.  Our results demonstrate that SHIVs display similar 
properties as HIV-1 and SIV with respect to human and pig-tailed BST-2.  That is, SHIVΔVpu 
was restricted by hBST-2 while SHIVΔNef was inhibited by ptBST-2. This suggests that the 
amino acid substitutions in the Nef protein during adaptation of SHIVKU-2MC4 to cause disease in 
rhesus and pig-tailed macaques did not result in a loss of Nef antagonism against ptBST-2.  
The resistance of the ptBST-2 to SHIV Vpu and its sensitivity to SHIV Nef allowed us to 
characterize the role of individual residues within the transmembrane domain of the ptBST-2 
associated with these properties.  While previous studies presented data on the role of the 
individual residues of the hBST-2 TMD, we used a series of cumulative sequential amino acid 
substitutions to “humanize” the ptBST-2 TMD (Gupta et al., 2009a; McNatt et al., 2009; Rong et 
al., 2009).  Our results are in accordance with these groups in that the two amino acid deletions 
in the ptBST-2 TMD (L29 and G30) are key residues involved in the susceptibility to HIV-1 
Vpu. However, our analysis of a series of proteins with a progressive “humanizing” of the TMD 
revealed a fluctuation in sensitivity to HIV-1 Vpu.  All of the ptBST-2 transmembrane domain 
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mutants displayed susceptibility to HIV-1 Vpu, SIV Nef or both.  However, the four mutations 
that displayed the most interesting effects were ptBST-2(+LG), ptBST-2(*G35V), ptBST-
2(*V38I) and ptBST-2(*L41I).  Insertion of the leucine and glycine at positions 29 and 30 
clearly increased the sensitivity of the protein to HIV-1 Vpu without significantly altering the 
susceptibility to SIV Nef.  Substitution of the glycine at position 35 with a valine eliminated the 
sensitivity to SHIV Vpu gained with the preceding mutations.  This substitution also seemed to 
eliminate sensitivity to SHIV Nef.  Mutation of the valine at position 38 to an isoleucine resulted 
in a complete loss of the sensitivity to HIV-1 Vpu gained with mutation of the preceding 
residues, but again without alteration of SHIV Nef susceptibility.  Finally, substitution of the 
leucine at position 41 with an isoleucine resulted in an increased sensitivity to HIV-1 Vpu and an 
increase in the additive effects of Vpu and Nef.  Any alterations in Nef susceptibility observed 
with the transmembrane domain mutations are most likely due to an alteration in the positioning 
of the cytoplasmic tail along the membrane.  These results suggest that the overall structure, the 
spatial orientation of amino acids in the membrane, or possibly the tilt angle of the TMD in the 
membrane may be important factors.  Insertion of the leucine and glycine at positions 29 and 30 
into the ptBST-2 resulted in the most observable effect on the antagonism by Vpu leading us to 
hypothesize that the length of the transmembrane domain was important for this interaction.  We 
tested this hypothesis by constructing three mutants of hBST-2 with either deletion of the LG 
(ΔLG), or substitution with amino acids with either a small hydrophobic side group (LG/AA) or 
a larger hydrophobic side group (LG/II).  The hBST-2ΔLG deletion restricted particle release of 
all four SHIVs tested, while the LG/AA and LG/II mutants remained highly sensitive to Vpu and 
resistant to Nef.  These results indicate that the length and not the degree of hydrophobicity of 
these amino acids is critical in defining susceptibility to HIV-1 Vpu.   
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The level of surface expression of hBST-2 compared to ptBST-2 is unknown and it is 
possible that differences in these levels may help explain the possible differences in viral 
restriction efficiency as well as mechanisms of antagonism by viral proteins. Differences in 
surface expression could be due to differences in protein expression, internalization rates and/or 
turnover rates of each species of protein.  Studies examining these properties are necessary in 
order to further elucidate the mechanisms by which different species of BST-2 proteins restrict 
virion release and how they are antagonized by different viral proteins.  Studies within our 
laboratory suggest that there are differences in expression levels of the hBST-2 compared to the 
ptBST-2 and present a possible explanation for the differences in restriction efficiency observed 
in this study (unpublished data).  However, the studies presented herein reflect intraspecies 
analysis and do not indicate cross-species examination.  This study introduces SHIV as an in 
vitro model for studying BST-2 mediated restriction laying a basis for future studies that could 
lead to an in vivo model.  These results also emphasize the necessity for studies focused on the 
structural components of BST-2 and their contributions to the anti-viral properties of the protein. 
These studies support the findings by (Perez-Caballero et al., 2009) that the amino acid identity 
of the protein is less significant than the structural properties in virion restriction.  Taken 
together, these results provide a basis for the development of new small molecule inhibitors 
designed to mimic the effects of BST-2 on multiple enveloped viruses.  
The physiological relevance of the anti-HIV activity of BST-2 has not yet been 
demonstrated in vivo. Previously published studies from our laboratory demonstrate that a 
functional Vpu protein is important for pathogenicity of SHIV in the pig-tailed macaque model, 
which expresses a Vpu resistant BST-2, suggesting a role for other functions of Vpu in viral 
pathogenesis (Hout et al., 2005; McCormick-Davis et al., 2000a; Singh et al., 2003; Singh et al., 
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2001; Stephens et al., 2002).  Of note are our studies using a SHIV expressing the VpuM2 protein 
(SHIVM2).  This protein has been shown to down-regulate CD4 from the surface of CD4
+
 cells, 
however it is unable to rescue virion release from cells expressing high levels of BST-2 (data not 
shown).  SHIVM2 caused a loss of CD4
+
 T cells within one month, high viral loads and 
histological lesions in infected macaques (Hout et al., 2006b).  These studies provide evidence 
for additional functions of the Vpu transmembrane domain in vivo unrelated to BST-2 
antagonism, which are potentially related to the ion channel properties exhibited by Vpu.  
Regardless of the physiological relevance of its anti-viral properties, BST-2 does represent a 
significant in vitro tool for examining the effects of different Vpu proteins, be they distinct 
subtypes or mutants, on protein function.  Just as the BST-2 transmembrane domain has amino 
acids/structures that are critical for interactions with Vpu, there are most likely amino acids 
within the Vpu transmembrane domain that are also critical for these interactions.  It will be of 
interest to identify these residues and determine if they are conserved in different subtypes of 
HIV-1. 
 
Materials and Methods 
Plasmid Construction 
The human bst-2 (hBST-2) gene was amplified from a plasmid expressing a full length 
cDNA of hBST-2 (Origene) using oligonucleotides containing 5′ BamHI and 3′ XhoI sites. The 
fragment was ligated into a pcDNA3.1(+) expression vector (Promega) digested with BamHI and 
XhoI restriction enzymes. The plasmid was sequenced to ensure no mutations were introduced 
during the cloning process. The pig-tailed bst-2 (ptBST-2) and rhesus bst-2 (rhBST-2) genes 
were amplified from cDNA generated from PBMC isolated from uninfected juvenile pig-tailed 
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and rhesus macaques using a reverse-transcriptase polymerase chain reaction (RT-PCR). 
Oligonucleotides used contained 5′ BamHI and 3′ NotI restriction sites. The resulting fragment 
was ligated into a pcDNA3.1(+) expression vector (Promega) digested with BamHI and NotI 
restriction enzymes. Mutations introduced into all plasmids were accomplished using a 
QuikChange site-directed mutagenesis kit (Stratagene) according to the manufacturer's protocol. 
All plasmids were sequenced to ensure the validity of the mutations and that no other mutations 
were introduced during the cloning process.  
 
Sequence Analysis of ptBST-2 and rhBST-2 Variants 
The bst-2 gene was amplified from five and seven different rhesus and pig-tailed macaque spleen 
tissues or PBMC, respectively, using a one-tube Titan reverse-transcriptase kit (Roche). The 
resulting fragments were purified using a Qiaquick Gel Extraction kit (Qiagen) and subjected to 
sequence analysis.  
 
Proviral DNA Plasmid Construction 
The construction of molecular clone SHIVKU-2MC4 has been described previously (Liu et 
al., 1999).  In order to construct SHIVΔVpu, SHIVΔNef, and SHIVΔVpu/ΔNef another molecular clone 
ΔvpuΔnefSHIVPPc was used and the construction of this clone has been described previously 
(Joag et al., 1998b). A 1444 base pair (bp) fragment was removed fromSHIVKU-2MC4 using 
restriction enzymes SphI and NheI. This fragment was replaced with the corresponding 1382 bp 
fragment of ΔvpuΔnefSHIVPPc.  The resulting construct expressed a Vpu protein with a 62 bp 
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deletion and an inactive start codon (SHIVΔVpu).  A 525 bp fragment was removed from SHIVKU-
2MC4 using restriction enzymes BamHI and NcoI. This fragment which encodes for part of the 
gp41 and nef genes was replaced with the corresponding 321 bp fragment of ΔvpuΔnefSHIVPPc. 
The resulting construct expressed a nef gene with a 204 bp deletion that included the start codon 
(SHIVΔNef).  A 525 bp fragment was removed from SHIVΔVpu using restriction enzymes BamHI 
and NcoI. This fragment which encoded for part of the gp41 and nef genes was replaced with the 
corresponding 321 bp fragment of ΔvpuΔnefSHIVPPc. The resulting construct expressed a vpu 
gene with a 62 bp deletion and an inactive start codon and a nef gene with a 204 bp deletion that 
included the start codon (SHIVΔVpu/ΔNef). 
 
Cell Lines and Transfections 
The TZM-bl cell line was was obtained through the NIH AIDS Research and Reference 
Reagent Program, Division of AIDS, NIAID, NIH: TZM-bl from Dr. John C. Kappes, Dr. 
Xiaoyun Wu and Tranzyme Inc.  The HEK 293 and TZM-bl cell lines were maintained in 
DMEM supplemented with 10% fetal bovine serum (FBS), gentamicin (5 μg per ml) and 
penicillin/streptomycin (100 U/100 μg per ml, respectively).  Both cell lines were transfected 
using a cationic polymer (polyethylenimine) transfection reagent (ExGen™ 500, MBI 
Fermentas) using the manufacturer's protocol.  
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Western Blot Assays 
Human 293 cells (10
5
) were seeded into each well of a 24-well tissue culture plate 24 
hours prior to transfection.  Cells were transfected as described above with 1 μg of plasmid 
expressing full length SHIV proviral DNA (either SHIVKU-2MC4, SHIVΔVpu, SHIVΔNef, and/or 
SHIVΔVpu/ΔNef) and empty vector or 10 ng of plasmid expressing various untagged bst-2 genes.  
Cells were incubated at 37C in 5% CO2 atmosphere for 48 hours.  Cells were lysed in 200 μl of 
1X RIPA buffer (50 mM Tris–HCl, pH 7.5; 50 mM NaCl; 0.5% deoxycholate; 0.2% SDS; 10 
mM EDTA) and the nuclei removed through high speed centrifugation. Cell lysates were made 
1X with sample reducing buffer (100 mM Tris–HCl pH 6.8, 30% glycerol, 2% SDS, 10% 2-
mercaptoethanol, 0.05% bromophenol blue) and boiled for 5 minutes.  Samples were separated 
on SDS-PAGE gels and transferred to PVDF membrane.  BST-2 proteins were detected using a 
rabbit polyclonal anti-BST-2 primary antibody obtained through the AIDS Research and 
Reference Reagent Program, Division of AIDS, NIAID, NIH: Anti-Bst-2 (cat# 11722) from Drs. 
Klaus Strebel and Amy Andrew (1:1000 dilution).  The secondary antibody used was an alkaline 
phosphatase-conjugated goat anti-rabbit IgG (whole molecule) (Sigma).  Alkaline phosphatase 
substrate used was CDP-Star (Sigma) for chemiluminescent detection and an LAS-4000 Imager 
(Fujifilm) was used for the visualization and analysis of proteins. 
 
Virion Release Assays 
Human 293 cells (10
5
) were seeded into each well of a 24-well tissue culture plate 24 
hours prior to transfection.  Cells were transfected as described above with 1 μg of plasmid 
expressing full length SHIV proviral DNA (either SHIVKU-2MC4, SHIVΔVpu, SHIVΔNef, or 
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SHIVΔVpu/ΔNef) and 10 ng of plasmid expressing various untagged bst-2 genes. Cells were 
incubated at 37C in 5% CO2 atmosphere for 48 hours.  Supernatants were collected and cellular 
debris removed through low speed centrifugation.  Cells were lysed in 200 μl of 1X RIPA buffer 
(50 mM Tris–HCl, pH 7.5; 50 mM NaCl; 0.5% deoxycholate; 0.2% SDS; 10 mM EDTA) and 
the nuclei removed through high speed centrifugation.  The amount of p27 present within the 
virion containing supernatant and the cell lysates was determined using a commercially available 
p27 ELISA kit (Zeptometrix Incorporated) and percent p27 release calculated.  All conditions 
were run at least three separate times, normalized to the empty vector control, and the average 
percent p27 release and standard error calculated. Significance in the restriction of p27 release 
for the SHIVKU-2MC4 samples was determined with respect to the parental SHIVKU-2MC4 empty 
vector control using a Student's t-test with p<0.05 considered significant. Significance in the 
restriction of p27 release for the SHIVΔVpu, SHIVΔNef, and SHIVΔVpu/ΔNef samples was calculated 
with respect to the SHIVKU-2MC4 in the presence of each respective BST-2 using a Student's t-test 
with p<0.05 considered significant. 
 
Infectious Units Release Assays 
TZM-bl cells (10
4
) cells were seeded into each well of a 96-well tissue culture plate 24 
hours prior to infection.  Supernatants collected from either the 293 cells co-transfected with 
SHIV and BST-2 expressing plasmids as described above were added to the TZM-bl cells and 
serially diluted.  At 48 hours post-infection, cells were washed twice in 1X PBS and fixed in a 
solution of 0.25% glutaraldehyde and 0.8% formaldehyde in PBS for 5 minutes at room 
temperature. The cells were washed three times in 1X PBS and covered in staining solution (400 
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μg per ml X-gal, 4 mM MgCl2, 4 mM K3Fe(CN)6, 4 mM K4Fe(CN)6–3H2O in phosphate-
buffered saline) and incubated for 2 hours at 37C.  Cells were washed once in 1X PBS and then 
covered in 1X PBS during counting.  The TCID50 for each supernatant was calculated based on 
wells containing cells expressing β-galactosidase.  All conditions were run at least three times 
and the TCID50 calculated.  The average TCID50 and standard error were calculated.  
Significance in the restriction of infectivity was determined with respect to the parental SHIV 
empty vector control using a Student's t-test with p<0.05 considered significant. 
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VIII.   Chapter 3: Different HIV-1 Vpu Subtypes Exhibit Distinct Biological Properties 
Abstract 
 Vpu proteins from HIV-1 group M isolates degrade the virus CD4 receptor and inhibit 
human BST-2 (hBST-2) in order to enhance viral pathogenesis.  In this study, we examined the 
biological properties of several different HIV-1 Vpu subtype isolates including each protein’s 
intracellular localization, ability to down-modulate CD4 from the cell surface, and the ability to 
enhance SHIV virion release in the presence of high levels of human BST-2 (hBST-2).  Our 
findings indicate that Vpu protein subtypes A, A2 and C are transported to the cellular plasma 
membrane more efficiently than Vpu proteins from subtypes B, D, F, and H, which are 
predominately localized within intracellular compartments.  We also show that while all isolates 
maintained the ability to down-modulate CD4 from the cell surface, subtypes A2 and C were 
significantly less efficient.  Finally, all isolates save subtype F were able to overcome hBST-2 
restriction of virion release in HeLa cells.  Taken together, these results indicate that different 
HIV-1 Vpu subtypes exhibit distinct biological properties that potentially regulate the ability of 
Vpu to enhance pathogenesis and could provide a partial explanation for the disproportionate 
global distribution of HIV-1 subtypes and the ability of HIV-1 to cause a pandemic. 
 
Introduction 
HIV-1 employs several intrinsic mechanisms to ensure viral evolution and survival, 
including integration into the host genome, a high mutation rate and the ability to evade the 
immune system.  The rapid evolution and continued transmission of HIV-1 into diverse 
geographic populations has led to unprecedented genetic diversity observed in the current 
pandemic.  Since its introduction into the human population, the pandemic causing HIV-1 Group 
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M viruses have diverged into nine classifiable subtypes (A, B, C, D, F, G, H, J, and K), sub-
subtypes (A1, A2, F1, and F2), circulating recombinant forms and unique recombinant forms.  
Epidemiological studies have revealed a disproportionate distribution of each subtype both 
geographically and based on modes of transmission (Arien et al., 2007; Hemelaar et al., 2006; 
Hu et al., 1999; Neilson et al., 1999; Renjifo et al., 1998).  While the trends associated with 
transmission routes are still controversial, the prevalence of particular subtypes, specifically the 
worldwide predominance of subtype C viruses, is certain. 
The predominance of the subtype C viruses could be due to genetic differences between 
subtypes, modes of transmissions or differences in socio-cultural behaviors.  Evolutionary 
studies have revealed an array of genotypic differences among HIV-1 subtypes, however these 
phylogenetically based analyses do not examine the mechanisms by which these genetic 
differences impact the pathogenicity of the virus.  Additional studies have addressed the viral 
fitness of different HIV-1 subtype isolates, both in PBMC and ex vivo tissues.  These studies 
found that subtype C viruses were less fit in peripheral blood mononuclear cell (PBMC) 
competition assays when compared to all other HIV-1 Group M subtypes (Arien et al., 2005; 
Ball et al., 2003).  However, the subtype C viruses were found to have similar replicative fitness 
to subtype B viruses in Langerhan cells suggesting that subtype C viruses may be more 
efficiently transmitted (Ball et al., 2003).  Finally, a study comparing the fitness and transmission 
efficiency of 33 different CCR5 (R5) and CXCR4-tropic (X4) HIV-1 isolates in PBMC and ex 
vivo tissues demonstrated a general order of replicative fitness in PBMC where subtype B and D 
isolates were slightly more fit than subtype A viruses and significantly more fit than 12 different 
subtype C viruses (Abraha et al., 2009).  However, when analyzed in primary human explants of 
penial, cervical and rectal tissues, the R5-tropic subtype C viruses were able to compete with all 
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other R5 isolates.  These results suggest that subtype C HIV-1 isolates may exhibit similar 
transmission efficiencies, but are less fit compared to other Group M HIV-1 isolates to cause 
disease.  Taken together, these studies suggest that different HIV-1 subtypes may have adapted 
specific molecular determinants to promote prosperity within specific host populations.  
However, more studies are needed to identify these specific molecular determinants and discern 
their potential as therapeutic targets. 
In this study, we examined the biological properties of seven different HIV-1 Vpu 
isolates (VpuA, VpuA2, VpuB, VpuC, VpuD, VpuF1, and VpuH).  Using a VpuEGFP reporter 
system developed in our laboratory previously, we determined the intracellular localization of 
each Vpu isolate and their ability to down-modulate CD4 from the cell surface (Singh et al., 
2003).  In addition to the down-modulation of CD4 from the cell surface, Vpu also enhances 
virion release to promote virus spread.  Therefore, we also analyzed the ability of each Vpu 
isolate to enhance virion release using SHIV Vpu, which has been previously described (Ruiz et 
al., 2010b).  Taken together, our results suggest that specific molecular determinants within 
different Vpu subtypes mediate protein trafficking and function and in turn, affect the role of the 
Vpu in HIV-1 pathogenesis. 
 
Results 
Sequence analysis of different HIV-1 Vpu subtypes 
The sequences of the different HIV-1 Vpu subtypes analyzed in this study are depicted in 
Figure 16.  All of the isolates contain a potential tyrosine motif (Yxx ) proximal to the 
transmembrane domain.  Vpu subtypes A2 (92UG037) and C (96BW16B01) contain a putative 
dileucine motif ([D/E]xxxL[L/I] overlapping the conserved tyrosine motif.  The importance of 
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these motifs will be discussed later (Chapter 5).  The residues that are invariant among all HIV-1 
Vpu subtypes are displayed in purple.  Each Vpu protein contains an N-terminal region followed 
by an uncleaved leader sequence/transmembrane domain and a cytoplasmic domain.  Two casein 
kinase II phosphorylation sites that are required for CD4 surface down-regulation are found 
within the cytoplasmic domain in the “hinge” region. 
 
Different HIV-1 Vpu subtypes are more readily transported to the cellular surface 
 Previous studies in our laboratory demonstrated that while both a subtype B Vpu isolate 
(US.HXB2) and a subtype C Vpu isolate (96BW16B01) were localized predominately within the 
ER and Golgi compartments, the subtype C Vpu isolate was efficiently expressed at the cellular 
surface (Pacyniak et al., 2005).  Based on these results we first analyzed the ability of each of our 
Vpu subtype isolates to be transported to the cell surface using confocal microscopy.  We 
constructed a series of plasmids expressing each of the vpu genes fused in frame to the gene for 
enhanced green fluorescence protein (eGFP) similar to pcvpuegfp and pcvpuSCegfp plasmids 
whose construction has been described previously (Pacyniak et al., 2005; Singh et al., 2003).  We 
transfected human 293 cells with vectors expressing VpuSAEGFP, VpuSA2EGFP, VpuEGFP, 
VpuSCEGFP1, VpuSDEGFP, VpuSFEGFP, or VpuSHEGFP.  At 48 hours post-transfection, these 
cells were analyzed by laser scanning confocal microscopy.  As shown in Figure 17, the 
VpuSAEGFP and VpuSA2EGFP were observed at the cell plasma membrane similar to 
VpuSCEGFP1.  In contrast, the VpuSDEGFP, VpuSFEGFP, or VpuSHEGFP proteins resided 
predominately within intracellular compartments similar to VpuEGFP. 
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Figure 16.  Sequence alignment of Vpu proteins used in this study.  Residues highlighted 
in purple are invariant among all Vpu subtypes.  The two casein kinase II 
phosphorylation sites are denoted with (*) symbols.  The putative transmembrane 
domain (black), tyrosine motif (blue), and dileucine motifs (green) within each isolate 
are identified by color and top-line.   
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Figure 17.  Intracellular localization of Vpu isolates used in this study.  293 cells were 
transfected with vectors expressing EGFP, VpuSAEGFP, VpuSA2EGFP, VpuEGFP, 
VpuSCEGFP1, VpuSDEGFP, VpuSFEGFP, or VpuSHEGFP.  At 48 hours, cells expressing 
EGFP were identified and images collected using laser scanning confocal microscopy as 
described in the Materials and methods section.  Panel A.  293 cell transfected with a 
vector expressing EGFP.  Panel B.  293 cell transfected with a vector expressing 
VpuSAEGFP.  Panel C.  293 cell transfected with a vector expressing VpuSA2EGFP.  
Panel D.  293 cell transfected with a vector expressing VpuEGFP.  Panel E.  293 cell 
transfected with a vector expressing VpuSCEGFP1.  Panel F.  293 cell transfected with a 
vector expressing VpuSDEGFP.  Panel G.  293 cell transfected with a vector expressing 
VpuSFEGFP.  Panel H.  293 cell transfected with a vector expressing VpuSHEGFP.   
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The ability to down-regulate CD4 from the cell surface is maintained among different HIV-
1 Vpu subtypes 
 We analyzed cell surface CD4 expression in the presence of each Vpu isolate with the 
subtype B (VpuEGFP) as a positive control.  HeLa CD4
+
 cells were transfected with vectors 
expressing VpuSAEGFP, VpuSA2EGFP, VpuEGFP, VpuSCEGFP1, VpuSDEGFP, VpuSFEGFP, or 
VpuSHEGFP.  At 48 hours post-transfection, these cells were immunostained for CD4 and 
analyzed by flow cytometry to measure the intensity of cell surface CD4 expression.  As shown 
in Figure 18, CD4 surface expression was significantly decreased in the presence of all Vpu 
isolates.  Of the seven isolates, the CD4 surface expression in the presence of VpuSA2EGFP and 
VpuSCEGFP1 was statistically distinct from the other subtypes when evaluated using a Student’s 
t-test, with a p<0.05 considered significant. 
  
HIV-1 Vpu subtype F isolate 93BR020 does not enhance virion release in the presence of 
hBST-2 
 In order to examine the ability of each Vpu isolate to counteract BST-2 we co-transfected 
HeLa cells, that constitutively express hBST-2, with a vector expressing SHIV Vpu (as described 
in Chapter 1) and each of the Vpu subtypes.  In order to eliminate the EGFP fusion tag as a 
variable we constructed vectors expressing codon-optimized vpu genes (pcVphuA, pcVphuA2, 
pcVphu, pcVphuC, pcVphuD, pcVphuF, and pcVphuH) and used these plasmids for exogenous 
expression of each Vpu isolate.  At 48 hours post-transfection, the supernatants were collected 
and cleared by centrifugation, and the cells were lysed and the nuclei removed by centrifugation.  
The cleared supernatants and cell lysates were used to quantify the percent p27 antigen release 
from cells and the supernatants were also evaluated for the 50% tissue culture infectious dose 
(TCID50) (Figure 19).  The percent release of p27 in the presence of each Vpu isolate is shown in 
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Figure 19A.  All samples were normalized to the SHIVKU-2MC4 co-transfected with empty vector 
control and the average p27 release and standard error calculated.  Significance in the 
enhancement of p27 release in the presence of each Vpu isolate was determined with respect to 
the SHIVKU-2MC4 empty vector control using a Student’s t-test (*).  The level of infectious virus 
released was determined using the TZM-bl indicator cell line (Figure 19B).  The results are 
represented as the average log10 infectious units and the significance in infectious units released 
was again determined with respect to the SHIVKU-2MC4 empty vector control.  All Vphu isolates 
except VphuF significantly enhanced p27 release compared to the SHIV Vpu empty vector 
control.  A caveat of this assay was our inability to confirm Vphu protein expression and 
stability, specifically VphuF, within each sample as there is no antibody available that recognizes 
each of these different isolates.  We addressed this issue using two distinct approaches: 1) 
reverse-transcriptase-PCR (RT-PCR) analysis on RNA isolated from the samples described 
above to confirm mRNA expression; and 2) conducting similar assays with vectors expressing 
Vpu fusion proteins and Western blot analysis using a mouse monoclonal anti-EGFP antibody 
(Clontech).  All samples examined to generate the data represented in Figure 19 were positive for 
Vphu mRNA expression as determined by RT-PCR (Figure 19C).  Assays conducted with the 
VpuEGFP fusion proteins yielded similar results and protein expression was confirmed by 
Western blot analysis (data not shown).  It was clear however, that the EGFP fusion tag 
significantly interfered with Vpu-mediated enhancement of virion release in the context of 
hBST-2 antagonism.  Therefore, data presented in Figure 19 is based on the results obtained with 
the native proteins. 
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Figure 18.  All Vpu proteins maintain CD4 surface down-modulation function.  HeLa 
CD4+ cells were transfected with plasmids expressing EGFP, VpuSAEGFP, 
VpuSA2EGFP, VpuEGFP, VpuSCEGFP1, VpuSDEGFP, VpuSFEGFP, or VpuSHEGFP.  At 
48 hours, live cells were immunostained for CD4.  Cells expressing EGFP or EGFP 
fusion proteins were assessed for CD4 surface expression using flow cytometry.  CD4 
expression in cells expressing the various Vpu proteins was normalized to CD4 
expression in EGFP expressing cells.  (*) symbol above bar represents Vpu isolates that 
were significantly less efficient at down-modulating CD4 from the cell surface compared 
to VpuEGFP, with a p < 0.05 considered significant. 
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Figure 19.  HIV-1 Vpu subtype F protein does not enhance virion release in the presence 
of hBST-2.  HeLa cells were co-transfected with SHIV Vpu and vectors expressing codon-
optimized Vpu proteins (VphuA, VphuA2, Vphu, VphuC, VphuD, VphuF, or VphuH).  
At 48 hours, the culture medium was collected and assayed for p27 and infectious virus 
released from the cells.  Panel A.  The level of p27 released from transfected cells.  
Significance in the enhancement of p27 release was calculated with respect to the 
SHIVKU-2MC4 empty vector using a Student’s t-test, with p ≤ 0.01 considered significant 
(*).  Panel B.  The level of infectious virus released as determined by infection of TZM-bl 
cells and staining for the presence of -galactosidase activity at 48 hours post-
inoculation as described in the Materials and methods section.  Significance in the 
enhancement of infectious units released was determined with respect to the Vphu 
sample using a Student’s t-test, with p ≤ 0.01 considered significant (*).  Panel C.  
Confirmation of transfection and mRNA expression of each Vphu protein as determined 
by RT-PCR analysis of RNA isolated from transfected cells (representative of all 
samples analyzed).      
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The inability of Vpu subtype F isolate 93BR020 to enhance virion release may in part be 
due to enhanced turnover of the protein 
 One possible explanation for the inability of VphuF to enhance SHIV release in the 
presence of high quantities of hBST-2 could be due to the stability of the protein.  We performed 
pulse-chase analysis of each of the Vpu/EGFP isolates to examine the rate of protein turnover.  
As shown in Figure 20, all of the Vpu isolates, except the subtype F protein, had between 40-
60% of the protein remaining following a 6 hour chase period.  The subtype F Vpu protein had 
approximately 25% protein remaining at the 6 hour chase period, which was significantly 
reduced compared to the VpuEGFP.  These results suggest that the protein stability could 
contribute to the results observed in Figure 19.  
 
Discussion 
 HIV-1 Group M isolates are responsible for more than 90% of HIV/AIDS cases 
worldwide (Jaffe and Schochetman, 1998; Simon et al., 1998a; Zekeng et al., 1994).  The 
disproportionate dissemination of subtypes could be due to random introduction into distinct 
populations, susceptibilities of different hosts based on genetics or transmission routes, and/or 
specific adaptations of the viruses.  While research over the years has provided great insight into 
specific mechanisms and molecular determinants of all of the HIV-1 encoded proteins, the 
majority of these studies have been conducted on several subtype B laboratory-adapted strains.  
Therefore, the potential for viral genetic determinants of the divergence of specific subtypes has 
remained elusive.  Several studies have been conducted comparing the relative fitness of 
different HIV-1 subtypes, providing evidence in support of specific properties exhibited by 
subtype C viruses that exacerbated their persistence in certain geographic populations 
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Figure 20.  Pulse-chase analyses of the Vpu fusion proteins.  293 cells were transfected 
with vectors expressing VpuSAEGFP, VpuSA2EGFP, VpuEGFP, VpuSCEGFP1, 
VpuSDEGFP, VpuSFEGFP, or VpuSHEGFP.  At 48 hours post-transfection, cells were 
starved for methionine/cysteine and radiolabled for 1 hour as described in the Materials 
and methods section.  The radiolabel was removed, cells washed and incubated in excess 
cold methionine/cysteine for 0-6 hours.  The cells were lysed and processed for 
immunoprecipitation assays using a rabbit anti-EGFP serum.  The immunoprecipitates 
were collected on protein A-Sepharose beads, boiled and visualized by SDS PAGE (10% 
gel) and standard autoradiographic techniques.  Untransfected 293 cells served as a 
negative control (Lane C).  The numbers above each lane represent the length of time 
chased in cold medium (Panel A).  The percent of the protein remaining at the 6 hour 
chase period was determined by densitometry (Panel B).  Significance was determined 
using a Student’s t-test, with a p<0.05 considered significant (*). 
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(Abraha et al., 2009; Arien et al., 2005; Ball et al., 2003).  Few studies have been conducted on 
specific genomic contributions of different subtypes to overall viral pathogenesis.  Hence, this 
study focused on an accessory protein involved in the enhancement of HIV-1 pathogenesis, Vpu, 
and the distinct biological properties that contribute to this phenotype. 
 In previous studies our laboratory showed that a subtype B Vpu isolate (US.HXB2) and a 
subtype C Vpu isolate (C.96BW16B01) are transported to the cell surface with distinct 
efficiencies (Pacyniak et al., 2005; Singh et al., 2003).  In this study we expanded our analyses of 
distinct biological properties exhibited by different HIV-1 Vpu subtypes.  All of the isolates 
examined maintained the ability to down-modulate CD4 from the cell surface.  Although the 
subtype A2 and C isolates were statistically less efficient at down-regulating CD4 molecules, the 
biological significance of these differences remains unknown.  All Vpu proteins, except the 
subtype F Vpu isolate enhanced SHIV virion release in HeLa cells, which express high amounts 
of hBST-2.  We observed that subtype A, A2 and C Vpu proteins more efficiently trafficked to 
the cell surface compared to the other Vpu proteins.  While it does not appear that the plasma 
membrane localization pattern affects the ability to down-modulate CD4 from the surface, it may 
have residual effects on the enhanced release function of Vpu.  It will be interesting to examine 
the replication kinetics of SHIV expressing these individual Vpu isolates in CD4
+
 T cells as well 
as in macrophages in order to further elucidate the impact that these distinct properties have on 
pathogenesis and potentially transmission.  Further studies are needed to identify the specific 
determinants, specifically signals that mediate intracellular protein trafficking and protein-
protein interactions involved in both functions of Vpu, within each of these proteins. 
During the conduction of these studies a collaborative group published a similar study 
evaluating the conservation of Vpu function among different human and non-human primate 
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lentiviruses (Sauter et al., 2009).  Sauter et al. demonstrated that both functions of Vpu were 
maintained among different vpu-containing lentiviruses, however, there were several important 
differences.  This group noted that the Vpu proteins from all 26 Group M HIV-1 isolates 
maintained the ability to down-regulate CD4 from the surface, albeit at different efficiencies, as 
did all 10 of the Group O Vpu proteins evaluated.  However, this function was not conserved 
among the rare Group N HIV-1 Vpu proteins.  These investigators also observed the 
maintenance of this function among 17 different SIV Vpu proteins, similar to results previously 
published by our laboratory (Gomez et al., 2005).  In contrast, the ability to antagonize BST-2 
was highly divergent among the different isolates and host-specific adaptations were found to be 
extremely important.  Vpu proteins from SIVGSN, SIVMUS and SIVMON were only active against 
monkey-derived BST-2 while Vpu from HIV-1 Group M isolates only counteracted hBST-2.  
HIV-1 Group N Vpu proteins also maintained the ability to counteract hBST-2, however the 
Group O Vpu proteins tested did not.  Also of note was the finding that SIVCPZ uses its Nef 
protein to antagonize BST-2 rather than the Vpu protein.  This result was interesting since 
SIVGSN, SIVMUS, SIVMON, and SIVCPZ all share a common ancestor and HIV-1 is thought to be 
derived from a cross-species transmission of SIVCPZ (Gao et al., 1999; Schindler et al., 2006).  
Based on these results, this group suggested that the evolution of the HIV-1 Group M Vpu 
proteins to antagonize hBST-2 while maintaining its ability to down-modulate CD4 contributed 
the global spread of these viruses over those of HIV-1 Group N, Group O, and HIV-2.  While the 
results of this group are extremely beneficial to the understanding of the evolution of different 
Vpu isolates and support the idea that there are specific differences among species and 
potentially subtypes of Vpu proteins, they do not address the question of the physiological 
relevance of Vpu-mediated BST-2 antagonism.  All of the experiments within this study were 
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conducted in a 293T cell line and do not address the potential for differences in functionality of 
each Vpu isolate in different cells including macrophages, dendritic cells and CD4
+
 T-
lymphocytes.  It would be interesting to see if similar results would be obtained in these different 
cell types and if not whether cell-type or subtype-specific molecular determinants could be 
identified. 
Since the subtype F Vpu isolate used in our study maintained the ability to down-
modulate CD4 from the cellular surface, but was completely devoid of any hBST-2 antagonistic 
function, it represents a potentially beneficial tool in beginning to determine: 1) whether BST-2 
antagonism is physiologically relevant; 2) whether Vpu uses mechanisms not related to BST-2 
antagonism to enhance virion release; and 3) the separation of importance for the two 
independent functions of Vpu in HIV-1 pathogenesis.  Additional studies examining the 
enhanced virion release function of this isolate in macrophages, dendritic cells and CD4
+
 T-
lymphocytes/PBMC are needed to determine if this isolate is in fact completely devoid of the 
ability to enhance virion release.  Studies determining the ability of this isolate to serve as an ion 
channel are also needed.  These results would provide the necessary data for speculation on the 
possibility for additional mechanisms of Vpu-mediated enhancement of virion release and the 
physiological relevance of BST-2 antagonism.  Also, if the subtype F Vpu isolate does lack the 
ability to enhance virion release, it would provide a wild-type Group M Vpu protein that could 
be used to test the sufficiency of CD4 surface down-modulation to modify pathogenesis using 
the SHIV macaque model of disease. 
The subtype F Vpu isolate is also a useful tool to determine specific residues that may 
contribute to the enhanced virion release function of Vpu.  Sequence analysis comparing our 
subtype F Vpu isolate to the HXB2 subtype B Vpu isolate used in our study as well as the two 
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subtype F Vpu isolates examined in Sauter et al., 2009, revealed a threonine residue at position 
19 that may be responsible for the failure to antagonize BST-2.  Sequence analysis of another 
subtype C Vpu isolate (C.96BW.H51), which preliminary results within our laboratory suggests 
is also deficient in counteracting hBST-2, also revealed a threonine at this position, suggesting 
this residue could represent a potential anti-retroviral target.  It will be interesting to determine 
whether this residue is responsible for the observed affects and whether substitution of a 
threonine at this position in fully functional Vpu proteins would result in a loss of function.   
To date, the major drawback of all studies conducted with the intention of determining 
whether subtype contributes to the progression and global distribution of different HIV-1 isolates 
is the limited number of isolates examined.  However, the number of studies being conducted is 
increasing resulting in an accumulation of the number of different isolates being analyzed.  Also, 
through the analyses of different isolates, we and other investigators have been able to identify 
specific targets within specific isolates allowing for examination of the prevalence of these 
targeted regions/residues within other isolates.   
 
Materials and Methods 
Plasmids, Viruses and Cell Culture 
The construction of plasmids expressing the subtype B Vpu (US.HXB2) and subtype C 
Vpu (96BW16B01) proteins fused to the gene for enhanced green fluorescent protein (EGFP) 
has been described previously (Pacyniak et al., 2005; Singh et al., 2003).  Vpu genes from other 
HIV-1 subtypes were amplified from near-full-length clones (VpuA, cat# 1743 (92UG037) 
obtained through the AIDS Research and Reference Reagent Program, Division of AIDS, 
NIAID, NIH: HIV-1 92UG037 from The UNAIDS Network for HIV Isolation and 
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Characterization; VpuA2, cat# 6175 (94CY017.41) obtained through the AIDS Research and 
Reference Reagent Program, NIAID, NIH: p94CY017.41 from Drs. Stanley A. Trask, Feng Gao, 
Beatrice H. Hahn, and the Aaron Diamond AIDS Research Center; VpuD, cat# 4003 (84ZR085) 
obtained through the AIDS Research and Reference Reagent Program, Division of AIDS, 
NIAID, NIH: p84ZR085.1 (Near-Full-Length) from Drs. Beatrice Hahn and Feng Gao, and the 
UNAIDS Network for HIV Isolation and Characterization; VpuF, cat# 2329 (93BR020) obtained 
through the AIDS Research and Reference Reagent Program, Division of AIDS, NIAID, NIH: 
HIV-1 93BR020 from The UNAIDS Network for HIV Isolation and Characterization; VpuH, 
cat# 4005 (90CF056) obtained through the AIDS Research and Reference Reagent Program, 
Division of AIDS, NIAID, NIH: p90CF056.1 (Near-Full-Length) from Drs. Beatrice Hahn and 
Feng Gao, and the UNAIDS Network for HIV Isolation and Characterization) with 5’ and 3’ 
NcoI restriction sites.  These fragments were purified using a Qiaquik Gel Extraction kit 
(Qiagen) and directly cloned into pGEMT-Easy by T/A overhang.  All plasmids were digested 
with the NcoI restriction endonuclease and the resulting fragments were subcloned into NcoI 
digested CIAP treated pEGFP vector (Clontech Laboratories) that has a NcoI site at the 5’ end of 
the gene for fusion to the gene expressing enhanced green fluorescent protein (EGFP).  The 
resulting plasmids were sequenced to ensure that: (1) the vpu genes were valid and inserted in the 
correct orientation and (2) the Vpu/EGFP fusions were in frame.  All vpu/egfp fusion genes were 
then purified following digestion of the plasmids with KpnI and StuI which are found on 
opposing sides of the gene fusions.  These fragments were then directly ligated into a 
pcDNA3.1(+) expression vector digested with KpnI and EcoRV.  The resulting plasmids 
contained each vpu gene fused in frame to the gene for EGFP under the control of the CMV 
immediate early promoter.  A similar plasmid was constructed that expressed only EGFP.  The 
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plasmids were identified as follows: pcvpuSAegfp; pcvpuSA2egfp; pcvpuSDegfp; pcvpuSFegfp; 
pcvpuSHegfp. 
Codon optimized sequences of HIV-1 Vpu genes from the different clinical isolates 
described above (VphuA (92UG037); VphuA2 (94CY017.41); VphuC (96BW16B01); VphuD 
(84ZR085); VphuF (93BR020); VphuH (90CR056)) were synthesized with 5’ KpnI and 3’ XbaI 
restriction sites and subcloned into a pUC57 vector (GenScript USA Inc.).  Each construct was 
digested using restriction enzymes KpnI and XbaI and subcloned into a pcDNA3.1(+) expression 
vector (Promega).  All plasmids were sequenced to ensure the validity of the gene and that no 
mutations were introduced during the cloning process.  The codon optimized subtype B Vphu 
was obtained through the NIH AIDS Research and Reference Reagent Program, Division of 
AIDS, NIAID, NIH: pcDNA-Vphu from Dr. Stephan Bour and Dr. Klaus Strebel. (cat# 10076). 
The construction of molecular clone SHIVKU-2MC4 has been described previously (Liu et 
al., 1999).  In order to construct SHIVΔVpu, another molecular clone ΔvpuΔnefSHIVPPc was used 
and the construction of this clone has been described previously (Joag et al., 1998b).  A 1444 
base pair (bp) fragment was removed from SHIVKU-2MC4 using restriction enzymes SphI and 
NheI.  This fragment was replaced with the corresponding 1382 bp fragment of 
ΔvpuΔnefSHIVPPc.  The resulting construct expressed a Vpu protein with a 62 bp deletion and 
an inactive start codon (SHIVΔVpu).   
The HeLa cell line was obtained through the AIDS Research and Reference Reagent 
Program, Division of AIDS, NIAID, NIH: (specify cell line) from Dr. Richard Axel.  The 293 
and HeLa cell lines were maintained in Dulbecco’s minimal essential medium (DMEM) 
supplemented with 10% fetal bovine serum, gentamicin (5 ug per mL) and 
penicillin/streptomycin (100 U per mL and 100 μg per mL, respectively).   The TZM-bl cell line 
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was obtained through the NIH AIDS Research and Reference Reagent Program, Division of 
AIDS, NIAID, NIH: TZM-bl from Dr. John C. Kappes, Dr. Xiaoyun Wu and Tranzyme Inc.  
The HeLa CD4
+
 cell line was obtained through the AIDS Research and Reference Reagent 
Program, Division of AIDS, NIAID, NIH: HeLa CD4 Clone 1022 from Dr. Bruce Chesebro.  
TZM-bl cells were maintained in Dulbecco’s minimal essential medium supplemented with 10% 
fetal bovine serum, gentamicin (5 µg per mL), and penicillin/streptomycin (100 U per mL and 
100 µg per mL, respectively).  HeLa CD4
+
 cells were maintained in Dulbecco’s minimal 
essential medium supplemented with 10% fetal bovine serum, gentamicin (5 µg per mL), 
penicillin/streptomycin (100 U per mL and 100 µg per mL, respectively) and G-418 (1 mg per 
mL).     
 
Laser Scanning Confocal Fluorescence Microscopy Analysis 
Plasmids expressing VpuEGFP fusion proteins were transfected into 293 cells to assess 
subcellular localization using a cationic polymer (polyethylenimine) transfection reagent 
(ExGen
TM
 500, MBI Fermentas) according to the manufacturer’s instructions.  Briefly, 105 cells 
were seeded onto cover slips in each well of a 6-well tissue culture plate 24 hours prior to 
transfection.  Plasmid DNA (4.75 µg) was diluted in 300 µl of 150 mM sodium chloride solution 
and vortexed gently.  Polyethylenimine was then added to the solution, vortexed and allowed to 
stand at room temperature for 10 minutes.  The 293 cells were washed and 3.0 mL of media was 
added.  The polyethylenimine/DNA mixture was added to the cells dropwise and the cultures 
were incubated at 37C in 5% CO2 atmosphere.  At 48 hours post-transfection, cells were washed 
in phosphate buffered saline (PBS, pH 7.2) and fixed in ice cold 2% paraformaldehyde for 5 
minutes.  The cells were washed again in PBS and the cover slips mounted onto microscope 
137 
 
slides using mounting media (Slowfade Antifade, Molecular Probes).  The cells were imaged 
with a Zeiss LSM 510 confocal microscope in the upright configuration.  The objective used was 
a 63X 1.4n.a. Plan Apochromat.  Images were captured at 12 bit resolution with a pixel array of 
2048 x 2048 and a zoom of 2.0X.  The EGFP was excited with light at 488 nm with a constant 
laser intensity, and the emitted light was collected after passing through a 505 nm long pass 
filter.  The amplifier offset and gain were identical for all images.  The pinhole was set to 96 µm 
which at this wavelength represents one airey unit.  The optical section had a width of 0.7 µm.  
 
Pulse-Chase Analysis to Assess Protein Stability 
Plasmids expressing VpuEGFP fusion proteins were transfected into 293 cells to assess 
the rate of protein degradation using the ExGen
TM
 500 transfection reagent.  Briefly, 2.5x10
5
 
cells were seeded into 35 mm dishes 24 hours prior to transfection.  Plasmid DNA (3 µg) was 
diluted in 300 µl of 150 mM sodium chloride solution and vortexed gently.  Polyethylenimine 
was then added to the solution, vortexed and allowed to stand at room temperature for 10 
minutes.  The 293 cells were washed and 3.0 mL of media was added.  The 
polyethylenimine/DNA mixture was added to the cells dropwise and the cultures were incubated 
at 37C in 5% CO2 atmosphere.  At 48 hours post-transfection, the medium was removed and 
cells were incubated in methionine/cysteine-free medium at 37C for 2 hours.  The cells were then 
radiolabeled with 200 µCi of 
35
S-Translabel (methionine and cysteine, MP Biomedical) for 1 
hour.  The radiolabel was chased in DMEM containing 100X unlabeled methionine/cysteine 
medium for 0, 3 and 6 hours.  VpuEGFP proteins were immunoprecipitated using a rabbit anti-
EGFP antiserum and collected on Protein A-Sepharose beads on a rotator for 18 hours.  Non-
transfected 293 cells, starved, radiolabeled and chased for 0 hours served as a negative control.  
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Beads were washed three times with 1X radioimmunoprecipitation buffer (RIPA: 50 mM Tris-
HCl, pH 7.5; 50 mM NaCl; 0.5% deoxycholate; 0.2% SDS; 10 mM EDTA) and the samples 
resuspened in 1X sample reducing buffer.  Samples were boiled and the VpuEGFP proteins 
separated by SDS-PAGE (10% gel).  Proteins were then visualized using standard 
autoradiographic techniques.  All conditions were run in duplicate, the pixel densities of each 
band determined using ImageJ software, normalized to the hour 0 sample, and the average 
percent protein remaining calculated.  Significance in percent protein remaining was determined 
using a Student’s t-test with p<0.05 considered significant.   
 
CD4 Surface Expression Analysis 
For analysis of cell surface CD4 expression in the presence of each Vpu subtype, 2.5 x 
10
5
 HeLa CD4
+
 cells were seeded into each well of a 6-well tissue culture plate 24 hours prior to 
transfection.  Cells were transfected with vectors expressing each VpuEGFP protein as described 
above.  Cells transfected with a vector expressing EGFP only were used as the control.  At 48 
hours post-transfection, cells were removed from the plate using Ca
2+
/Mg
2+
-free PBS containing 
10 mM EDTA and stained with Phycoerythrin-Cyanine 5 (PE-Cy5) conjugated anti-CD4 
antibody (BD Bioscience).  Cells were analyzed using an LSRII flow cytometer determining the 
mean fluorescence intensity (MFI) of PE-Cy5 for transfected (EGFP positive) and untransfected 
(EGFP negative) cells within the same well.  An MFI ratio was calculated for each sample with 
the EGFP only control normalized to 1.0.  Normalized ratios from at least three separate 
experiments were averaged and the standard error calculated.  Significance was determined by 
comparing all groups to the EGFP only control as well as the VpuEGFP sample using a 
Student’s t-test with a p<0.05 considered significant.   
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Virion Release Assays 
Hela cells (10
5
) were seeded into each well of a 24-well tissue culture plate 24 hours prior 
to transfection.  Cells were transfected as described above with 1 µg of plasmid expressing full 
length SHIV proviral DNA (either SHIVKU-2MC4 or SHIVΔVpu) and 500 ng of plasmid expressing 
each Vphu subtype.  Cells were incubated at 37C in 5% CO2 atmosphere for 48 hours.  
Supernatants were collected and cellular debris removed through low speed centrifugation.  Cells 
were lysed in 250 µl of 1X RIPA buffer and the nuclei removed through high speed 
centrifugation. The amount of p27 present within the supernatant and the cell lysates was 
determined using a commercially available p27 ELISA kit (Zeptometrix Incorporated) and the 
percent of p27 release calculated.  All conditions were run at least three separate times and the 
average percent p27 release and standard error calculated.  Significance with respect to the 
SHIV Vpu control was calculated using a Student’s t-test with a p<0.05 considered significant. 
 
Infectious Units Release Assays 
TZM-bl cells (10
4) expressing luciferase and β-galactosidase genes under the control of 
an HIV-1 promoter were seeded into each well of a 96-well tissue culture plate 24 hours prior to 
infection.  Supernatants collected from HeLa cells co-transfected with SHIV Vpu and Vphu 
subtype expressing plasmids as described above were added to the TZM-bl cells and serially 
diluted (10-fold).  At 48 hours post-infection, cells were washed twice in 1X PBS and fixed in a 
solution of 0.25% glutaraldehyde and 0.8% formaldehyde in PBS for 5 minutes at room 
temperature.  The cells were washed three times in 1X PBS and covered in staining solution (400 
µg per mL X-gal, 4 mM MgCl2, 4 mM K3Fe(CN)6, 4 mM K4Fe(CN)6-3H2O in phosphate 
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buffered saline) and incubated for 2 hours at 37C.  Cells were washed once in 1X PBS and then 
covered in 1X PBS during counting.  The TCID50 for each supernatant was calculated based on 
wells containing cells expressing β-galactosidase.  All conditions were run at least three times 
and the TCID50 calculated.  The average TCID50 and standard error were calculated.  
Significance in the restriction of infectivity was determined with respect to the SHIVKU-2MC4 
sample using a Student’s t-test with p<0.05 considered significant. 
  
141 
 
IX.   Chapter 4: Modulation of the Severe CD4
+
 T Cell Loss Caused by a Pathogenic 
Simian-Human Immunodeficiency Virus by Replacement of the Subtype B Vpu with the 
Vpu from a Subtype C HIV-1 Clinical Isolate 
 
Abstract 
Previously, we showed that the Vpu protein from human immunodeficiency virus type 1 
(HIV-1) subtype C was efficiently targeted to the cell surface suggesting that this protein has 
biological properties that differ from the well-studied subtype B Vpu protein.  In this study, we 
have further analyzed the biological properties of the subtype C Vpu protein.  Flow cytometric 
analysis revealed that the subtype B Vpu (strain HXB2) was more efficient at down-regulating 
CD4 surface expression than the Vpu proteins from four subtype C clinical isolates.  We 
constructed a simian-human immunodeficiency virus, designated as SHIVSCVpu, in which the 
subtype B vpu gene from the pathogenic SHIVKU-1bMC33 was substituted with the vpu from a 
clinical isolate of subtype C HIV-1 (strain C.96BW16B01).  Cell culture studies revealed that 
SHIVSCVpu replicated with slightly reduced kinetics when compared with the parental SHIVKU-
1bMC33 and that the viral Env and Gag precursor proteins were synthesized and processed 
similarly compared to the parental SHIVKU-1bMC33.  To determine if substitution of the subtype C 
Vpu protein affected the pathogenesis of the virus, three pig-tailed macaques were inoculated 
with SHIVSCVpu and circulating CD4
+
 T cell levels and viral loads were monitored for up to 44 
weeks.  Our results show that SHIVSCVpu caused a more gradual decline in the rate of CD4
+
 T 
cells in pig-tailed macaques compared to those inoculated with parental subtype B SHIVKU-
1bMC33.  These results show for the first time that different Vpu proteins of HIV-1 can influence 
the rate at which CD4
+
 T cell loss that occurs in the SHIV/pig-tailed macaque model. 
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Introduction 
All the naturally occurring primate lentiviruses encode for Tat, Rev, Nef, Vif and Vpr 
accessory proteins.  In addition to these accessory proteins, human immunodeficiency virus type 
1 virus (HIV-1) and a select number of simian immunodeficiency virus (SIV) isolates (SIVCPZ, 
SIVDEN, SIVGSN, SIVMON, SIVMUS) also encode for a Vpu protein (Barlow et al., 2003; 
Courgnaud et al., 2002; Dazza et al., 2005; Huet et al., 1990).  Previously, we and others 
demonstrated that different HIV-1 Vpu subtypes exhibit distinct biological properties that could 
alter their ability to modify transmission and/or pathogenicity (See Chapter 3).  This included the 
intracellular localization of the different proteins, their ability to down-modulate CD4 from the 
cell surface, and their ability to enhance SHIV virion release in the presence of hBST-2.  These 
studies, however, did not explore the physiological relevance of these differences.  Hence, this 
study focused on determining whether subtypes that exhibit distinct biological properties also 
differentially modify pathogenesis.  Because SIVMAC strains commonly used in pathogenicity 
studies do not encode for the Vpu protein, we have used the pathogenic simian human 
immunodeficiency virus (SHIV), which has the tat, rev, vpu and env genes of HIV-1 in a genetic 
background of the SIVMAC239, to analyze the role of Vpu in pathogenicity.  Infection with these 
pathogenic SHIVs results in high viral loads, a rapid loss of CD4
+
 T cells within one month of 
infection, and severe depletion within lymphoid organs such as the thymus, lymph nodes and 
spleen.  To date, all studies assessing the role of Vpu in macaques have been performed using the 
well-studied subtype B Vpu protein from a laboratory-adapted HIV-1 isolate (NL4-3).  Based on 
our previous examination of seven different HIV-1 Vpu proteins, we chose to further analyze the 
biological properties of subtype C Vpu.   
143 
 
Previously, we reported that a clinical isolate of subtype C Vpu (C.96BW16B01) was: 1) 
more efficiently transported to the cell surface compared to other Vpu proteins; 2) maintained the 
ability to degrade CD4, although slightly less efficiently than other Vpu proteins; and 3) 
maintained the ability to enhance virion release in the presence of hBST-2.  Other investigators 
have also shown that while subtype C HIV-1 isolates are less replicatively fit in peripheral blood 
mononuclear cell (PBMC) competition assays, they display equal fitness in Langerhan cells as 
well as in penial, cervical and rectal tissue explants (Abraha et al., 2009; Arien et al., 2005; Ball 
et al., 2003).  These studies suggest that subtype C viruses may have evolved to be more 
efficiently transmitted sexually and less virulent in order to ensure long-term persistence within 
the host, which may contribute to the predominance of subtype C HIV-1 viruses worldwide.  In 
this study, we report that the trend of slightly diminished CD4 down-modulation compared to the 
subtype B Vpu protein was maintained among four separate subtype C Vpu isolates.  Also, using 
the pathogenic molecular clone, SHIVKU-1bMC33, we report on the construction of a SHIV in 
which the subtype B vpu was exchanged with the vpu from a clinical isolate of subtype C HIV-1 
(SHIVSCVpu). Our results show that following inoculation into macaques, SHIVSCVpu had a 
decreased rate of CD4
+
 T cell loss compared with the parental SHIVKU-1bMC33.  These results 
show for the first time that different Vpu proteins can influence the rate of CD4
+
 T cell loss in 
the SHIV/macaque model. 
 
Results 
CD4 down-regulation by subtype B and C Vpu proteins 
The sequence of the subtype B and C Vpu proteins analyzed in this study are shown in 
Figure 21.  Previously, we showed that fusion of the Vpu protein to enhanced green fluorescent 
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protein (EGFP) still resulted in the ability to down-modulate cell surface CD4 (Hout et al., 2005; 
Singh et al., 2003). We analyzed the efficiency of cell surface CD4 down-regulation by the 
subtype B and C Vpu fusion proteins.  HeLa CD4+ cells were transfected with vectors 
expressing either the subtype B or C Vpu fusion proteins. At 48 hours post-transfection, live 
cells were immunostained for CD4 and analyzed by flow cytometry to measure the intensity of 
cell surface CD4 expression. As shown in Figure 22, the cells transfected with the vector 
expressing the subtype B fusion (VpuEGFP) consistently down-regulated CD4 more efficiently 
(p<0.008) than cells transfected with the vector expressing the subtype C Vpu fusion protein 
(VpuSCEGFP1).  We also analyzed the ability of three additional subtype C Vpu fusions to EGFP 
(IN21068, BW04.07, and BW06.H51) fusion proteins to down-regulate CD4 surface expression. 
As shown in Figure 22, all three Vpu proteins were significantly less efficient (p<0.05) at 
preventing CD4 surface expression compared to the HXB2 Vpu protein. 
 
The SHIVSCVpu virus expresses the Vpu protein within infected cells 
We analyzed the expression of the Vpu protein in C8166 cultures inoculated with 
parental SHIVKU-1bMC33 or SHIVSCVpu.  Cultures were inoculated with equivalent amounts of 
virus and at 5 days post-inoculation, cells were radiolabeled and Vpu proteins 
immunoprecipitated from cell lysates.  As shown in Figure 23, a protein with a relative 
molecular mass (Mr) of 16,000 was immunoprecipitated from SHIVKU-1bMC33-inoculated 
cultures.  A Vpu protein was also immunoprecipitated from SHIVSCVpu-inoculated C8166 
cultures with a slightly slower mobility in SDS–PAGE, which may be due to the larger size (85 
vs. 82 amino acids) of the subtype C Vpu protein (Figure 23). 
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Figure 21.  Comparison of the Vpu sequences analyzed in this study. 
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Figure 22.  The subtype C Vpu is less efficient at down-modulating surface CD4 than the 
subtype B Vpu protein.  HeLa CD4
+
 cells were transfected with plasmids expressing 
EGFP, VpuEGFP, VpuSCEGFP1, VpuSC(95IN21068)EGFP, VpuSC(96BW06.H51), or 
VpuSC(96BW04.07).  At 48 hours, live cells were immunostained for CD4.  Cells 
expressing EGFP or EGFP fusion proteins were assessed for CD4 surface expression 
using flow cytometry.  CD4 expression in cells expressing the various Vpu proteins was 
normalized to CD4 expression in EGFP expressing cells.  (*) symbol above bar 
represents Vpu isolates that were less efficient at down-modulating CD4 from the cell 
surface compared to VpuEGFP, with a p < 0.05 considered significant. 
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Figure 23.  The Vpu protein is expressed in C8166 cells infected with SHIVSCVpu.  C8166 
cells were infected with SHIVKU-1bMC33 or SHIVSCVpu for 5 days.  The cells were 
incubated in DMEM lacking methionine and cysteine for 2 hours.  Cells were 
radiolabeled with 500 µCi of 
35
S Translabel (ICN Biomedical) for 12 hours.  
Supernatants were removed, cells lysed in 1X RIPA buffer and the nuclei removed 
through centrifugation.  Cell lysates were immunoprecipitated using an antisera 
generated against the cytoplasmic domain of the subtype B Vpu protein and protein A-
Sepharose beads.  Immune precipitates were washed and separated on a 10% SDS-
PAGE gel and visualized using standard autoradiography techniques.  (Lane 1) Vpu 
proteins immunoprecipitated from SHIVKU-1bMC33-inoculated cultures.  (Lane 2)  Vpu 
proteins immunoprecipitated from SHIVSCVpu-inoculated cultures.  (Lane 3) Vpu 
proteins immunoprecipitated from uninfected cultures. 
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Pulse-chase analysis reveals that SHIVSCVpu precursor proteins are synthesized and 
processed with similar kinetics compared to parental SHIVKU-1bMC33 
Previous studies have shown that Vpu expression results in more efficient release of virus 
particles from infected cells.  We used pulse-chase analysis to determine if substitution of the 
subtype B vpu for the subtype C vpu would result in similar release of viral structural proteins 
from infected cells.  These results indicate that the substitution of the subtype B vpu with the 
subtype C vpu did not significantly alter the processing of Gag and Env precursor proteins 
(Figure 24). 
 
SHIVSCVpu replicates with delayed kinetics and is less cytopathic compared to parental 
SHIVKU-1bMC33 
We analyzed the growth kinetics of the parental SHIVKU-1bMC33 and the SHIVSCVpu 
following inoculation of C8166 cell cultures.  As shown in Figure 25, SHIVSCVpu replicated with 
reduced kinetics as compared to the parental SHIVKU-1bMC33.  While the amount of p27 released 
appeared to be delayed by 2 days, the rate of p27 release from 7 to 10 days was reproducibly 
similar. At the end of the experiment, the amount of p27 released from SHIVSCVpu-inoculated 
cultures was 86% of the p27 found in the parental SHIVKU-1bMC33-inoculated cultures.  However, 
the kinetics of p27 release was different from C8166 cells inoculated with SHIVTM, which has a 
scrambled transmembrane domain (Hout et al., 2005), or from cultures inoculated with 
novpuSHIVKU-1bMC33, which lacks the vpu sequences prior to the env (Stephens et al., 2002).  We 
also compared the pattern of virus maturation in cultures inoculated with parental SHIVKU-1bMC33 
and SHIVSCVpu using electron microscopy. The results shown in Figure 26 indicate that 
SHIVSCVpu matures from the cell surface similar to parental SHIVKU-1bMC33.  The reduced kinetics 
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of p27 release was also reflected in the time before the appearance of syncytial cytopathology.  
With the parental SHIVKU-1bMC33, cytopathology generally appears 3 to 4 days post-inoculation, 
whereas SHIVSCVpu-inoculated cultures displayed cytopathology starting 5 to 6 days post-
inoculation. Additionally, the syncytia formation did not appear to be as extensive as SHIVKU-
1bMC33, suggesting that this subtype C Vpu protein could influence the ability to form syncytia in 
culture (data not shown). 
 
The subtype C Vpu does not influence the incorporation of envelope glycoprotein into viral 
particles 
We determined if substitution of the subtype B vpu with the subtype C vpu would 
influence the incorporation of Env into viral particles. SHIVKU-1bMC33 and SHIVSCVpu were used 
to infect C8166 cells and radiolabeled at 6 days post-inoculation.  The virus containing culture 
medium was harvested and virus pelleted through a 20% sucrose cushion.  The pellet was lysed 
and the SHIV proteins immunoprecipitated using an anti-SHIV serum.  The immunoprecipitated 
proteins were analyzed by SDS–PAGE and densitometry to determine the ratio of Gag p27 
protein to Env gp120.  As shown in Figure 27, the ratio of immunoprecipitated p27 to gp120 was 
approximately equal for the two viruses, SHIVKU-1bMC33 (ratio 4.31) and SHIVSCVpu (ratio 4.89), 
suggesting that exchanging the subtype B vpu for the subtype C vpu did not influence the level of 
Env (gp120) associated with particles. 
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Figure 24.  Pulse-chase analysis of the SHIVSCVpu proteins.  C8166 cells were inoculated 
with 10
3
 TCID50 of either SHIVKU-1bMC33 or SHIVSCVpu.  At 7 days post-infection, the 
medium was removed and the cells were incubated in DMEM lacking methionine and 
cysteine for 2 hours.  The cells were radiolabeled for 30 minutes with 1mCi per ml of 
35
S-Translabel (ICN Biomedical) and the radiolabel chased for various periods of time 
(0-6 h) in DMEM containing 100X unlabeled methionine/cysteine.  SHIV proteins were 
immunoprecipitated from cell lysates using plasma pooled from several pig-tailed 
macaques infected previously with non-pathogenic SHIV-4 and protein A-Sepharose 
beads as described in the Materials in methods section.  Immune precipitates were 
washed and separated on a 10% SDS-PAGE gel and visualized using standard 
autoradiography techniques.  Uninfected C8166 cells, radiolabeled and chased for 6 
hours, served as a negative control (C).  Panel A.  Results of pulse-chase analysis of viral 
proteins immunoprecipitated from SHIVKU-1bMC33 infected cell lysates.  Panel B.  Results 
of pulse-chase analysis of viral proteins immunoprecipitated from SHIVSCVpu infected 
cell lysates. 
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Figure 25.  The kinetics of replication of SHIVKU-1bMC33 and SHIVSCVpu in C8166 cell 
cultures.  Cultures of C8166 cells were inoculated with either SHIVKU-1bMC33 or 
SHIVSCVpu.  Aliquots of the culture medium were assayed for the presence of p27 
antigen.  The growth curves were performed in triplicate and the mean of the three 
experiments plotted.   
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Figure 26.  Electron microscopy examination of C8166 cells inoculated with SHIVKU-
1bMC33 or SHIVSCVpu.  C8166 cells were inoculated with either SHIVKU-1bMC33 or 
SHIVSCVpu for 7 days.  Cells were washed three times with PBS and processed for 
electron microscopy as described in the Materials and methods section.  Panel A.  C8166 
cells inoculated with SHIVSCVpu.  Panel B.  C8166 cells inoculated with parental 
SHIVSCVpu showing a virus particle maturing at the cell surface.  Panel C.  C8166 cells 
inoculated with parental SHIVKU-1bMC33.  Panel D.  C8166 cells inoculated with parental 
SHIVKU-1bMC33 showing a particle maturing at the cell surface.  
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Figure 27.   Envelope incorporation into SHIVKU-1bMC33 and SHIVSCVpu virions.  C8166 
cells were inoculated with either SHIVKU-1bMC33 or SHIVSCVpu for 6 days.  At 6 days post-
inoculation, cultures were radiolabeled as described in the Materials and methods 
section.  The virus culture supernatants were centrifuged through a 20% sucrose 
cushion and lysed for immunoprecipitation.  SHIV proteins were immunoprecipitated 
from cell lysates using plasma pooled from several pig-tailed macaques inoculated 
previously with SHIV-4 and protein A-Sepharose beads as described in the Materials 
and methods section.  Uninfected C8166 cells served as a negative control.  All 
immunoprecipitates were washed and separated on a 10% SDS-PAGE gel and 
visualized using standard autoradiography techniques.  (Lane 1) Proteins 
immunoprecipitated from SHIVSCVpu infected cell lysates.  (Lane 2)  Proteins 
immunoprecipitated from uninfected cell lysates.  (Lane 3)  Proteins 
immunoprecipitated from SHIVKU-1bMC33 infected cells.  Molecular weight markers 
(kDa) are to the right of the gel. 
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The rate of CD4
+
 T cell loss was decreased and viral loads lower in SHIVSCVpu inoculated 
macaques 
To determine whether the SHIVSCVpu was capable of causing disease in pig-tailed 
macaques, three macaques (CX56, CX57, and PLG2) were inoculated with SHIVSCVpu and CD4
+
 
T cells, and viral loads followed for up to 44 weeks.  Macaque CX56 and CX57 were euthanized 
in a moribund condition at 36 and 44 weeks post-inoculation.  Macaque PLG2 was euthanized at 
40 weeks post-inoculation following development of severe enteritis.  The circulating CD4
+
 T 
cell levels are shown in Figure 28A and indicate that all three macaques developed a gradual 
decline in the levels of circulating CD4
+
 T cells during the course of their infection. The rate of 
circulating CD4
+
 T cell loss in macaques inoculated with SHIVSCVpu was clearly decreased 
compared to parental SHIVKU-1bMC33 (Figure 28B).  The rate of CD4
+
 T cell loss was found to be 
statistically significant (p ≤ 0.01).  We also found that the early peak viral loads (between 1 and 3 
weeks) in macaques inoculated with SHIVSCVpu were approximately 10-fold less than in 
macaques inoculated with the parental SHIVKU-1bMC33 (Figures 28C and D). 
 
Sequence analysis of the vpu gene isolated from SHIVSCVpu inoculated macaques 
We analyzed the sequence of the vpu genes amplified from PBMC at different times post-
inoculation and three lymphoid tissues (spleen, thymus and mesenteric lymph node) at necropsy.  
In all three macaques, we found scattered amino acid substitutions at different times post-
inoculation but no consensus amino acid substitutions (data not shown). 
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Figure 28.  Circulating CD4
+
 T cell levels and plasma viral loads following inoculation of 
macaques with SHIVKU1b-MC33 and SHIVSCVpu.  Panel A.  The levels of circulating CD4
+ 
T 
cells in macaques (2000, ♦; CM4G, ■; CM4K, ▲) following inoculation with SHIVKU-
1bMC33.  Panel B.  The levels of circulating CD4
+
 T cells in macaques (CX56, ♦; CX57, ■; 
PLg2, ▲) following inoculating with SHIVSCVpu.  Panel C.  Plasma viral RNA levels in 
macaques (2000, ♦; CM4G, ■; CM4K, ▲) following inoculation with SHIVKU-1bMC33.  
Panel D.  Plasma viral RNA levels in macaques (CX56, ♦; CX57, ■; PLg2, ▲) following 
inoculating with SHIVSCVpu.  RNA samples were subjected to real-time RT-PCR and 
Taqman probe homologous to the SIV gag gene.  Standard curves were generated using 
five dilutions of viral RNA of known concentrations. 
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The pathology in lymphoid organs at necropsy was similar to the parental SHIVKU-1bMC33 
We examined the histological sections from tissues of macaques inoculated with 
SHIVSCVpu at necropsy and compared the lesions to those observed following inoculation with 
parental SHIVKU-1bMC33.  No significant histological lesions were observed in the 15 regions of 
the brain and spinal cord (central nervous system; CNS), the heart, liver, lungs, kidney, or 
pancreas.  The lack of histological lesions in the CNS is not surprising as the parental SHIVKU-
1bMC33 is not a neuropathogenic virus.  As shown in Figure 29, the SHIVSCVpu inoculated 
macaque CX56 developed severe atrophy of the thymus, marked lymphoid depletion with little 
follicular activity in the lymph nodes, and moderate lymphoid depletion in the spleen. These 
lesions were similar to that seen in macaques inoculated with parental SHIVKU-1bMC33.  Macaque 
CX57 developed similar lymphoid depletion in the thymus and lymph nodes but no significant 
lesions were found in the spleen.  Macaque PLG2 developed severe enteritis and protracted 
diarrhea.  This macaque developed thymus atrophy and moderate depletion in the lymph nodes.  
The distribution of virus in the various visceral organs was determined by PCR for viral gag and 
2-LTR sequences.  All three macaques were positive for gag sequences in all 13 visceral organs 
despite exsanguination with 1 liter of saline (data not shown).  We also examined tissue RNA for 
the presence of viral RNA.  As shown in Figure 30, viral RNA sequences were detected in RNA 
sequences isolated from 7 of 13, 7 of 13, and 6 of 13 visceral organs from CX56, CX57, and 
PLG2, respectively.  The majority of the tissue RNAs that were positive for the presence of viral 
RNA sequences were from lymphoid organs.  We also analyzed the RNA samples of tissues 
from 15 regions of the CNS for viral RNA sequences.  Macaques CX56, CX57, and PLG2 had 
no regions of the brain and spinal cord that were positive for viral RNA sequences (data not 
shown). 
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Figure 29.  Histopathology associated with SHIVSCVpu infection of macaques.  
Hematoxylin and eosin stains of sections from the thymus (Panels A and B), mesenteric 
lymph node (Panels C and D), and spleen (Panels E and F) from a non-infected age-
matched macaque (Panels A, C, and E) and macaque CX56 (Panels B, D, and F). 
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Figure 30.  Distribution of virus in macaques CX56, CX57, and PLg2.  Viral sequences 
were amplified using RT-PCR from RNA samples isolated from visceral and lymphoid 
organs from macaques CX56 (Panel A), CX57 (Panel B), and PLg2 (Panel C).  The 
order of the gels are: (Lane 1) Positive control (RNA from SHIV infected C8166 cells),  
(Lane 2) Negative control (RNA isolated from lymph node of an uninfected macaque),  
(Lane 3) Heart, (Lane 4) Liver, (Lane 5) Lung, (Lane 6) Kidney, (Lane 7) Pancreas, 
(Lane 8) Salivary gland, (Lane 9) Mesenteric lymph node, (Lane 10) Axillary lymph 
node, (Lane 11) Inguinal lymph node, (Lane 12) Small intestine, (Lane 13) Spleen, (Lane 
14) Thymus, and (Lane 15) Tonsil.   
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Discussion 
The vast majority of HIV-1 infections are in Sub-Saharan Africa, where an estimated 60–
70% of infected people reside (UNAIDS, 2008).  Within the HIV-1 Group M pandemic, subtype 
C has increased in prevalence over the past 10 years, accounting for approximately 50% of the 
infections worldwide (Essex, 1999; Hemelaar et al., 2006; Takeb et al., 2004), and is most 
prominent in east Africa, south Africa, India and parts of China.  In one study, both NSI/R5 and 
SI/X4 subtype C HIV-1 isolates were found to be significantly less fit in PBMC competition 
assays compared to all other group M isolates of the same phenotype (Ball et al., 2003).  More 
recently, in a study that evaluated the replicative fitness of representative strains from subtypes 
A, B, C, D and CRF01_AE, the subtype C viruses had less replicative fitness in PBMC 
compared to the other subtypes.  However, the subtype C isolates still replicated 100-fold higher 
than HIV-2 or group O isolates (Arien et al., 2005; Arien et al., 2007).  Although less fit for 
replication in PBMC, the subtype C viruses were found to be similar to subtype B viruses for 
replicative fitness in skin-derived Langerhans cells, suggesting that these viruses might be more 
efficiently transmitted (Ball et al., 2003).  In another study, subtype C HIV-1 was associated with 
the increased vaginal shedding of virus (John-Stewart et al., 2005).  These data suggest that the 
relatively poor replication efficiency of subtype C in PBMCs (and possibly lymphoid organs) 
may be related to slower disease progression, hence, longer survival of the human host, which in 
turn could lead to increased time for transmission (Ball et al., 2003; Quinones-Mateu et al., 
2000).   
The subtype C Vpu protein has structural motifs that differ from the well-studied subtype 
B Vpu protein, and these may be associated with different biological properties of these two 
proteins (Hout et al., 2004).  The subtype C Vpu proteins have an additional potential CK-II site 
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(TMVD) downstream from the two consensus sites.  Other, potentially interesting sequence 
motifs unique to the subtype C Vpu proteins are two canonical dileucine motifs (E/D-X-X-X-L-
L/I), one proximal to the transmembrane domain and one towards the carboxyl terminus of the 
Vpu protein.  An acidic residue located at position 4, 5, or 6 upstream of the dileucine motif has 
been shown by investigators to be required for the efficient internalization of several proteins 
(Bonifacino and Traub, 2003).  Dileucine motifs are known to interact with adaptor protein 
complexes AP-1, AP-2, and AP-3, resulting in the recruitment of cargo into clathrin coated pits 
and clathrin-coated vesicles (Bonifacino and Traub, 2003).  Previous studies have implicated 
dileucine-based motifs in the sorting of membrane proteins to cellular sites such as the trans-
Golgi network (TGN), endosomes, lysosomes, and plasma membrane (Bonifacino and Traub, 
2003).  The HIV-1 Nef protein associates with the inner side of the cell plasma membrane via its 
myristylated amino terminus.  Importantly, the HIV-1 Nef, which also interacts with and down-
regulates CD4 from the surface of infected cells, has a dileucine motif at the carboxyl terminus.  
This dileucine motif is required for CD4 down-regulation (Aiken et al., 1994; Bresnahan et al., 
1998; Craig et al., 1998; Goldsmith et al., 1995).  Our analysis indicates that the subtype C Vpu 
proteins from Indian and African subtype C isolates have “DM-GRLRLL” or “DMDGLRLL” 
motifs close to the carboxyl terminus, which closely fit the consensus motif described above.  
Thus, if these sequences are found to be responsible for altered biological properties, it has 
potential significance to HIV-1 pathogenesis, since subtype C isolates represent approximately 
50% of the HIV-1 infections worldwide (Takeb et al., 2004).   
In addition to differences regarding structural motifs, the subtype B and C have different 
biological properties. Using a reporter system that fused the Vpu protein to enhanced green 
fluorescent protein (EGFP), we previously showed that the subtype B Vpu protein is 
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predominantly localized in the Golgi complex of the cell while the subtype C Vpu protein was 
transported to the cell plasma membrane (Pacyniak et al., 2005).  In our data presented here, we 
used flow cytometric analysis to compare the efficiency of subtype C Vpu proteins at down-
regulating CD4 from the cell surface.  These studies revealed that the efficiency of subtype B 
Vpu CD4 down-regulation was statistically different than four subtype C Vpu proteins. Although 
the physiological significance of this difference is currently unknown, these results demonstrate 
a potentially additional distinction in the biological properties of the subtype C and B Vpu 
proteins. 
In previous studies using a pathogenic molecular clone of simian–human 
immunodeficiency virus known as SHIVKU-1bMC33, we showed that the subtype B Vpu protein 
contributes to the profound CD4
+
 T cell loss following inoculation into pig-tailed macaques 
(Hout et al., 2005; Singh et al., 2003; Singh et al., 2001; Stephens et al., 2002).  These studies 
showed that the two casein kinase II sites and the transmembrane domain contribute to the rapid 
CD4
+
 T cell loss following inoculation into macaques. Furthermore, we showed that the Vpu 
transmembrane domain could be replaced with the TM domain of the M2 protein of influenza A 
virus and retain pathogenicity in pig-tailed macaques (Hout et al., 2006b).  Thus, this model has 
been useful in the molecular analysis of those domains of Vpu that are necessary for disease 
progression.  Attempts have been made to construct pathogenic SHIVs expressing the env gene 
from subtype C HIV-1 (Chen et al., 2000; Ndung'u et al., 2001).  In one of these studies, 
investigators constructed a SHIV expressing an R5 envelope glycoprotein (including the C-
terminal end of the Vpu protein which contains the most amino acid divergence between the 
subtype B and C Vpu proteins) from a subtype C HIV-1 isolate (strain CHN19).  These 
investigators found that this virus was capable of replicating in pig-tailed macaque PBMC but 
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not rhesus macaque PBMC.  They observed that with serial passage in pig-tailed macaques, the 
virus replicated more efficiently.  However, these macaques never developed significant CD4
+
 T 
cell loss and functionality of this chimeric Vpu was not determined (Chen et al., 2000).  In 
another study, a SHIV was constructed with the majority of the subtype C env gene (the gp120 
region starting just past the vpu ORF and part of gp41) into a SHIV89.6P based virus (Ndung'u 
et al., 2001).  This virus was found to replicate in both rhesus and pig-tailed macaques. This 
virus was capable of replicating to high peak viral loads in rhesus macaques but did not result in 
significant CD4
+
 T cell loss.  In our studies presented here, we have concentrated on the 
contribution of the subtype C Vpu in the pathogenic SHIV/macaque model system. We 
hypothesized that if a SHIV expressing a Vpu protein from another subtype of HIV-1 (in this 
case, subtype C) still resulted in severe CD4
+
 T-cell loss, it would suggest that the divergent 
sequence of this Vpu (particularly the carboxyl terminus) was not a factor in disease progression. 
Our results presented here indicate that a SHIV constructed with the Vpu from a subtype C Vpu 
(SHIVSCVpu) significantly differed in the rate of CD4
+
 T cell loss compared to parental 
pathogenic SHIVKU-1bMC33.  As SHIVSCVpu and parental SHIVKU-1bMC33 are identical with the 
exception of the vpu gene and the overlapping env sequences (which do not appear to 
significantly affect envelope glycoprotein synthesis and processing), these results suggest that 
the efficiency of the CD4 down-regulation by the Vpu protein may correlate with the rate of 
CD4
+
 T cell loss in vivo.  As previously suggested, Vpu may use alternative mechanisms 
unassociated with BST-2 antagonism that are also important in the SHIV macaque model of 
disease, which also may correlate with the rate of CD4
+
 T cell loss.  A potential caveat of this 
study is that the expressed Vpu may not be reflective of all subtype C Vpu proteins.  Although a 
valid concern, the subtype C Vpu protein we used to construct SHIVSCVpu is similar to other 
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subtype C Vpu sequences from Botswana (data not shown).  Further, our experiments examining 
the down-regulation of CD4 from the cell surface revealed similarities among the four subtype C 
Vpu proteins (both from Botswana and India) when compared to the HXB2.  Whether the 
decreased rate of CD4
+
 T cell loss in SHIVSCVpu-inoculated macaques was due to the rate of 
turnover of the Vpu protein in cells in vivo, the magnitude of CD4 down-regulation or the ability 
to influence virus release within infected cells remains to be determined. 
 
Materials and Methods 
Plasmids and Cell Culture 
The construction of plasmids expressing a subtype B vpu (US.HXB2) and subtype C vpu 
(96.BW16B01) gene have been described previously (Pacyniak et al., 2005; Singh et al., 2003).  
These fragments were purified using a Qiaquik Gel Extraction kit (Qiagen) and directly cloned 
into pGEMT-Easy by T/A overhang.  All plasmids were digested with the NcoI restriction 
endonuclease and the resulting fragments were subcloned into NcoI digested CIAP treated 
pEGFP vector (Clontech Laboratories) that has a NcoI site at the 5’ end of the gene for enhanced 
green fluorescent protein (EGFP).  The resulting plasmids were sequenced to ensure that (1) the 
vpu genes were valid and inserted in the correct orientation and (2) the Vpu/EGFP junction was 
in frame.  All vpu/egfp fusion genes were then purified following digestion of the plasmids with 
KpnI and StuI which are found on opposing sides of the gene fusions.  These fragments were 
then directly ligated into a pcDNA3.1(+) expression vector digested with KpnI and EcoRV.  The 
resulting plasmids contained each vpu gene fused in frame to the gene for EGFP under the 
control of the CMV immediate early promoter.  A similar plasmid was constructed that 
expressed only EGFP. 
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C8166 cells were maintained in RPMI-1640 supplemented with 10% fetal bovine serum, 
10 mM Hepes buffer, pH 7.3, 2mM glutamine, penicillin/streptromycin (100 U per mL and 100 
µg per mL, respectively) and gentamicin (5 µg per mL).   
 
Construction of SHIV 
The derivation of SHIVKU-1bMC33 has been described previously (McCormick-Davis et al., 
2000a; Singh et al., 2003; Stephens et al., 2002).  In order to construct SHIVSCVpu a plasmid 
containing the 96BW16B01 vpu and env genes was used to amplify a 258 bp fragment with a 
NsiI site at the 5’ end of the vpu gene and a KpnI site within the env gene.  The amplicon was gel 
purified according to a Millipore isolation protocol and ligated into a pGEMT-Easy vector 
(Promega).  Insertion of the 258 bp amplicon into SHIV was accomplished in a three step 
process.  First, the pUC19 SN#12 plasmid, which has the SphI/KpnI fragment of SHIVKU-1bMC33 
in a pUC19 background and a NsiI site introduced at the beginning of the subtype B vpu gene 
was digested with NsiI and KpnI restriction endonucleases and gel purified to remove the vpu 
containing fragment.  The 258 bp amplicon containing the scvpu gene was directly ligated into 
this purified digested plasmid yielding pUCscvpu.  For introduction of scvpu into the plasmid 
containing the 3’ end of SHIV, both the pUCscvpu and p3’-SHIVKU-1bMC33 were digested with 
SphI and KpnI, gel purified, and ligated.  The resulting plasmid p3’-SHIVSCVpu was sequenced to 
ensure that the tat, rev, vpu and env genes did not have any mutations during the cloning process.  
For the production of SHIVSCVpu, p3’SHIVSCVpu and p5’SHIV-4 were digested with SphI 
overnight, purified, ligated and used to transfect C8166 cells as previously described (Hout et al., 
2006b; Hout et al., 2005; McCormick-Davis et al., 2000a; McCormick-Davis et al., 2000b; Singh 
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et al., 2003; Stephens et al., 2002).  Stocks were prepared, titrated in C8166 cells and stored at -
80C until used. 
 
Viral Replication Kinetics Assessment 
Standard p27 assays (Beckman Coulter, SIV core antigen kit) were used to assess release 
of viral particles from cells infected with SHIVKU-1bMC33 and SHIVSCVpu.  Cultures of 10
6
 C8166 
cells were inoculated with equivalent amounts of infectious cell free virus (10
3
) for 4 hours.  At 
the end of 4 hours, the cells were washed three times in fresh medium.  The cells were 
resuspended in C8166 growth medium and this was considered the 0 time point of the assay.  
Cultures were incubated at 37C in a 5% CO2 atmosphere and aliquots of the culture were 
removed at 0, 1, 3, 5, 7, and 9 days post-inoculation with fresh medium added to the cultures at 
days 3 and 6.  The culture medium was separated from the cells by centrifugation and assayed 
for p27 according to the manufacturer’s instructions. 
 
Macaques and Virus Inoculation   
Pig-tailed macaques were obtained from the Caribbean Primate Center in Puerto Rico.  
All macaques were housed in the AAALAC-approved animal facility at the University of Kansas 
Medical Center.  Three pig-tailed macaques (CX56, CX57, and PLG2) were inoculated 
intravenously with 10
4
 TCID50 of SHIVSCVpu. These macaques were euthanized at 36 to 44 
weeks post-inoculation.  We previously reported on the circulating CD4
+
 T cell levels and virus 
loads in macaques inoculated with pathogenic SHIVKU-1bMC33 (Singh et al., 2003; Stephens et al., 
2002).  EDTA-treated blood was collected weekly for 6 weeks, then at 3-week intervals for the 
next 6 weeks, and thereafter at monthly intervals. 
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Processing of Blood Samples 
The PBMCs were prepared by centrifugation on Ficoll-Hypaque gradients as described 
previously (Joag et al., 1996; Joag et al., 1994).  Ten-fold dilutions of PBMCs (10
6
 cells/ml) 
were inoculated into replicate cultures and were examined for development of cytopathic effects 
as previously described (McCormick-Davis et al., 2000a; McCormick-Davis et al., 2000b; 
Stephens et al., 2002).  Alterations in the circulating CD4
+
 lymphocytes levels after experimental 
inoculations were monitored sequentially by flow cytometric analysis (Becton Dickinson).  T-
lymphocyte subsets were labeled with OKT4 (CD4; Ortho Diagnostics Systems, Inc), SP34 
(CD3; Pharmingen) or FN18 (CD3; Biosource International) monoclonal antibodies. 
 
Processing of Tissue Samples at Necropsy 
At the time of euthanasia, animals were anesthetized by administration of 10 mg/kg 
ketamine (IM) followed by an intravenous administration of sodium pentobarbital at 20–30 
mg/kg. A laparotomy was performed on the animal and exsanguinated by aortic cannulation.  
The chest was opened, the left ventricle cannulated, the right atrium nicked, and the animal 
perfused with 1 liter of cold pyrogen-free Ringer's saline.  All aspects of the animal studies were 
performed according to the institutional guidelines for animal care and use at University of 
Kansas Medical Center. At necropsy, tissues from the heart, kidney, liver, lungs, axillary lymph 
nodes (LN), mesenteric LN, inguinal LN, pancreas, salivary gland, small intestine, spleen, 
thymus, and tonsil were fixed in 10% neutral buffered formalin and embedded in paraffin.  
Sections (5 μm) were stained with hematoxylin and eosin for routine histological examination by 
Dr. David Pinson, a board certified veterinary pathologist.  In addition, the right half of the brain 
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and spinal cord were dissected into frontal, motor, parietal, temporal and occipital cortices, 
corpus callosum, thalamus, basal ganglia, midbrain, pons, medulla, cerebellum, cervical, thoracic 
and lumbar spinal cord and were also processed as above.  In addition to each of the visceral 
organs, regions of the CNS were also frozen in liquid nitrogen for DNA isolation.  PCR 
amplification and sequence analysis of gag DNA was extracted from the visceral organs and 
different regions of the CNS as previously described (McCormick-Davis et al., 2000a) and used 
to amplify viral gag sequences. We also analyzed tissues for the presence of viral RNA, 
indicative of actively replicating virus. RNA was extracted from approximately 30 mg of each 
tissue from each visceral organ using an RNeasy kit (Qiagen) according to the manufacturer's 
instructions.  RNA samples were digested with DNase I for 30 min. Samples were run on 
agarose formaldehyde gels before and after DNase treatment to check for the presence of 
contaminating DNA. RNA samples were amplified by using primers for the SHIV gag gene and 
the Easy-A One-Tube RT-PCR System (Stratagene). The amplified gag fragment is 240 base 
pairs. 
 
Plasma Virus Loads 
Plasma viral RNA loads were determined on RNA extracted from EDTA-treated plasma.  
Virus was pelleted and RNA extracted using the Qiagen viral RNA kit (Qiagen).  RNA samples 
were analyzed by real-time RT-PCR using gag specific primers and a 5'FAM and 3'TAMRA 
labeled Taqman probe that was homologous to the SIV gag gene.  Standard curves were 
prepared using a series of six 10-fold dilutions of viral RNA of known concentration. The 
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sensitivity of the assay was 100 RNA equivalents per milliliter. Samples were analyzed in 
triplicate and the number of RNA equivalents was calculated per ml of plasma. 
 
Sequence Analysis of the vpu Gene 
The vpu was amplified from DNA samples isolated from several tissues taken at 
necropsy to examine the sequence of vpu.  For sequence analysis, the PCR products from three 
separate PCRs were separated by electrophoresis in a 1% agarose gel, isolated, and each PCR 
reaction directly sequenced.  Cycle sequencing reactions were done using the BigDye 
Terminator Cycle Sequencing Ready Reaction Kit with AmpliTaq DNA polymerase, FS (PE 
Applied Biosystems) and sequence detection was conducted with an Applied Biosystems 377 
Prism XL automated DNA sequencer and visualized using the ABI Edit view program. 
Sequences were compared to the intact sequences from SHIVSCVpu. Sequences showing 
differences were confirmed by molecularly cloning the PCR fragments into the pGEMT-Easy 
vector (Promega) followed by sequencing as described above. 
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X. Chapter 5:  Membrane Raft Association of the Vpu Protein of Human 
Immunodeficiency Virus Type 1 Correlates with Enhanced Virus Release 
 
Abstract 
The Vpu protein of human immunodeficiency virus type 1 (HIV-1) is known to enhance 
virion release from certain cell types.   To accomplish this function, Vpu interacts with the 
restriction factor known as bone marrow stromal cell antigen 2 (BST-2)/tetherin.  In this study, 
we analyzed whether the Vpu protein is associated with microdomains known as lipid or 
membrane rafts.  Our results indicate that Vpu partially partitions into detergent resistant 
membrane (DRM) fractions when expressed alone or in the context of simian-human 
immunodeficiency virus (SHIV) infection.  The ability to be partitioned into rafts was observed 
with both subtype B and C Vpu proteins.  The use of cholesterol lowering Lovastatin/M-β-
cyclodextrin and co-patching experiments confirmed that Vpu can be detected in cholesterol rich 
regions of membranes.  Finally, we present data showing that raft association-defective 
transmembrane mutants of Vpu have impaired enhanced virus release function, but still maintain 
the ability to down-regulate CD4.  
 
Introduction 
Viral protein U (Vpu) encoded by human immunodeficiency virus type I (HIV-1) 
augments viral pathogenesis by down-modulating CD4 molecules from the surface of infected 
cells and enhancing virion release (Fujita et al., 1997; Klimkait et al., 1990; Ruiz et al., 2010a; 
Schubert et al., 1998).  Membrane association is critical for both activities although an earlier 
study indicated that the primary structure of the transmembrane domain was irrelevant for CD4 
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down-modulation (Schubert et al., 1996a).  The ability of Vpu to enhance virion release from 
some cell types has been attributed to antagonism of the cellular protein bone marrow stromal 
antigen 2 (BST-2; also known as CD317, HM1.24 and tetherin) (Neil et al., 2008; Van Damme 
et al., 2008).  BST-2 localizes to the sites of HIV-1 budding and provides a physical, protease-
sensitive link between the cellular and viral membranes (Perez-Caballero et al., 2009).  BST-2 is 
a type II integral membrane protein that is anchored into the cell membrane by an amino terminal 
transmembrane domain and by a glycophosphatidylinositol (GPI) anchor at the carboxyl terminal 
region.  GPI anchored proteins are often found in membrane microdomains known as membrane 
rafts and fully processed BST-2 has been shown to partition to these domains (Kupzig et al., 
2003).  A more recent study documented a punctate distribution of BST-2 on the surface of HIV-
1 infected cells and that removal of the GPI anchor resulted in BST-2 being exclusively 
associated with sites of assembly suggesting that BST-2 may partition to multiple types of 
microdomains with distinct membrane compositions (Perez-Caballero et al., 2009).  As it is 
documented that the subtype B Vpu is neither incorporated into virions nor is it present at the 
sites of HIV-1 assembly and maturation, the location of Vpu mediated antagonism of BST-2 has 
remained in question (Strebel et al., 1989).   However, since BST-2 may partition to multiple, 
compositionally distinct rafts during intracellular processing, it may interact with Vpu in rafts 
distinct from those essential to HIV-1 maturation and egress.   The mechanism(s) by which Vpu 
counteracts BST-2 are under investigation but the down-regulation of BST-2 from the cellular 
surface, increased degradation of BST-2 and sequestration at alternate intracellular sites are all 
potentially dependent co-partitioning to similar membrane rafts. 
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Membrane rafts are essential to HIV-1 replication as the assembly and budding of virions 
is a dynamic process that is dependent upon the association of viral proteins with these 
microdomains (Ono and Freed, 2001).  HIV-1 proteins Gag, Env and Nef have been identified as 
membrane raft associated proteins and the partitioning to these microdomains is essential for 
assembly, budding and enhancement of viral infectivity (Alexander et al., 2004; Nguyen and 
Hildreth, 2000).  Membrane rafts are enriched in cholesterol and sphingolipids forming tightly 
packed, highly ordered regions within the membrane.  The presence of cholesterol and 
sphingolipids in rafts confers resistance to solubilization by some non-ionic detergents such as 
Triton X-100 at low temperatures.  Due to their insolubility, membrane rafts are often referred to 
as detergent resistant membranes (DRMs).  Because the isolation of DRMs is accomplished at 
4C and isolated DRMs are 0.1 to 1µm vesicles, some investigators have questioned their 
existence in live cells.  However, more recent studies have shown that DRMs can also be isolated 
by extraction at physiological temperature (Chen et al., 2009).  Additionally, morphological 
approaches (confocal microscopy; atomic force microscopy, and fluorescence resonance energy 
transfer) have been used to study in situ localization of membrane rafts (Kusumi and Suzuki, 
2005; Pralle et al., 2000; Prior et al., 2003; Sharma et al., 2004).   
In this study, we employed both biochemical and morphological approaches to determine 
whether Vpu associates with membrane rafts and further characterized the potential for this 
association to affect both functions of Vpu.  We report here that Vpu partially partitions to 
detergent resistant membrane microdomains in a cholesterol dependent manner.  We also 
demonstrate the involvement of the transmembrane domain in this partitioning and identify 
targeted mutations within this domain that abolish membrane raft association.  Furthermore, 
membrane raft association of the Vpu protein correlates with the enhancement of virion release 
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function, but not CD4 surface down-regulation.  Taken together, these results establish that 
separate Vpu functions require distinct membrane localization patterns, implicate specific 
regions of the transmembrane domain as targets for disrupting Vpu function and provide further 
evidence for the importance of membrane rafts in HIV-1 pathogenesis. 
 
Results 
The subtype B Vpu protein partially partitions to the detergent resistant membrane 
fractions 
We transfected 293 cells with a vector expressing a codon-optimized version of the 
subtype B Vpu (Vphu) and at 48 hours the DRMs were isolated on sucrose gradients using 
ultracentrifugation.   Fractions were collected from the top of the gradients, the proteins 
concentrated and analyzed by Western blotting.  Vphu was detected predominantly in the soluble 
fractions at the bottom of the gradient (Figure 31; upper panel) where a non-raft protein 
(transferrin receptor) was located (Figure 31; lower panel).   However, the Vphu protein was also 
detected in fractions at the top of the gradient that corresponded to the DRMs.  The DRM 
fractions were identified by the presence of Flotillin 1 (a raft protein) (Figure 31; middle panel).  
All experiments were performed at least twice, and the blots shown are representative of all 
experiments. These results provide evidence that Vpu is partially partitioned into membrane raft 
proteins. 
 
Vpu is detected in the DRM fractions isolated from virus infected cells 
We next determined if Vpu could be detected in DRM fractions from virus-infected cells.  
C8166 cells were inoculated with 10
4
 TCID50 of simian-human immunodeficiency virus  
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Figure 31.  Vpu partitions into detergent resistant membrane (DRM) fractions.  293 cells 
were transfected with a plasmid expressing the Vphu protein.  At 48 hours, cells were 
lysed in ice cold DRM buffer containing 1% Triton X-100, and raft proteins separated 
from non-raft proteins on discontinuous sucrose gradients by ultracentrifugation as 
described in the Materials and methods section.  Fractions were collected from the top of 
the gradient, and Vpu proteins detected by Western blot analysis using a rabbit Vpu 
anti-serum (upper panel) or stripped and reprobed with either an antibody directed 
against raft protein Flotillin 1 (middle panel) or the non-raft protein transferrin 
receptor (lower panel).  Fraction 1 is the top of the gradient and fraction 12 the bottom 
of the gradient.    
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expressing an intact subtype B Vpu protein (SHIVKU-1bMC33) or no Vpu protein (novpuSHIVKU-
1bMC33) and incubated for 5 days.  At 5 days, cells were starved and radiolabeled with 
35
S-
methionine/cysteine for 2 hours followed by DRM extraction and isolation by 
ultracentrifugation.   Fractions containing the DRMs (fractions 1-3; I (insoluble)), the middle of 
the gradient (fraction 6-7; M (middle)), and the soluble non-raft proteins (fractions 10-12; S 
(soluble))  were each pooled, the Vpu proteins immunoprecipitated using a rabbit Vpu anti-
serum, and then the proteins separated by SDS-PAGE.   Aliquots were analyzed by Western blot 
for Flotillin 1 or transferrin receptor (TfR).  Vpu could be detected in both the DRM and soluble 
fractions, but very little was detected in fractions collected from the middle of the gradient 
(Figure 32).  All experiments were performed at least twice, and the blots shown are 
representative of all experiments.  These results indicate that Vpu could also be detected in 
DRMs isolated from virus-infected T cells.     
 
Vpu fusion proteins also partition to DRMs 
To facilitate the detection of Vpu in different compartments of the cell, we previously 
developed a vector that expressed Vpu fused to the protein enhanced green fluorescent protein 
(VpuEGFP) (Pacyniak et al., 2005; Singh et al., 2003).  In order to determine if the VpuEGFP 
protein would also partition to the DRM fractions, 293 cells were transfected with vectors 
expressing either the subtype B fusion protein (VpuEGFP) or the subtype C Vpu protein 
(VpuSCEGFP1) and fractionated as described above.    Both the VpuEGFP and VpuSCEGFP1 
were detected in the DRM fractions, indicating that these tagged proteins could be used to study 
raft association (Figure 33A-B).     All experiments were performed at least twice, and the blots 
shown are representative of all experiments.   
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Figure 32.  Vpu expressed in virus-infected cells also partitions into DRM fractions.    
C8166 cells were inoculated with 100 ng of SHIVKU-1bMC33 or novpuSHIVKU-1bMC33 and 
incubated for 5 days.  At this time cells were starved for methionine/cysteine for 2 hours 
and radiolabeled for 2 hours with 1 mCi of 
35
S-methionine/cysteine.  The cells were 
harvested by low speed centrifugation, washed, and lysed in ice cold DRM buffer 
containing 1% Triton X-100.  Raft proteins were separated from non-raft proteins using 
discontinuous sucrose gradients by ultracentrifugation as described in the Materials and 
methods section.  Fractions 1-3, 6-7 and 10-12 were pooled and the Vpu proteins 
immunoprecipitated using a rabbit Vpu anti-serum and immunoprecipitates collected 
on protein A-Sepharose beads.  The remaining supernatants were analyzed by Western 
blot for Flotillin 1 and transferrin receptor.  The proteins were separated using SDS-
PAGE and proteins visualized using standard autoradiographic techniques.    
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Cholesterol depletion abolishes the ability of VpuEGFP and VpuSCEGFP1 to be partitioned 
to the DRM fractions 
As membrane rafts are rich in cholesterol, compounds that reduce cholesterol levels in 
cells such as M-β-cyclodextrin (M-β-CD) or statins disrupt membrane raft formation (Keller and 
Simons, 1998; Scheiffele et al., 1999).   We examined if Lovastatin/M-β-CD treatment would 
reduce the level of Vpu in DRM fractions.  293 cells were transfected with vectors expressing 
VpuEGFP or VpuSCEGFP1, treated with 4 μM Lovastatin for 48 hours and with M-β-CD for the 
last 30 minutes prior to cell lysis.   The cells were lysed as described above, DRM and soluble 
fractions separated by ultracentrifugation and fractions collected as described above.  All 
experiments were performed at least twice, and the blots shown are representative of all 
experiments.  The results clearly indicate that there were reduced levels of Vpu B and C fusion 
proteins in the DRM fractions following treatment with Lovastatin and M-β-CD, indicating that 
Vpu resistance to Triton-X-100 is cholesterol dependent and likely correlates with raft 
association (Figure 33A-B).   The observation of Flotillin 1 in rafts of Lovastatin/M-β-CD 
treated cells may relate to the ability of Flotillin 1 to occupy detergent-resistant, buoyant 
complexes that do not rely on cholesterol for their integrity and has been previously reported 
(Browman et al., 2006; Gkantiragas et al., 2001).  Companion monolayers of 293 cells treated 
with Lovastatin and M-β-CD showed no toxicity/cell death compared to untreated cells using 
microscopy (Figure 33C-D) and trypan blue staining (data not shown). 
 
Vpu partially partitions into membrane rafts isolated at physiological temperature 
Classical methods of the isolation of DRMs involve solubilization at 4C, which has been 
challenged by some investigators.  Therefore, we also examined Vpu partitioning into membrane 
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raft fractions when the extraction was performed at 37C.  293 cells were transfected with a 
vector expressing VpuEGFP and at 48 hours post-transfection the cells were lysed in DRM37 
buffer plus 1% Triton-X-100 and rafts isolated as described in the Materials and methods section 
(Chen et al., 2009).  Rafts were separated from non-rafts by ultracentrifugation and fractions 
collected.   The fractions were analyzed by Western blotting for the presence of Vpu, Flotillin 1, 
and transferrin receptor.  The raft (Flotillin 1) and non-raft (TfR) markers were predominantly 
localized at the top and bottom of the gradients, respectively (Figure 34).  Vpu was detected in 
both raft and non-raft fractions, similar to what we observed with solubilization of cells in the 
presence of 1% Triton-X-100 at 4C.  All experiments were performed at least twice, and the 
blots shown are representative of all experiments.   These results show that the Vpu protein could 
be detected in DRMs at physiological temperature as well as at 4C.   
 
The subtype C Vpu protein co-localizes with a patched membrane raft protein  
To further verify that Vpu is found in membrane rafts, we employed co-patching 
techniques for aggregating membrane rafts to a size visible by confocal microscopy and then 
examined if VpuSCEGFP1 co-localized with a known membrane raft protein.  We used plasmids 
expressing either a fluorescent or non-fluorescent form of YFP with an ER translocation signal 
and a GPI anchor sequence.  This protein is recognized by a mouse anti-GFP antibody 
(Clontech) in live cells, as the YFP portion of the protein is found extracellularly.  While all 
known Vpu proteins are found in small amounts at the cell surface, most are prominently 
retained in the Golgi apparatus, making visualization of raft association difficult in live cells.  
Most live cell methods of raft detection involve surface staining or aggregation of rafts by 
cholera toxin or antibody co-patching.  To increase the likelihood of visualizing Vpu in  
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Figure 33.  Vpu fusion proteins also partition into DRM fractions and cholesterol 
depletion reduces the amount of VpuEGFP and VpuSCEGFP1 in DRM fractions.  Left 
side of panels A and B. 293 cells were transfected with vectors expressing either 
VpuEGFP (Panel A) or VpuSCEGFP1 (Panel B) proteins.  At 48 hours, cells were lysed 
in ice cold DRM buffer containing 1% Triton X-100, and raft proteins separated from 
non-raft proteins on discontinuous sucrose gradients by ultracentrifugation as described 
in the Materials and methods section.  Fractions 1-3 (I), fractions 6-7 (M) and 10-12 (S) 
were pooled, concentrated and the Vpu proteins detected by Western blot analysis using 
a mouse anti-EGFP antibody.  Right side of panels A and B.  293 cells were transfected 
with vectors expressing either VpuEGFP (Panel A) or VpuSCEGFP1 (Panel B) proteins.  
Following transfection, cells were incubated in the presence of 4 μM Lovastatin for 48 
hours.  Thirty minutes prior to lysis, M-β-CD was added to a final concentration of 10 
mg/ml.  Cells were processed as described for the untreated samples.  Panels C-D.  
Micrographs of untreated cultures (Panel C) or those treated with Lovastatin/M-β-CD 
(Panel D). 
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Figure 34.  Vpu partitions into membrane rafts isolated at physiological temperature.  
293 cells were transfected with a vector expressing VpuEGFP and incubated at 37C.  At 
48 hours post-transfection, cells solubilized in DRM37 buffer containing 1% Triton-X-
100 and raft proteins separated from non-raft proteins using discontinuous flotation 
sucrose gradients and ultracentrifugation as described in the Materials and methods 
section.  Fractions were collected and VpuEGFP, Flotillin 1 or transferrin receptor 
detected by Western blot analysis using antibodies described in the Materials and 
methods section.  Panel A.  Detection of VpuEGFP.  Panel B. Detection of Flotillin 1. 
Panel C. Detection of transferrin receptor.  Fraction 1 is the top of the gradient and 
fraction 9 the bottom of the gradient. 
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membrane rafts by antibody co-patching, we utilized a Vpu protein which is predominantly 
found at the cell surface, VpuSC (Pacyniak et al., 2005).  We used several controls to validate this 
approach. First, cells were transfected with a plasmid expressing VpuSCEGFP1 and live stained 
with anti-GFP as described in the Materials and methods (Figure 35A-C).  As expected, these 
cells show no staining, since the EGFP tag of VpuSCEGFP1 is cytoplasmic.  We next transfected 
cells with the plasmid expressing the fluorescent YFP-GPI, fixed and then stained with mouse 
anti-GFP (Figure 35D-F).  The antibody staining in Figure 35F shows nearly complete co-
localization at the cell surface, indicative of antibody specificity to the extracellular YFP tag.  
Finally, we transfected cells with the plasmid expressing the fluorescent YFP-GPI, stained and 
then fixed the live cells at 37C as described in Materials and methods (Figure 35G-I).  This 
induces aggregation of the membrane rafts, making them visible by standard microscopy.  Note 
the punctate staining of the co-patched YFP-GPI compared to the pre-fixed (i.e. fixed and then 
stained) sample.  To determine if VpuSCEGFP1 would co-localize with this membrane raft 
protein, we used a plasmid expressing a non-fluorescent version of the same YFP-GPI construct 
(NFP-GPI), which produces no background (data not shown).  This allowed us to use the 
VpuSCEGFP1 protein without having overlapping fluorescent signals.  Cells were co-transfected 
with plasmids expressing NFP-GPI and VpuSCEGFP1, then stained at 37C and fixed post-stain 
(Figure 35J-O).  VpuSCEGFP1 partially co-localized with the patches of NFP-GPI, indicating 
that Vpu is found in at least some GPI-anchored protein containing membrane rafts.  This 
provides additional evidence that Vpu is a membrane raft protein and has the potential to 
partition into rafts similar to the BST-2 protein (a known GPI, lipid raft associated protein). 
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Figure 35.  Co-patching experiments reveal that VpuSCEGFP1 partially co-localizes with 
NFP-GPI.  Panels A, D, G, J, and M are fluorescent micrographs using a filter for 
YFP/EGFP .  Panels B, E, H, K, and N are fluorescent micrographs for Cy5.  Panels C, 
F, I, L, and O are a merge of the two fluorescent micrographs to the left.  Panels A-C.  
293 cells were transfected with vector expressing VpuSCEGFP1.  Panels D-F.  293 cells 
were transfected with a vector expressing YFP-GPI and fixed prior to staining (i.e. pre-
fixed).  Panels G-I.  293 cells were transfected with a vector expressing YFP-GPI and co-
patched.  Panels J-O.  293 cells were transfected with both VpuSCEGFP1 and NFP-GPI 
and co-patched. 
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The transmembrane domain of Vpu is involved in raft association  
We next determined if amino acids within the transmembrane domain were involved in 
the transport of VpuEGFP to membrane rafts.   Previous studies have shown that scrambling the 
hydrophobic amino acids of the transmembrane domain (VpuRD or VpuTMEGFP) results in a 
protein that is membrane bound, transported to similar compartments within the cell, but unable 
to enhance virus release.   The VpuRD protein maintained the capability of binding CD4 and 
inducing CD4 degradation, while the VpuTMEGFP protein was unable to down-modulate surface 
expression of CD4 (Hout et al., 2005; Schubert et al., 1996a).  We determined if the VpuTM fused 
to EGFP (VpuTMEGFP) would partition to raft fractions.   The results shown in Figure 36 
indicate that VpuTMEGFP partitioned exclusively to the detergent soluble fractions of the 
gradient.  All experiments were performed at least twice, and the blots shown are representative 
of all experiments.  Appropriate controls for raft isolation and purity were performed and are 
shown.  These results provide genetic evidence for the specificity of Vpu partitioning to the 
DRM fractions.   
 
Characterization of Vpu transmembrane mutants 
Based on the above results suggesting the involvement of the transmembrane domain in 
raft association, we constructed a series of vectors expressing Vphu proteins with 1-3 amino acid 
changes in the transmembrane domain (Figure 37A).   We first analyzed the stability of these 
mutants using pulse-chase analysis.  293 cells were transfected with each mutant or the 
unmodified Vphu.  At 48 hours, the cells were starved and radiolabeled with 
35
S-
methionine/cysteine and then the radiolabel chased in cold excess methionine/cysteine for 0 and 
6 hours.  All conditions were run at least in duplicate and the average percent protein remaining  
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Figure 36.  Scrambling the transmembrane domain prevents VpuEGFP raft association. 
293 cells were transfected with vectors expressing either VpuEGFP or VpuTMEGFP 
proteins.   At 48 hours, cells were lysed in ice cold DRM buffer containing 1% Triton X-
100, and raft proteins separated from non-raft proteins on discontinuous sucrose 
gradients by ultracentrifugation as described in the Materials and methods section.  
Fractions were collected from the top of the gradient, and fractions from the top (1-3; I) 
middle (6-7; M) and bottom (10-12;S) were analyzed for the presence of Vpu, Flotillin 1 
and transferrin receptor proteins by Western blot analysis using antibodies described in 
the Materials and methods section.  
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and standard deviation calculated.  The results indicate that the majority of the Vphu mutants had 
a similar stability or were more stable than the unmodified Vphu, which had 47% remaining at 
the 6 hour chase period (Figure 37B-C).   The average protein remaining at the 6-hour chase 
period for Vphu mutants W22A and SI23,24AA was lower than for the unmodified Vphu protein 
(28% and 38%, respectively).   
 
Identification of critical amino acids in the transmembrane domain of Vpu that are 
required for membrane raft association 
We determined if one or more amino acid residues within the transmembrane domain 
were critical for membrane raft association.  Vectors expressing these mutant Vphu proteins 
were transfected into 293 cells and at 36 hours the DRMs were isolated as described above.  All 
experiments were performed at least twice, and the blots shown are representative of all 
experiments.  Appropriate controls for raft isolation and purity were performed and are shown. 
We found that two mutants, W22A and IVV19-21AAA had no detectable Vpu in the DRM 
fractions (Figure 38A).  Additionally, substitution of the W22 with the more hydrophobic leucine 
did not affect raft association (Figure 38B).  Taken together, these results suggest that membrane 
raft association can be manipulated by substituting specific amino acids in the TM domain.  
 
The W22A mutant is localized to the same compartments as the unmodified VpuEGFP 
As the W22A mutant appeared to have the greatest effect on raft association, we 
determined if this mutant displayed localization within the cells distinct from the observed with 
the unmodified Vpu protein.  293 cells were transfected with vectors expressing either VpuEGFP  
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Figure 37.  Characterization of Vphu transmembrane mutants.   Panel A. Sequences of 
the series of transmembrane mutants constructed and used in this study.  Panel B. Pulse 
chase analysis of the Vphu transmembrane mutants.  293 cells were transfected with 
either the unmodified Vphu or the Vphu TM mutants. At 48 hours, cells were starved 
for methionine/cysteine and radiolabled for 1 hour as described in the Materials and 
methods section.  The radiolabel was removed, cells washed and incubated in excess cold 
methionine/cysteine for 0 or 6 hours.  The cells were lysed and processed for 
immunoprecipitation assays using a rabbit Vpu anti-serum.  The immunoprecipitates 
were collected on protein A-Sepharose beads, boiled and visualized by SDS PAGE (12% 
gel) and standard autoradiographic techniques.  The numbers above each lane represent 
the length of time chased in cold medium.  Panel C.  Graphical representation of the 
percent protein remaining for each Vphu TM mutant at the 6-hour post-chase 
timepoint.    
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Figure 38.  Identification of Vphu transmembrane mutants that are not associated with 
membrane rafts.  293 cells were transfected with vectors expressing each of the Vphu 
TM mutants described in Figure 7A.  At 48 hours, DRMs were extracted and isolated as 
described in the Materials and methods section.  Fractions 1-3 (rafts; I), 5-6 (middle of 
the gradient; M) and 10-12 (non-raft; S) were pooled and analyzed for the presence of 
Vpu, Flotillin 1, and transferrin receptor.  Panel A. Fractions from 293 cells transfected 
with vectors expressing each of the Vphu mutants described in Figure 7A.  Panel B. 
Fractions from 293 cells transfected with vectors expressing either VpuEGFPW23A or 
VpuEGFPW23L described in Figure 7A.    
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or VpuEGFPW23A (W residue is at position 23 in the corrected Vpu sequence fused to EGFP) 
and ER, Golgi or membrane markers.  The results indicate that the VpuEGFP (Figure 39A-I) and 
the VpuEGFPW23A (Figure 39J-R) were localized to similar compartments, suggesting that 
transport to the intracellular compartments was not the reason for the lack of raft association by 
the W22A/W23A mutants.  
 
Membrane raft association correlates with enhanced virus release 
  We examined these same mutants for the ability to enhance virus release from infected 
cells.  For these experiments, we used HeLa cells, which express bone marrow stromal antigen 2 
(BST-2).  Vpu has been shown to directly interact with BST-2 to permit enhanced virus release 
from infected cells (Douglas et al., 2009).   HeLa cells were co-transfected with plasmids 
expressing the Vphu mutants described above and SHIVΔVpu and assessed for p27 release as 
described in the Materials and methods section.  All conditions were run at least four separate 
times and the average percent p27 release and standard error calculated.  The results indicate that 
Vpu mutants W22A and IVV19-21AAA and to a lesser extent LVV11-13AAA showed a 
significant decrease in p27 release, which correlated well with the lack of association with 
membrane rafts (Figure 40A).  Analysis of infectious virus released also showed the same 
general pattern when compared to the p27 assays (Figure 40B).  Significance of the p27 and 
infectious virus release for each virus mutant was assessed by comparison to the Vphu control 
with a p ≤ 0.01 considered significant.  
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Figure 39.  VpuEGFPW23A and VpuEGFP are localized to similar compartments.  293 
cells were transfected with a vectors expressing either VpuEGFP or VpuEGFPW23A 
and ER-DsRed2, Golgi-DsRed2 or Membrane-DsRed2 as described in the Materials and 
methods section.  At 48 h, cells were processed for confocal microscopy.  Figure 9A-I.  
293 cells transfected with VpuEGFP.  Panels A, D, and G are fluorescent micrographs 
showing expression of VpuEGFP.  Panels B, E, and H are fluorescent micrographs  
showing expression of DsRed2 proteins.  Panels C, F, and I are a merge of the two panels 
to the left. Panels A-C. 293 cells transfected with VpuEGFP and ER-DsRed2.  Panels D-
F.  293 cells transfected with VpuEGFP and Golgi-DsRed2.   Panels G-I. 293 cells 
transfected with VpuEGFP and Mem-DsRed2.  Figures 9J-R.  293 cells transfected with 
VpuEGFPW23A. Panels J, M, and P are fluorescent micrographs showing expression of 
VpuEGFPW23A.  Panels K, N, and Q are fluorescent micrographs showing expression 
of DsRed2 proteins.  Panels L, O, and R are a merge of the two panels to the left.  Panels 
J-L. 293 cells transfected with VpuEGFPW23A and ER-DsRed2.  Panels M-O.  293 cells 
transfected with VpuEGFPW23A and Golgi-DsRed2.   Panels P-R. 293 cells transfected 
with VpuEGFPW23A and Mem-DsRed2.      
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Figure 40.  Raft association correlates with enhanced virus release.  The same mutants 
described in Figure 7A were used to determine the level of virus release in the presence   
of human BST-2.  HeLa cells were co-transfected with SHIVΔVpu and vectors expressing 
Vphu or the different transmembrane mutants.  At 48 hours, the culture medium was 
collected and assayed for p27 and infectious virus released from cells.  Panel A.  The 
level of p27 released from transfected cells.  Significance in the enhancement of p27 
release was calculated with respect to the SHIVKU-2MC4 using a Student’s t-test with p <  
0.01 considered significant (*).  Panel B. The level of infectious virus released as 
determined by infection of TZM-bl cells and staining for the presence of β-galactosidase 
activity at 48 hours post-inoculation as described in the Materials and methods section. 
Significance in the enhancement of release of infectious units was determined with 
respect to the unmodified Vphu using a Student’s t-test with p ≤ 0.01 considered 
significant (*). 
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Membrane raft association is not required for CD4 down-regulation   
As the other major function of Vpu is shunting of CD4 to the proteasome for degradation, 
we also examined surface expression of CD4 in the presence of these Vpu mutants.   HeLa CD4
+
 
cells were transfected with vectors expressing Vphu or the mutants described above and EGFP.  
Cells were analyzed for CD4 surface expression by flow cytometry as previously described (Hill 
et al., 2008; Hill et al., 2010; Ruiz et al., 2008).  All conditions were run three separate times and 
the average CD4 surface expression and standard error calculated.  This Vpu function was not 
impaired with the majority of these mutants (Figure 41).   The two Vphu mutants that were not 
detected in rafts, Vphu-IVV19-21AAA and W22A, had normal (VphuIVV19-21AAA) or 
slightly impaired (W22A) surface CD4 down-modulation compared to the unmodified Vphu 
protein.  Taken together, these results indicate that raft association was not a requirement for 
Vpu-mediated down-modulation of CD4. 
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Figure 41.  CD4 down-regulation by Vphu transmembrane mutants.  HeLa CD4
+
 cells 
were transfected with plasmids expressing the unmodified Vphu or each of the mutant 
Vphu proteins and one expressing EGFP.   At 48 hours, live cells were immunostained 
for CD4.  Cells were assessed for CD4 surface expression using flow cytometry. A mean 
fluorescent intensity (MFI) ratio of transfected (EGFP positive) to untransfected cells 
(EGFP negative) was calculated for each sample with the EGFP transfection control 
normalized to 1.0.  Normalized ratios from three separate experiments were averaged 
and the standard error calculated. 
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Discussion 
Many enveloped viruses such as vaccinia virus, the orthomyxoviruses (influenza), 
paramyxoviruses (measles, RSV), filoviruses (Ebola, Marburg) herpesviruses (EBV, HSV-1, 
pseudorabies), flaviviruses (West Nile virus), rhabdoviruses (VSV), and retroviruses (MLV) use 
membrane rafts as portals for entry and/or egress from cells (Barman and Nayak, 2000; Bavari et 
al., 2002; Bender et al., 2003; Brown and Lyles, 2003; Chung et al., 2005; Keller and Simons, 
1998; Li et al., 2002; Manie et al., 2000; Marty et al., 2004; Medigeshi et al., 2008; Scheiffele et 
al., 1999).  In addition to the viruses listed above, HIV-1 also exploits membrane rafts at several 
steps in its replication cycle.  The HIV-1 envelope is known to be enriched in cholesterol and 
both Gag and Env have been found in detergent resistant membranes (Aloia et al., 1993; Brugger 
et al., 2006; Nguyen and Hildreth, 2000).  These investigators found that GPI-anchored proteins 
such as Thy1 and CD59 as well as GM-1 ganglioside were present but that a non-raft protein, 
CD45, was largely absent from viral particles.  It was subsequently shown that membrane rafts 
were critical for virus assembly and release (Ono and Freed, 2001).  These investigators found 
that the myristylated N-terminal domain of Gag and the I domain of the nucleocapsid protein 
were critical for raft association and that the cholesterol depleting compound, M-β-CD, reduced 
the efficiency of virus release.  The palmitoylation of Env gp41 was initially shown to be 
important for raft targeting and infectivity but later studies showed that substitution of the 
cysteines in the cytoplasmic domain of gp41 (thus resulting in no palmitoylation) only partially 
affected infectivity or had no effect (Bhattacharya et al., 2004; Chan et al., 2005; Rousso et al., 
2000).  It was later shown that mutations in the Gag p17 protein would prevent Env 
incorporation into rafts and virions, suggesting that Gag regulates Env incorporation into rafts 
(Bhattacharya et al., 2006; Patil et al., 2010).  Other investigators have shown that the HIV-1 
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Env has a cholesterol recognition/interaction amino acid consensus (CRAC) domain that is 
responsible for raft association (Epand et al., 2006; Vishwanathan et al., 2008).   
In this study, we have determined that the Vpu protein partially associates with 
membrane rafts.  We have shown this using biochemical fractionation, through the use of 
cholesterol reducing drugs and co-patching experiments.  In the results presented here, Vpu 
expressed either exogenously in the absence of other viral proteins or in virus-infected T cells 
(C8166 cell line), partitions into DRMs.  Our studies used Triton-X-100 as it is the most 
stringent with respect to extraction of DRMs (Schuck et al., 2003; Shogomori and Brown, 2003).  
We also showed that Vpu partially partitions into DRMs when extracted at physiological 
temperature as rafts isolated at 37C are thought to be more similar to rafts in live cells.  In 
addition to showing that Vpu partitions into DRMs, it was necessary to show that disruption of 
membrane rafts by cholesterol depletion would prevent Vpu from partitioning into DRMs.  
Drugs that reduce cholesterol levels in cells, either by inhibiting an HMGCoA reductase in the 
cholesterol synthesis pathway (e.g. Lovastatin) or by extracting cholesterol from cell membranes 
(e.g. methyl-β-cyclodextrin; M-β-CD), are known to disrupt membrane rafts.  We determined if a 
combination of Lovastatin and M-β-CD would eliminate Vpu from DRMs, which would indicate 
that Vpu resistance to Triton-X-100 is a specific property of raft inclusion.  This treatment 
significantly reduced the level of Vpu in membrane rafts.  Finally, Vpu association with lipid 
rafts was confirmed by co-localization of VpuSCEGFP1 with a raft marker in live cells.  As the 
subtype B Vpu used in most of the experiments in this study is found predominantly in the Golgi, 
ER, and endosomes, and only small amounts are found at the surface, we used VpuSC, which is 
efficiently transported to the cell surface for this assay.  While it seems likely that Vpu is 
associated with rafts internally, these rafts are, as yet, difficult to visualize.  Most studies of rafts 
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in Golgi bodies or endosomes have been done using biochemical lipidomic techniques rather 
than live cell imaging.  Taken together, these experiments provide strong evidence that Vpu is 
partially localized to membrane rafts and at least some rafts containing GPI-anchored proteins. 
As the transmembrane (TM) or membrane proximal domains are most likely to be 
involved in membrane raft targeting, we examined the detergent resistance of a Vpu fusion 
protein with a scrambled TM domain (VpuTMEGFP).  This protein was not associated with DRM 
fractions, indicating that the TM domain may be involved in membrane raft association.  
However, since this scrambled TM domain has a total of 15 amino acid changes, it is possible 
that these substitutions may have caused an alteration of the spatial orientation of the protein in 
the membrane, the flexible linker region following the TM domain or the first α-helical region 
proximal to the membrane.  Also, previous modeling studies have indicated that changes in the 
Vpu TM domain have the ability to cause secondary structure changes downstream (Candler et 
al., 2005; Sramala et al., 2003).    In order to address this concern, we used Vpu mutants with 
more targeted mutations.  Our results indicate that Vpu mutants Vphu-IVV19-21AAA and 
Vphu-W22A were no longer associated with membrane raft fractions.  While these results show 
that amino acid substitutions in the TM domain can affect incorporation into rafts, they do not 
necessarily rule out that other amino acids in the TM domain (i.e. the alanine residues) or 
residues in the cytoplasmic domain may also be involved.  Recent computer modeling studies 
have suggested that the transmembrane domain of Vpu is flexible in adapting to different lipid 
environments (Kruger and Fischer, 2008).  When Vpu was simulated moving through various 
lipid environments representative of the Golgi apparatus, Vpu exhibited no particular preference 
for lipid thickness or composition.  Rather, the tilt angle and kink around the region I17 to S23 
adjust to the membrane.  This modeling data correlates well with the loss of DRM association of 
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IVV19-21AAA and W22A.  If these residues are important to the structural flexibility of the Vpu 
transmembrane domain, substitution with alanines could reduce the ability of the protein to adapt 
to a changing lipid environment, thus excluding it from membrane rafts.  Substitution of the W23 
with a longer, more hydrophobic leucine resulted in a protein which was still found in the DRMs.  
As this protein was more similar to wild-type Vpu in efficiency of CD4 down-modulation than 
W23A (data not shown), this further suggests that structural changes are involved in raft 
inclusion and exclusion of Vpu. 
To demonstrate that membrane raft association was relevant to Vpu functions and to 
virus replication, we assayed the various Vphu TM mutants for the ability to down-modulate 
CD4 surface expression and enhance virus release.  Our results showed that all of the Vphu TM 
mutants down-modulated CD4 surface expression although Vphu-W22A was slightly impaired 
compared to the other mutants.  We measured enhanced virus release by two methods, release of 
p27 antigen from cells and by quantifying levels of infectious virus released from cells.  The two 
assays were in agreement and indicate that virus release was significantly reduced by the 
LVV11-13AAA, IVV19-21AAA and W22A mutants with the W22A consistently displaying the 
most reduction in particle release.  Of these three mutants, both IVV19-21AAA and W22A were 
not incorporated into rafts, implying a correlation between membrane raft association and Vpu-
mediated virus release.   One question that arises is, “Why did LVV11-13AAA have impaired 
release since it was clearly observed in DRM fractions?”  While the answer is presently 
unknown, it is possible that substitution of three hydrophobic residues with less hydrophobic 
alanines may have altered the structure/flexibility of the protein or protein-protein interactions 
(such as with BST-2) of the domain although it had no effect on CD4 down-modulation.  As is a 
caveat of all mutagenesis based studies, it is unknown whether the results observed in this study 
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were based on structural alterations of the protein or roles for specific amino acids.  Further 
studies will be needed to determine the affects the mutations introduced in this study have on the 
overall protein structure as well as any protein-protein interactions.  However, regardless of the 
mechanisms by which the membrane raft association and enhanced virion release function of the 
Vpu proteins were altered these results demonstrate the ability of exogenous forces to disrupt 
function.  This introduces the potential for therapeutic molecules designed to alter the spatial 
orientation of the TMD such that membrane raft association and/or protein-protein interactions 
(such as BST-2) would be disrupted. 
Recently, Vpu was shown to antagonize the activity of a molecule known as bone 
marrow stromal cell antigen 2 (BST-2) or tetherin (Neil et al., 2008; Van Damme et al., 2008).  
BST-2 is thought to work by “tethering” particles at the cell surface, which may account for the 
observed maturation of HIV-1Δvpu (adherence of particles to the cell plasma membrane with a 
common observation of several virus particles in the “string of pearls” arrangement and the 
observation of virus particles being taken or maturing into vesicles).  BST-2 has been shown to 
associate with membrane rafts, including the sites of HIV-1 maturation and release (Kupzig et 
al., 2003; Perez-Caballero et al., 2009; Rollason et al., 2007).  In the absence of Vpu, BST-2 may 
become associated with rafts that are ultimately involved in virus assembly and release from 
cells.  This is supported by findings that HIV-1 Gag and BST-2 co-localize in intracellular 
compartments of the cell (Neil et al., 2008; Van Damme et al., 2008).  Vpu is not incorporated 
into virions suggesting that Vpu may associate with membrane rafts that are not involved in virus 
assembly and release (Strebel et al., 1989).  It is known that membrane rafts are diverse in both 
lipid and protein composition and it has been shown that distinct rafts can be isolated using 
immune selection procedures (Drevot et al., 2002; Knorr et al., 2009).  One group of 
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investigators showed that wild type BST-2 was found in several different clusters on the plasma 
membrane and that removal of the GPI anchor resulted in a BST-2 exclusively associated with 
sites of budding (Perez-Caballero et al., 2009).  This implies that wild type BST-2 is found in 
more than one type of membrane raft.  Thus, it is conceivable that Vpu could possibly interact 
with BST-2 before or after transport to the Golgi complex and become associated with a 
subpopulation of membrane rafts not associated with virus assembly and release at the cell 
surface.  Membrane rafts were originally shown to initially form in the Golgi complex (Simons 
and van Meer, 1988) and to be enriched in the trans Golgi network.  However, more recent 
studies have shown that the ER and cis Golgi are also sites for sorting of proteins and lipids 
(Alfalah et al., 2005; Browman et al., 2006).  BST-2 was found in membrane rafts only after its 
N-linked carbohydrate chains were fully processed, suggesting that raft association of this 
protein occurs in the Golgi complex (Kupzig et al., 2003).  Recent data has been presented that 
suggests the presence of Vpu in the trans Golgi is important for Vpu antagonism of BST-2 
(Dube et al., 2009).  It will be of interest to determine if Vpu and BST-2 can be co-
immunoprecipitated from similar rafts and if so, where does this association occur?  Finally, 
identification of Vpu mutants that are functional for either CD4 down-modulation or enhanced 
virus release will be useful in determining if one function is more important for pathogenesis 
using the SHIV/macaque model.   
 
Materials and Methods 
Plasmids, Viruses and Cell Culture 
The HeLa cell line was obtained through the AIDS Research and Reference Reagent 
Program, Division of AIDS, NIAID, NIH: (specify cell line) from Dr. Richard Axel.  The 293 
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and HeLa cell lines were maintained in Dulbecco’s minimal essential medium supplemented 
with 10% fetal bovine serum, gentamicin (5 μg per ml) and penicillin/streptomycin (100 U per 
ml and 100 μg per mL, respectively).  The TZM-bl cell line was obtained through the NIH AIDS 
Research and Reference Reagent Program, Division of AIDS, NIAID, NIH: TZM-bl from Dr. 
John C. Kappes, Dr. Xiaoyun Wu and Tranzyme Inc.  The HeLa CD4
+
 cell line was obtained 
through the AIDS Research and Reference Reagent Program, Division of AIDS, NIAID, NIH: 
HeLa CD4 Clone 1022 from Dr. Bruce Chesebro.  TZM-bl cells were maintained in DMEM 
containing 10% fetal bovine serum with antibiotics. HeLa CD4+ cells were maintained in 
DMEM containing 10% fetal bovine serum antibioics and 1 mg per mL of G-418. The derivation 
and pathogenicity of SHIVKU-1bMC33 and novpuSHIVKU-1bMC33 have been described (McCormick-
Davis et al., 2000a; Singh et al., 2003; Stephens et al., 2002). The derivation of the SHIVKU-
2MC4ΔVpu plasmid has been described (Ruiz et al., 2010b).  Vectors expressing the subtype B 
(pcvpuegfp) and C Vpu (pcvpuSCegfp) proteins fused to enhanced green fluorescent protein 
(eGFP) and the VpuTMEGFP (pcvpuTMegfp) mutant have been previously described (Gomez et 
al., 2005; Pacyniak et al., 2005; Ruiz et al., 2008; Singh et al., 2003). The pcVphu construct was 
obtained through the NIH AIDS Research and Reference Reagent Program, Division of AIDS, 
NIAID, NIH: pcDNA-Vphu from Dr. Stephan Bour and Dr. Klaus Strebel (Nguyen et al., 2004).  
The YFP-GPI and NFP-GPI constructs were kindly provided by Dr. Akira Ono. The YFP-GPI 
construct has the ER translocation signal from rabbit phlorizin hydrolase fused to the N-terminus 
of Venus YFP and a GPI anchor sequence from CD59 fused to the C-terminus. The non-
fluorescent version (NFP-YFP) contains the mutation Y67C that abolishes fluorophore 
formation.  The vectors expressing ER-DsRed2, Golgi-DsRed2, and Mem-DsRed2 were 
obtained from Clontech.  Mutations introduced into all plasmids used in this study were 
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accomplished using a QuikChange site-directed mutagenesis kit (Stratagene) according to the 
manufacturer’s protocol.  All plasmid inserts were sequenced to ensure the validity of the 
mutations and that no other mutations were introduced during the cloning process. 
 
Isolation of Detergent Resistant Membranes (DRMs) 
293 cells were cultured in 60 mm well dishes for 24 hours, then transfected using 
branched polyethylenimine (PEI; Sigma).  At 48 hours post-transfection, cells were lysed in ice 
cold DRM buffer (25 mM Tris pH 7.5, 150 mM NaCl, 10 mM EDTA) containing 1% Triton-X-
100. Cells remained on ice in lysis buffer for 20min before being pushed through a 22 gauge 
needle at least 7 times. The lysate was then mixed with an equal volume of 80% sucrose (w/v) in 
DRM buffer to a final concentration of 40% sucrose. The lysate was placed in the bottom of a 
SW41 ultracentrifuge tube and overlaid with 8 mL 30% sucrose and 2 mL 5% sucrose. Gradients 
were spun to equilibrium at 38,000 rpm (247,000x g) for 18 hours (SW41 rotor, Beckman 
Coulter).  One mL fractions were taken from the top, concentrated, and analyzed by Western blot 
using a rabbit anti-EGFP antibody or a rabbit Vpu antiserum obtained through the AIDS 
Research and Reference Reagent Program, Division of AIDS, NIAID, NIH: HIV-1NL4-3 Vpu 
Antiserum from Dr Frank Maldarelli and Dr. Klaus Strebel.  Controls include the raft protein 
flotillin-1 (mouse anti-flotillin-1, BD Biosciences) and the non-raft protein, transferrin receptor 
(mouse anti-transferrin receptor, BD Biosciences).  For isolation of DRMs from virus infected 
cells, C8166 cells were inoculated with 10
4 
TCID50 of either SHIVKU-1bMC33 or novpuSHIVKU-
1bMC33 for 4 hours. At this time, cells were washed twice and incubated in fresh medium for 5 
days at 37C. Cultures were starved and radiolabled with 1 mCi of 
35
S-methionine/cysteine for 2 
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hours. The cells were centrifuged at low speed (800x g) to pellet the cells, washed three times in 
medium without serum and processed as above. One ml fractions were taken from the top and 
raft (fractions 1-3), middle (fractions 6-7), and non-raft (fractions 10-12) fractions were analyzed 
by immunoprecipitation using the rabbit Vpu antiserum antibody and by Western blot for raft 
and non-raft control proteins. 
 
Isolation of Detergent Resistant Membranes (DRMs) at Physiological Temperature 
For these experiments, we used the procedure of (Chen et al., 2009).  293 cells were 
cultured in 12 well dishes for 24 hours and then transfected using PEI.  At 36-48 hours post-
transfection, cells were lysed in DRM37 (10 mM HEPES pH 7.0, 50 mM KOAc, 1 mM 
Mg(OAc)2, 1 mM EDTA, 200 mM sucrose).  The lysates were pushed through a 22 gauge needle 
at least 7 times, then incubated at 37C for 5 minutes.  Lysates were then mixed with an equal 
volume of 2% Triton X-100 in DRM37 and incubated at 37C for 5 minutes. The lysates were 
mixed with an equal volume of 80% sucrose in DRM37, layered at the bottom of an 
ultracentrifuge tube and overlaid with 7 ml 30% sucrose/DRM37 and 2 ml DRM37 (6.5% 
sucrose). Gradients were spun to equilibrium at 38,000 rpm overnight (SW41 rotor, Beckman 
Coulter) at 4C. One ml fractions were taken from the top and analyzed for various proteins by 
Western blot. 
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Cholesterol Depletion Experiments 
293 cells were transfected with a plasmid expressing VpuEGFP or VpuSCEGFP and 
treated with 4μM Lovastatin for 48 hours. Thirty minutes prior to lysis of cells, the cultures were 
incubated with M-β-cyclodextrin (M-β-CD; 10 mg/ml).  Lysates were prepared, and subjected to 
ultracentrifugation as described above. One mL fractions were collected from the top of the 
gradient. Fractions 1-3, 6-7, and 10-12 were each pooled, methanol precipitated and resuspended 
in 1X sample reducing buffer. The samples were then analyzed for the presence of VpuEGFP or 
VpuSCEGFP by Western blot using an antibody directed against EGFP. 
 
Co-patching Experiments 
293 cells cultured on cover slips were transfected with YFP-GPI or NFP-GPI and 
VpuSCEGFP using PEI.  At 48 hours post-transfection, cover slips were washed three times in 
1X PBS, then incubated in primary antibody (mouse anti-GFP, Clontech) for 30 minutes at 37C.  
Unbound antibody was removed by washing three times in 1X PBS followed by reaction with a 
secondary antibody (goat anti-mouse-Cy5, Molecular Probes) at 37C for 30 minutes. Unbound 
antibody was removed by washing three times in 1X PBS and cells fixed in 2% 
paraformaldehyde/PBS for 15 minutes. Cover slips were mounted in SlowFade Antifade solution 
A (Molecular Probes). A Nikon A1 confocal microscope was used to collect 100X images with a 
2X digital zoom, using EZ-C1 software. The pinhole was set to large (100 nm) for all 
wavelengths. EGFP was excited using an argon 488 nm laser and viewed through the FITC filter 
(525/25 nm) and Cy5 was excited at 638 nm and viewed through a Cy5 filter (700/38 nm). 
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Pulse-Chase Analysis of Vphu TMD Mutant Proteins 
293 cells were transfected with vectors expressing each mutant protein.  At 48 hours 
post-transfection, the medium was removed and cells were incubated in methionine/cysteine-free 
medium for 2 hours. The cells were then radiolabeled with 200 µCi of 
35
S-Translabel 
(methionine and cysteine, MP Biomedical) for 1 hour. The radiolabel was chased in DMEM 
containing 100X unlabeled methionine/cysteine medium for 0 and 6 hours. Vphu proteins were 
immunoprecipitated using a rabbit anti-Vpu serum and collected on Protein A-Sepharose beads 
overnight on a rotator for 18 hours.  Non-transfected 293 cells, starved, radiolabeled and chased 
for 0 hours served as a negative control. Beads were washed three times with 1X 
radioimmunoprecipitation buffer (RIPA: (50 mM Tris-HCl, pH 7.5; 50 mM NaCl; 0.5% 
deoxycholate; 0.2% SDS; 10 mM EDTA), and the samples resuspended in sample reducing 
buffer. Samples were boiled and the Vphu proteins separated by SDS-PAGE (12% gel).  Proteins 
were then visualized using standard autoradiographic techniques.  All conditions were run in 
duplicate, the pixel densities of each band determined using ImageJ software, normalized to the 
hour 0 sample, and the average percent protein remaining calculated. 
 
Confocal Microscopy Studies 
293 cells were cultured on cover slips one day prior to being transiently transfected with 
plasmids expressing either VpuEGFP or VpuEGFPW23A and one of the intracellular marker 
proteins (ER-DsRed2, Golgi-DsRed2 or Membrane-DsRed2) using PEI (Sigma).  Cultures were 
maintained for 36-48 hours before being washed three times in PBS, and fixed in 2% 
paraformaldehyde/PBS.  Cover slips were mounted in glycerol containing mounting media 
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(Slowfade Antifade solution A).  A Nikon A1 confocal microscope was used to collect 100X 
images with a 2X digital zoom, using EZ-C1 software.  The pinhole was set to large (100 nm) for 
all wavelengths. EGFP was excited using an argon 488 nm laser and viewed through the FITC 
filter (525/25 nm).  DsRed2 were excited using a 561 DPSS laser and viewed through the Texas 
Red filter (595/50 nm). 
 
Virion Release Assays 
Hela cells (10
5
) were seeded into a 24-well tissue culture plate 24 hours prior to 
transfection.  Cells were transfected as described above with 1 µg of plasmid expressing full 
length SHIV proviral DNA (either SHIVKU-2MC4 or SHIVΔVpu) and 200 ng of plasmid expressing 
various mutant vphu genes. Cells were incubated at 37C in 5% CO2 atmosphere for 48 hours. 
Supernatants were collected and cellular debris removed through low speed centrifugation. Cells 
were lysed in 250 µl of 1X RIPA buffer and the nuclei removed through high speed 
centrifugation. The amount of p27 present within the supernatant and the cell lysates was 
determined using a commercially available p27 ELISA kit (Zeptometrix Incorporated) and the 
percent of p27 release calculated.  All conditions were run at least four separate times and the 
average percent p27 release and standard error calculated. Significance with respect to the 
unmodified Vphu was calculated using a Student’s t-test with a p<0.01 considered significant. 
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Infectious Units Release Assays 
TZM-bl cells (10
4
) were seeded into a 96-well tissue culture plate 24 hours prior to 
infection. Supernatants collected from HeLa cells co-transfected with SHIV Vpu and Vphu 
expressing plasmids as described above were added to the TZM-bl cells and serially diluted.  At 
48 hours post-infection, cells were washed twice in 1X PBS and incubated in a fixative solution 
(0.25% glutaraldehyde, 0.8% formaldehyde in phosphate buffered saline) for 5 minutes at room 
temperature. The cells were washed three times in 1X PBS and covered in staining solution (400 
µg/ml X-gal, 4 mM MgCl2, 4 mM K3Fe(CN)6, 4 mM K4Fe(CN)6-3H2O in phosphate buffered 
saline) and incubated for 2 hours at 37C. Cells were washed once in 1X PBS and then immersed 
in 1X PBS during counting. The TCID50 for each supernatant was calculated based on wells 
containing cells expressing β-galactosidase.  All conditions were run at least four times and the 
TCID50 calculated. The average TCID50 and standard error were calculated.  Significance in the 
restriction of infectivity was determined with respect to the unmodified Vphu using a Student’s t-
test with p<0.01 considered significant. 
 
Assessment of CD4 cell surface expression 
For analysis of cell surface CD4 expression in the presence of the various Vphu mutant 
proteins, HeLa CD4
+
 cells were seeded into each well of a 6-well tissue culture plate 1 day prior 
to transfection.  Cells were co-transfected with plasmids expressing one of the various Vphu 
mutant proteins and EGFP.  Cells transfected with EGFP only were used as the control. At 48 
hours post-transfection, cells were removed from the plate using Ca
2+
/Mg
2+
-free PBS containing 
10mM EDTA and stained with PE-Cy5 conjugated anti-CD4 (BD Bioscience). Cells were 
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analyzed using an LSRII flow cytometer and the mean fluorescence intensity (MFI) of PE-Cy5 
for transfected cells (EGFP positive) and untransfected cells (EGFP negative) was calculated. An 
MFI ratio was calculated for each sample with the EGFP control (no Vphu) normalized to 1.0 
and untransfected cells (EGFP negative).  Normalized ratios from three separate experiments 
were averaged and the standard error calculated.  All groups were compared to the EGFP control 
as well as the Vphu only control using a Student’s t-test (unpaired, p<0.05 significant). 
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XI.   Chapter 6: Requirements of the Membrane Proximal Tyrosine and Dileucine Based 
Sorting Signals for Efficient Transport of the Subtype C Vpu Protein to the Plasma 
Membrane and in Virus Release 
 
Abstract 
Previously, we showed that the Vpu protein from HIV-1 subtype C is more efficiently 
transported to the cell surface than the well studied subtype B Vpu (Pacyniak et al., 2005) and 
that a SHIV expressing the subtype C Vpu exhibited a decreased rate of CD4
+
 T cell loss 
following inoculation in macaques (Hill et al., 2008).  In this study, we examined the role of 
overlapping tyrosine-based (YxxΦ) and dileucine-based ([D/E]xxxL[L/I]) motifs in the 
membrane proximal region of the subtype C Vpu (EYRKLL) in Vpu intracellular transport, CD4 
surface expression and virus release from the cell surface.  We constructed three site-directed 
mutants of the subtype C vpu and fused these genes to the gene for enhanced green fluorescent 
protein (EGFP).  The first mutation altered the tyrosine (EARKLL; VpuSCEGFPY35A) , the 
second altered the dileucine motif (EYRKLG; VpuSCEGFPL39G), and the third contained both 
amino acid substitutions (EARKLG; VpuSCEGFPYL35,39AG) in this region of the Vpu protein.  
The VpuSCEGFPY35A protein was transported to the cell surface similar to the unmodified 
VpuSCEGFP1 while VpuSCEGFPL39G was expressed at the cell surface at significantly reduced 
levels. The VpuSCEGFPYL35,39AG was found to have an intermediate level of cell surface 
expression.   All three mutant Vpu proteins were analyzed for the ability to prevent cell surface 
expression of CD4.  We found that both single mutants did not significantly affect CD4 surface 
expression while the double mutant (VpuSCEGFPYL35,39AG) was significantly less efficient at 
preventing cell surface CD4 expression.  Chimeric simian-human immunodeficiency viruses 
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were constructed with these mutations in vpu (SHIVSCVpuY35A, SHIVSCVpuL39G and 
SHIVSCVpuYL35,39AG).   Our results indicate that SHIVSCVpuL39G replicated much more efficiently 
and was much more cytopathic than SHIVSCVpu.  In contrast, SHIVSCVpuY35A and 
SHIVSCVpuYL35,39AG replicated less efficiently when compared to the parental SHIVSCVpu.  Taken 
together, these results show for the first time that the tyrosine-based sorting motif in the 
cytoplasmic domain of Vpu is essential for efficient virus release. These results also indicate that 
the dileucine-based sorting motif affects the intracellular trafficking of clade C Vpu proteins, 
virus replication, and release. 
 
Introduction 
Subtype C HIV-1 accounts for over 50% of the infections worldwide (Hemelaar et al., 
2006; Takeb et al., 2004).   While the reasons for the rapid spread of these viruses in the human 
population is currently unknown, several studies have suggested differences between  the 
subtype C HIV-1 and viruses from the other subtypes of HIV-1 group M.  In one study, both 
non-syncytia-inducing (NSI)/R5 and syncytia inducing (SI)/X4 subtype C HIV-1 isolates were 
found to be significantly less fit in peripheral blood mononuclear cells (PBMC)  competition 
assays than all other group M isolates of the same phenotype (Ball et al., 2003).   Another study 
evaluated the replicative fitness of representative strains from subtypes A, B, C, D and 
CRF01_AE.  In this study, subtype C viruses were found to have less replicative fitness in 
PBMC compared to the other subtypes but were 100 fold more fit in these assays than  HIV-2 or 
group O isolates (Arien et al., 2005).   More recently, a study evaluating the fitness and 
transmission efficiency of 33 different isolates from various HIV-1 subtypes found that while the 
subtype C HIV-1 viruses were the least replicatively fit in PBMC, these viruses were able to 
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compete with other subtypes in primary human explants of penial, cervical and rectal tissues 
(Abraha et al., 2009).  In addition to replication in in vitro assays, the Vpu proteins from subtype 
C HIV-1 isolates have biological properties and structural features that differ from the well 
studied subtype B Vpu protein.   Previously, we showed that the subtype C Vpu protein was 
efficiently transported to the cell surface while the subtype B Vpu protein appears to be 
predominantly localized to intracellular compartments (Pacyniak et al., 2005).    Recently, we 
also showed that the subtype C Vpu was less efficient at preventing surface expression of CD4 
than the subtype B protein and that replacement of the subtype B vpu from a pathogenic 
molecular clone of SHIV (SHIVKU-1bMC33) with the vpu gene from a subtype C clinical isolate 
resulted in a decreased rate of CD4
+
 T cell loss following inoculation into macaques (Hill et al., 
2008).  Taken together, these studies suggest that specific molecular determinants within 
different Vpu subtypes mediate protein trafficking and function and in turn, affect the role of the 
Vpu in HIV-1 pathogenesis. 
The distinct biological properties exhibited by different HIV-1 Vpu subtypes suggest that 
their function and effects on HIV-1 pathogenesis are mediated by different domains within each 
protein.  Tyrosine and dileucine motifs have been implicated in the intracellular sorting of a 
multitude of viral and cellular proteins.  For the human and simian immunodeficiency viruses, 
the intracellular trafficking function of the envelope (Env) protein as well as the negative factor 
(Nef) protein have been shown to be modulated by conserved GYxx  and ExxxLL motifs, 
respectively (Aiken et al., 1994; Day et al., 2006; Greenberg et al., 1998a).  HIV-1 Vpu also 
contains several potential sorting signal sequences within the cytoplasmic domain.  The subtype 
C Vpu contains overlapping conserved EYxx  and [D/E]xxxL[L/I] motifs at the membrane 
proximal region of the cytoplasmic domain.  It also contains an ExxxLL motif at the carboxy 
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terminus region of the cytoplasmic domain.  The membrane proximal Yxx  motif is highly 
conserved among all Vpu subtypes while the two dileucine motifs are only highly conserved 
among subtype C Vpu.  Finally, an invariant leucine residue is present within the predicted 
second α-helical domain of all Vpu.  This leucine residue is part of a potential dileucine-based 
sorting signal (ExxxLV) within the subtype B Vpu protein.  The presence or absence of these 
dileucine motifs may play a role in the differences in biological properties exhibited by subtype 
C Vpu as well as the reduced replicative fitness of this subset of viruses.  In this study, we 
examined the role of the unique overlapping tyrosine (YxxΦ; with Φ being an amino acid with a 
large hydrophobic amino acid) and dileucine ([D/E]xxxL[L/I])  motifs on the intracellular 
trafficking of the subtype C Vpu, CD4 surface expression and viral release from infected cells.  
Our results show for the first time that a dileucine-based sorting signal can affect trafficking of 
the Vpu protein, the level of cytopathology, the enhanced release function of Vpu and the 
efficiency of cell surface CD4 surface expression . 
 
Results 
Substitution in the dileucine motif causes retention of subtype C Vpu in ER/Golgi 
compartments 
The sequences of the Vpu mutants analyzed in this study are shown in Figure 42.  We 
first analyzed the ability of the Vpu mutants to be transported to the cell surface using two 
different assays.  293 cells were transfected with vectors expressing either VpuSCEGFP1, 
VpuSCEGFPY35A, VpuSCEGFPL39G, or VpuSCEGFPYL35,39AG. At 36 hours post-
transfection, cells were analyzed by laser scanning confocal microscopy.  As shown in Figure 
43A-D, the VpuSCEGFP1 and VpuSCEGFPY35A predominately localized at the cell plasma  
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Figure 42.  Sequence alignment of the Vpu proteins analyzed in this study.  The putative 
transmembrane domain (black), tyrosine motif (blue), and dileucine motifs (green) 
within each protein are identified by color and bottom-line.  The parental proteins used 
in this study were used as references.      
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membrane.  In contrast, the VpuSCEGFPL39G and VpuSCEGFPYL35,39AG clearly had reduced 
expression at the cell surface (Figure 43E-H).   Of these two constructs, the VpuSCEGFPL39A 
consistently had the lowest surface expression.  As the results in Figure 43 suggested that 
VpuSCEGFPL39G and VpuSCEGFPYL35,39AG were expressed at reduced levels, we analyzed 
which compartment these proteins were predominantly localized.  293 cells were transfected 
with vectors expressing VpuSCEGFP1, VpuSCEGFPY35A, VpuSCEGFPL39G, or 
VpuSCEGFPYL35,39AG and DsRed2-Golgi.  As shown in Figure 44, VpuSCEGFPY35A (Figure 
44E-H) was efficiently expressed at the cell surface while the majority of the VpuSCEGFPL39G 
(Figure 44I-L) and VpuSCEGFPYL35,39AG (Figure 44M-P) co-localized with the DsRed2-
Golgi marker.  To confirm the differences in surface expression of each mutant, transfected cells 
were surface biotinylated followed by immunoprecipitation with an anti-EGFP antibody.  As 
shown in Figure 45, biotinylated VpuSCEGFP1 (100%) and VpuSCEGFPY35A (110-120%) were 
easily detected at the cell surface.  In contrast, decreased levels of VpuSCEGFPL39G (30%) and 
VpuSCEGFPYL35,39AG (40%) were found at the cell surface.  Together, these results indicate 
that VpuSCEGFPY35A had slightly higher (but not statistically significant) levels at the cell 
surface, VpuSCEGFPYL35,39AG had an intermediate level of expression and VpuSCEGFPL39G 
had the lowest level of surface expression.  
 
The reduction in surface expression of VpuSCEGFPL39G and VpuSCEGFPYL39AG was 
not due to enhanced turnover of the protein 
One possible explanation for the reduced expression of VpuSCEGFPL39G and 
VpuSCEGFPYL35,39AG at the cell surface could be due to the stability of the viral proteins.  
Pulse-chase experiments were performed to examine the rate of turnover of VpuSCEGFP1 and  
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Figure 43.  Expression of EGFP, VpuSCEGFP1, VpuSCEGFPY35A, VpuSCEGFPL39G, 
or VpuSCEGFPYL35,39AG in 293 cells.  293 cells were co-transfected with vectors 
expressing VpuSCEGFP1, VpuSCEGFPY35A, VpuSCEGFPL39G, 
VpuSCEGFPYL35,39AG or EGFP.  At 48 hours, cells expressing EGFP were identified 
and images collected using laser scanning confocal microscopy as described in the 
Materials and methods section.  Panel A. Phase image merged with fluorescence 
micrograph of a cell expressing VpuSCEGFP1.  Panel B. Fluorescence micrograph of a 
cell expressing VpuSCEGFP1.  Panel C. Phase image merged with fluorescence 
micrograph of a cell expressing VpuSCEGFPY35A.  Panel D. Fluorescence micrograph 
of a cell expressing VpuSCEGFPY35A.  Panel E. Phase image merged with fluorescence 
micrograph of a cell expressing VpuSCEGFPL39G.  Panel F. Fluorescence micrograph 
of a cell expressing VpuSCEGFPL39G.  Panel G. Phase image merged with fluorescence 
micrograph of a cell expressing VpuSCEGFPYL35,39AG.  Panel H. Fluorescence 
micrograph of a cell expressing VpuSCEGFPYL35,39AG.      
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Figure 44.  Expression of EGFP, VpuSCEGFP1, VpuSCEGFPY35A, VpuSCEGFPL39G or 
VpuSCEGFPYL35,39AG and DsRed2-Golgi  in 293 cells.  293 cells were co-transfected 
with vectors expressing VpuSCEGFP1, VpuSCEGFPY35A, VpuSCEGFPL39G, 
VpuSCEGFPYL35,39AG or EGFP and DsRed2-Golgi.  At 48 h, cells expressing EGFP 
were identified and images collected using laser scanning confocal microscopy as 
described in the Materials and methods  section.  Panels A-D. 293 cells co-transfected 
with VpuSCEGFP1 and DsRed2-Golgi.  Panel A. Phase contrast image of a cell 
expressing VpuSCEGFP1 and DsRed2-Golgi.  Panel B. Fluorescence micrograph of a cell 
expressing VpuSCEGFP1.  Panel C. Fluorescence micrograph of a cell expressing 
DsRed2-Golgi.  Panel D. Merge of panels B and C.  Panels E-H. 293 cells co-transfected 
with VpuSCEGFPY35A and DsRed2-Golgi.  Panel E. Phase contrast image of a cell 
expressing VpuSCEGFPY35A and DsRed2-Golgi.  Panel F. Fluorescence micrograph of 
a cell expressing VpuSCEGFPY35A.  Panel G. Fluorescence micrograph of a cell 
expressing DsRed2-Golgi.  Panel H. Merge of panels F and G.  Panels I-L. 293 cells co-
transfected with VpuSCEGFPL39G and DsRed2-Golgi.  Panel I. Phase contrast image of 
a cell expressing VpuSCEGFPL39G and DsRed2-Golgi.  Panel J. Fluorescence 
micrograph of a cell expressing VpuSCEGFPL39G.  Panel K. Fluorescence micrograph 
of a cell expressing DsRed2-Golgi.  Panel L. Merge of panels J and K.  Panels M-P. 293 
cells co-transfected with VpuSCEGFPYL35,39AG and DsRed2-Golgi.  Panel M. Phase 
contrast image of a cell expressing VpuSCEGFPYL35,39AG and DsRed2-Golgi.  Panel N.  
Fluorescence micrograph of a cell expressing VpuSCEGFPYL35,39AG.  Panel O.  
Fluorescence micrograph of a cell expressing DsRed2-Golgi.  Panel P. Merge of panels N 
and O.      
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Figure 45.  Detection of subtype C Vpu mutants by surface biotinylation.  293 cells were 
transfected with vectors expressing VpuSCEGFP1, VpuSCEGFPY35A, 
VpuSCEGFPL39G, VpuSCEGFPYL35,39AG, or EGFP.  At 48 hours, cells were 
radiolabeled and surface biotinylated as described in the Materials and methods section.  
EGFP containing proteins were immunoprecipitated using an anti-EGFP serum and run 
on SDS-PAGE.  The proteins were transferred to membranes and reacted with a 
substrate to visualize the biotinylated proteins.  (Lane 1) Cells transfected with EGFP.  
(Lane 2) Cells transfected with VpuSCEGFP1.  (Lane 3) Cells transfected with 
VpuSCEGFPY35A.  (Lane 4) Cells transfected with VpuSCEGFPL39G.  (Lane 5) Cells 
transfected with   VpuSCEGFPYL35,39AG.  (Lane 6)  Untransfected cells, control. 
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the three mutant Vpu proteins.  As shown in Figure 46A-D, VpuSCEGFP1 and the three mutant 
Vpu proteins had 62-69% of the protein remaining at the 6 hour chase period.  These results 
indicate that protein stability was not the reason for the observed results in Figures 43-45.  
 
Cell surface expression of CD4 in the presence of tyrosine and dileucine mutants 
We examined the ability of VpuSCEGFP1 and the three Vpu mutants to down-regulate 
cell surface CD4 expression. HeLa CD4
+
 cells were transfected with vectors expressing 
VpuSCEGFP1 and the three Vpu mutants.  At 48 hours, cells were removed from the plates, 
stained for surface CD4 and analyzed by flow cytometry.  The results in Figure 47 show that 
CD4 surface expression levels in cells expressing either VpuSCEGFPL39G or VpuSCEGFPY35A 
were not statistically significant when compared to VpuSCEGFP1.  However, cells transfected 
with VpuSCEGFPYL35,39AG had a statistically significant reduction in CD4 cell surface 
expression when compared to VpuSCEGFP1 (p < 0.05).  These results indicate that removal of 
both the tyrosine and dileucine signals effected CD4 surface level down-modulation.  
 
SHIVs expressing Vpu proteins with mutations in the dileucine motif replicate with 
increased kinetics compared to those with mutations in the tyrosine motif  
We constructed simian human immunodeficiency viruses that expressed a Vpu protein 
with either the Y35A (SHIVSCVpuY35A), the L39G (SHIVSCVpuL39G) or the YL35,39AG 
(SHIVSCVpuYL35,39AG) amino acid substitutions.  The replication of these viruses and the 
unmodified SHIVSCVpu were compared using p27 growth curves.  The results of these assays are 
shown in Figure 48 and indicate that SHIVSCVpuL39G released p27 into the culture medium at a 
faster rate and was 5.6-fold higher than parental SHIVSCVpu at day 7 post-inoculation.   
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Figure 46.  Pulse-chase analyses of the Vpu fusion proteins.  To determine if the amino 
acid substitutions resulted in altered turnover of the Vpu fusion proteins, 293 cells were 
transfected with vectors expressing VpuSCEGFP1, VpuSCEGFPY35A, 
VpuSCEGFPL39G, or VpuSCEGFPYL35,39AG.  At 48 hours post-transfection,  the 
medium was removed and cells were incubated in methionine/cysteine-free medium for 
2 hours.  The cells were then radiolabeled for 30 minutes with 1 mCi of 
35
S-Translabel 
(methionine and cysteine, ICN Biomedical, Costa Mesa, CA) and the radiolabel chased 
for various periods of time (0-6 hours) in DMEM containing 100X unlabeled 
methionine/cysteine.   Vpu fusion proteins were immunoprecipitated using an anti-
EGFP serum as described in the Material and methods section.  Non-transfected 293 
cells, radiolabeled and chased for 0 hours served as a negative control (lane C).  All 
immune precipitates were collected on protein A Sepharose, the beads washed three 
times with RIPA buffer, and the samples resuspended in sample reducing buffer.  
Samples were boiled and the SHIV specific proteins analyzed by SDS-PAGE (10% gel).  
Proteins were then visualized by standard autoradiographic techniques. Panel A. 
Results of pulse-chase analysis of viral proteins immunoprecipitated from VpuSCEGFP1 
transfected cells.  Panel B.  Results of pulse-chase analysis of viral proteins 
immunoprecipitated from VpuSCEGFPY35A transfected cells.  Panel C.  Results of 
pulse-chase analysis of viral proteins immunoprecipitated from VpuSCEGFPL39G 
transfected cells.  Panel D.  Results of pulse-chase analysis of viral proteins 
immunoprecipitated from VpuSCEGFPYL35,39AG transfected cells. 
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Figure 47.  Substitution of tyrosine and leucine residues at positions 35 and 39 results in 
a protein that is less efficient at down-regulating cell surface CD4 expression.   HeLa 
CD4
+
 cells were transfected with plasmids expressing EGFP, VpuSCEGFP1, 
VpuSCEGFPY35A, VpuSCEGFPL39G, or VpuSCEGFPYL35,39AG.  At 48 hours, live 
cells were immunostained for CD4.   Cells expressing EGFP or EGFP fusion proteins 
were assessed for CD4 surface expression using flow cytometry. CD4 expression in cells 
expressing the various Vpu proteins was normalized to CD4 expression in EGFP 
expressing cells.  (*) symbol above bar represents Vpu proteins that were less efficient at 
down-modulating CD4 from the cell surface compared to VpuEGFP, with a p ≤ 0.05 
considered significant. 
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Figure 48.  Growth curves of SHIVSCVpu, SHIVSCVpuY35A, SHIVSCVpuL39G and 
SHIVSCVpuYL35,39AG in C8166 cells.  Cultures of C8166 cells were inoculated with 
SHIVSCVpu (♦), SHIVSCVpuY35A (■), SHIVSCVpuL39G (▲), and SHIVSCVpuYL35,39AG  (●) as 
described in the text.  Aliquots of the culture medium were assayed for the presence of 
p27 antigen.  The growth curves were performed in triplicate and the mean of the three 
experiments plotted.   
 
247 
 
  
248 
 
Additionally, we observed that cultures inoculated with SHIVSCVpuL39G developed syncytial 
cytopathology at a faster rate (and larger) compared to the other three viruses (data not shown).  
In contrast, the SHIVSCVpuY35A and SHIVSCVpuYL35,39AG  released  p27 into the culture medium at 
a slower rate and at day 7 were 10.3 and 7.4-fold less, respectively, when compared to the 
parental SHIVSCVpu.  It should be noted that in four attempts to prepare stocks of SHIVSCVpuY35A, 
three of the stocks selected for a highly cytopathic variant.  Sequence analysis of the vpu gene 
amplified from cells isolated from infected cultures revealed a premature stop codon in vpu at 
amino acid position 28 (data not shown).   Since we have never encountered this problem in 
construction of other SHIVs, it suggests that the lack of a tyrosine residue at this position is 
being compensated for by truncation of the protein.   Taken together, these results indicate that 
the tyrosine residue appeared to be required for efficient virus particle release and that removal 
of the dileucine motif resulted in a virus that replicated much more efficiently. 
 
SHIVSCVpuL39G processes Gag and Env precursors faster than SHIVSCVpuY35A and 
SHIVSCVpuYL35,39AG    
Pulse-chase experiments were used to analyze the processing of viral Gag and Env 
proteins.  C8166 cells were inoculated with either SHIVSCVpu, SHIVSCVpuY35A SHIVSCVpuL39G, or 
SHIVSCVpuYL35,39AG for 5 days at which time pulse-chase analyses were performed.  The results of 
the pulse-chase analysis for SHIVSCVpu are shown in Figure 49A and have been previously 
described (Hill et al., 2008).  The results of the pulse-chase analyses for SHIVSCVpuL39G (Figure 
49B) indicate that Env and Gag protein precursors were processed similar to SHIVSCVpu but 
faster than either SHIVSCVpuY35A (Figure 49C) but not SHIVSCVpuYL35,39AG (Figure 49D).  This  
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Figure 49.  Pulse-chase analyses revealed that SHIVSCVpuY35A, SHIVSCVpuL39G and 
SHIVSCVpuYL35,39AG have altered processing of viral proteins.  To determine if viral 
structural proteins were released with reduced efficiency in SHIVSCVpu-inoculated 
cultures, C8166 cells were inoculated with 10
3
 TCID50 of SHIVSCVpu, SHIVSCVpuY35A, 
SHIVSCVpuL39G or SHIVSCVpuYL35,39AG.  At 7 days post-infection, the medium was removed 
and infected cells were incubated in methionine/cysteine-free medium for 2 hours.  The 
cells were then radiolabeled for 30 minutes with 1 mCi of 
35
S-Translabel (methionine 
and cysteine, ICN Biomedical, Costa Mesa, CA) and the radiolabel chased for various 
periods of time (0-6 hours) in DMEM containing 100X unlabeled methionine/cysteine.   
SHIV proteins were immunoprecipitated from cell lysates using plasma pooled from 
several pig-tailed monkeys infected previously with SHIV as described in the Material 
and methods section.  Uninfected C8166 cells, radiolabeled and chased for 0 hours 
served as a negative control (lane C).  All immune precipitates were collected on protein 
A-Sepharose, the beads washed three times with RIPA buffer, and the samples 
resuspended in sample reducing buffer.  Samples were boiled and the SHIV specific 
proteins analyzed by SDS-PAGE (10% gel).  Proteins were then visualized by standard 
autoradiographic techniques. Panel A. Results of pulse-chase analysis of viral proteins 
immunoprecipitated from SHIVSCVpu infected cell lysates.  Panel B. Results of pulse-
chase analysis of viral proteins immunoprecipitated from SHIVSCVpuL39G infected cell 
lysates.  Panel C.  Results of pulse-chase analysis of viral proteins immunoprecipitated 
from SHIVSCVpuY35A infected cell lysates.  Panel D. Results of pulse-chase analysis of 
viral proteins immunoprecipitated from SHIVSCVpuYL35,39AG infected cell lysates.   
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was also reflected in the release of the viral proteins into the culture medium (data not shown).  
Together, these data correlated well with the p27 growth curves.  
 
SHIVs with the L39G amino acid substitution exhibit more particles on the cell surface 
We examined the maturation of SHIVSCVpu, SHIVSCVpuY35A, SHIVSCVpuL39G and 
SHIVSCVpuYL35,39AG by electron microscopy to determine if these amino acid substitutions altered 
the pattern of  virus  maturation.  As shown in Figure 50A, the SHIVSCVpu was found to mature at 
the cell surface as we recently reported (Hill et al., 2008).   SHIVSCVpuY35A, SHIVSCVpuL39G,   and 
SHIVSCVpuYL35,39AG were also found to mature predominantly at the cell surface (Figure 50B-D) 
although viral particles were occasionally observed within vesicles of  SHIVSCVpuL39G-infected 
cells (Figure 50E).  The salient feature of the electron microscopy studies was the number of 
viral particles associated per infected cell.  We determined the mean number of particles per 50 
cells at five days post-inoculation.   As shown in Figure 51A, the mean number of virus particles 
from 50 SHIVSCVpu-infected C8166 cells was approximately 16.    The number of particles per 
cell for SHIVSCVpuY35A and SHIVSCVpuYL35,39AG-infected cells was approximately 3 and 8, 
respectively (Figure 51B-C).   Contrasting with these results, SHIVSCVpuL39G had a mean of 
approximately 75 particles per cell or approximately 5 times as many particles as parental 
SHIVSCVpu (Figure 51D).   The difference in the mean number of particles per cell between 
SHIVSCVpu and SHIVSCVpuL39G, SHIVSCVpu and SHIVSCVpuYL35,39AG, and SHIVSCVpu and 
SHIVSCVpuY35A were found to be very significant (p < 0.001).  Analysis of the distribution of the 
number of particles per cell also showed a clear difference between SHIVSCVpuL39G and the other 
three viruses.  For SHIVSCVpu, the number of particles per cell was generally less than 30 (Figure 
51A) while for SHIVSCVpuYL35,39AG and SHIVSCVpuY35A the number of particles per cell was less  
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Figure 50.  Electron microscopic examination of C8166 cells inoculated with SHIVSCVpu, 
SHIVSCVpuY35A, SHIVSCVpuL39G, or SHIVSCVpuYL35,39AG.  C8166 cells were inoculated with 
each virus for 7 days.   Cells were washed three times with PBS and processed for 
electron microscopy as described in the Materials and methods section.   Panel A. C8166 
cells inoculated with parental SHIVSCVpu.  Panel B. C8166 cells inoculated with 
SHIVSCVpuY35A.   Panels C and D.  C8166 cells inoculated with SHIVSCVpuYL35,39AG.  
Panels E and F.  C8166 cells inoculated with SHIVSCVpuL39G.   
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Figure 51.  Enumeration of the number of viral particles associated with the infected 
C8166 cells following inoculation with SHIVSCVpu, SHIVSCVpuY35A, SHIVSCVpuL39G, or 
SHIVSCVpuYL35,39AG.  Cells were inoculated with equivalent doses of infectious virus and 
at 5 days processed for electron microscopy as described in the Material and methods 
section.  The number of viral particles associated with 50 cells per virus and mean values 
calculated.    
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than 20 and 10, respectively (Figure 51B-C).  These results were in contrast with those for   
SHIVSCVpuL39G, which showed a more even distribution in the number of particles per cell 
(Figure 51D).  Combined with the p27 growth curves, while there were increased numbers of 
virus particles on the surface, the virus replicated with increased kinetics and released more p27 
into the culture medium. 
 
Discussion 
The subtype C Vpu proteins have canonical tyrosine (YxxΦ) and dileucine 
([D/ExxxL[L/I]) motifs that could be involved in the targeting of this protein to different 
intracellular compartments.   The targeting of proteins containing these motifs is generally 
mediated through interactions with various adaptor protein complexes (AP-1, AP-2, AP-3, AP-
4).   The YxxΦ signals have been shown to be involved in endocytosis of membrane proteins 
from the cell plasma membrane as well as targeting of membrane proteins to lysosomes and 
lysosome-related vesicles.  The YxxΦ motifs that are involved in endocytic functions generally 
have a glycine residue at the Y+1 position and are located 10-40 amino acids from the 
transmembrane of the protein.  Those YxxΦ motifs that are involved in lysosomal targeting 
generally have an acidic residue at the Y+1 position and are generally located 6-9 residues from 
the transmembrane domain (Bonifacino and Traub, 2003).  Tyrosine signals generally interact 
with the μ subunit of adaptor protein complexes.   The best-studied interactions with the AP 
complexes have been predominantly with μ2, although the μ1, μ3, and μ4 subunits can interact 
with these motifs.   The μ3A and μ3B subunits have a preference for binding to tyrosine signals 
with an acidic amino acid before and/or after the tyrosine residue.  The most characteristic 
feature of the μ4 subunit binding is the presence of aromatic amino acids near the tyrosine 
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residue.  With dileucine motifs, the first leucine is generally invariant and replacement of the 
first leucine with an isoleucine reduces the potency of the signal.  However, the second leucine 
can be replaced with an isoleucine and in some cases a methionine residue with an acidic amino 
acid at the +4 and/or +5 position and retain signal function.   Dileucine motifs also interact with 
adaptor protein complexes AP-1, AP-2, and AP-3 (Bonifacino and Traub, 2003), but they appear 
to interact with a hemi-complex formed by the small subunit and the large specific subunit 
(Janvier et al., 2003).  Similar to the tyrosine motifs, the proximity to the transmembrane domain 
appears to affect whether it is involved in endocytosis or lysosomal targeting.   As the 
overlapping tyrosine and dileucine motifs of Vpu are membrane proximal, it suggests that they 
may be involved in lysosomal targeting.   
In this study we analyzed the role of overlapping tyrosine and dileucine signals within the 
cytoplasmic domain of the subtype C Vpu in intracellular targeting.  The two other membrane 
proteins of HIV-1, Env and Nef, use tyrosine and dileucine motifs for either trafficking within 
the cell and/or removal of cellular proteins from the cell surface (Boge et al., 1998; Bresnahan et 
al., 1998; Byland et al., 2007; Chaudhuri et al., 2007; Coleman et al., 2005; Craig et al., 1998; 
Day et al., 2006; Greenberg et al., 1998a; Lodge et al., 1997; Noviello et al., 2008; Roeth et al., 
2004; Schwartz et al., 1996).  Our findings indicate that the tyrosine motif within Vpu may have 
a role in enhanced virus release.  The finding that the tyrosine based motif was important to virus 
release is not entirely surprising as this motif is conserved in virtually all of the Vpu sequences 
from the different HIV-1 subtypes in the Los Alamos National Laboratory (LANL)-HIV-1 group 
M database.  Bone marrow stromal antigen 2 (BST-2) was recently identified as a target for Vpu 
identifying a mechanism by which Vpu enhances virion release in certain cell types (Neil et al., 
2008; Van Damme et al., 2008).  However, the physiological relevance of BST-2 antagonism as 
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a mechanism for Vpu mediated enhancement of pathogenesis has been brought under question 
based on several observations: 1) human PBMC do not express high levels of BST-2 even 
following treatment with interferon-α; 2) HIV-1 Vpu has been shown to enhance pathogenesis in 
a macaque model even though the BST-2 protein expressed by these species is not antagonized 
by HIV-1 Vpu and 3) subtype B and subtype C Vpu exhibit distinct replication kinetics in C8166 
cells and pig-tailed PBMC even though they display equal antagonistic properties against human 
BST-2 (Hill et al., 2008; Joag et al., 1996; Liu et al., 1999; McCormick-Davis et al., 2000a; 
Miyagi et al., 2009; Singh et al., 2001; Stephens et al., 2002).  Also, no studies have been 
conducted to determine whether endogenous expression of BST-2 in C8166 cells significantly 
affects virion release and determines the Vpu phenotype of this cell line.  Therefore, as changing 
the tyrosine residue at position 35 to an alanine in the subtype C Vpu protein resulted in a virus, 
SHIVSCVpuY35A, that replicated very poorly in C8166 cells, it raises several questions.  First, is the 
membrane proximal tyrosine motif important in the Vpu interactions with BST-2?  Secondly, if 
it is important, does it affect binding (perhaps through structural alterations of the 
transmembrane domain) or does it affect the mechanism by which Vpu antagonizes BST-2?  
Finally, is the tyrosine motif involved in alternate mechanisms of Vpu mediated enhancement of 
virion release that are not associated with BST-2?  Additional studies are needed to determine 
the affects these amino acid substitutions have on the interaction of Vpu with BST-2 and whether 
these results correlate with what remains to be seen in cells that express high levels of BST-2 
(i.e. HeLa cells).  This would provide additional insight into the physiological relevance of Vpu 
mediated antagonism of BST-2 for enhancement of pathogenesis.  
Dileucine motifs are found in a high percentage of subtype C Vpu sequences in the 
LANL-HIV-1 database, with approximately 80% of the sequences having a dileucine, leucine-
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isoleucine or leucine-valine motif at the membrane proximal location.   In contrast, of 271 
subtype B Vpu sequences in the LANL-HIV database, the majority (~95%) of the sequences 
have an isoleucine in place of the primary leucine (EYRKIL) with only 5.2% of the sequences 
having dileucine, leucine-isoleucine or leucine-valine motif. Similar to YxxΦ signals, 
[D/E]xxxL[L/I] signals in mammalian membrane proteins can mediate both rapid internalization 
as well as targeting to endosomal and lysosomal compartments.   This indicates that they can be 
recognized at the plasma membrane and the intracellular compartments.  In addition, 
[D/E]xxxL[L/I] signals have been implicated in trafficking of membrane proteins to basolateral 
membranes in polarized epithelial cells (Hunziker and Fumey, 1994; Matter et al., 1994; Miranda 
et al., 2001).  Our results indicate that the dileucine sorting signal within the subtype C Vpu 
protein was important for efficient transport and expression at the cell surface.  Substitution of 
the second leucine with a glycine resulted in a protein (VpuSCEGFPL39G) that was transported 
to the cell surface less efficiently with the majority being retained within the Golgi complex.  
The virus constructed with this mutation, SHIVSCVpuL39G, was found to replicate much better than 
the SHIV with the unmodified subtype C Vpu protein (SHIVSCVpu).   We also find that 
SHIVSCVpuL39G replicates as well as the SHIV expressing the subtype B Vpu protein (SHIVKU-
1bMC33).   While speculative at this juncture, one possible explanation for these observations is 
that the presence of the [D/E]xxxL[L/I] motif may interfere with the function of the tyrosine-
based signal.   Possibly, the subtype C Vpu protein does not interact with AP complexes for 
sorting of the protein to intracellular compartments resulting in the transport of the protein to the 
cell surface. By removing the dileucine sequence, the protein may be allowed to interact with 
cellular components that target the protein to an intracellular compartment. 
260 
 
Our results raise the important question, “Why would the subtype C viruses select for a 
dileucine signal that would hinder virus replication?”  It has been hypothesized that subtype C 
HIV-1 may be evolving to a less virulent form (Arien et al., 2007).  Data to support this 
hypothesis include that the subtype C viruses were found to be less fit in PBMC competition 
assays (Arien et al., 2005; Ball et al., 2003).    Additional support comes from our recent study 
using SHIVSCVpu where we exchanged the subtype B vpu with one from a clinical subtype C 
isolate (Hill et al., 2008).  In this study, we showed that inoculation of pig-tailed macaques with 
this virus resulted in a slower rate of CD4
+
 T cell loss compared to our highly pathogenic 
subtype B SHIVKU-1bMC33.   It will be of interest to determine if inoculation of macaques with the 
SHIVSCVpuL39G causes a more rapid loss of CD4
+
 T cells. 
 
Materials and Methods 
Plasmids and Cell Culture   
The derivation and pathogenicity of SHIVKU-1bMC33 has been described (McCormick-
Davis et al., 2000a; Singh et al., 2003; Stephens et al., 2002).   A derivative of this virus, known 
as SHIVSCVpu, is identical to SHIVKU-1bMC33 except that this virus expresses the subtype C Vpu 
protein (Hill et al., 2008).  Vectors expressing the subtype B (pcvpuegfp) and C Vpu 
(pcvpuscegfp) proteins fused to enhanced green fluorescent protein (EGFP) have been previously 
described (Gomez et al., 2005; Pacyniak et al., 2005; Singh et al., 2003).   The vector expressing 
the DsRed2-Golgi was obtained from Clontech.  For the construction of the subtype C Vpu 
mutants, site-directed mutagenesis was performed on the parental plasmid, pcvpuSCegfp.  Site 
directed mutagenesis was performed using this plasmid in the Quik Change Mutagenesis kit 
(Stratagene) according to the manufacturer’s instructions.   With all mutants, the entire insert was 
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sequenced (both vpu and egfp genes) to ensure the validity of the mutations introduced and that 
no additional changes were introduced during the mutagenesis process.   
The 293 cell line was maintained in DMEM supplemented with 10% fetal bovine serum, 
gentamicin (5 ug per mL) and penicillin/streptomycin (100 U per mL and 100 μg per mL, 
respectively).   A C8166 cell line was used as the indicator cells to measure infectivity and 
cytopathicity of the viruses used in this study.   C8166 cells were maintained in RPMI-1640, 
supplemented with 10 mM Hepes buffer pH 7.3, 2 mM glutamine, gentamicin (5 µg per mL) and 
10% fetal bovine serum (R10FBS).  HeLa CD4
+
 cells were obtained through the AIDS Research 
and Reference Reagent Program, Division of AIDS, NIAID, NIH: HeLa CD4 Clone 1022 from 
Dr. Bruce Chesebro and were maintained in DMEM supplemented with 10% fetal bovine serum, 
gentamicin (5 µg per mL), and G-418 (1 mg per mL).   
 
Laser Scanning Confocal Fluorescence Microscopy Analysis 
VpuEGFP and other plasmids were transfected into human 293 cells to assess their 
subcellular localization using ExGen
TM
 500 (MBI Fermentas) using the manufacturer’s protocol.  
Briefly, 10
5
 cells were seeded onto cover slips in each well of a 6-well tissue culture plate 24 
hours prior to transfection.  Plasmid DNA (4.75 µg) was diluted in 300 µl of 150 mM sodium 
chloride solution and vortexed gently.  Polyethylenimine was then added to the solution, 
vortexed and allowed to stand at room temperature for 10 minutes.  The 293 cells were washed 
and 3.0 mL of media was added.  The polyethylenimine/DNA mixture was added to the cells 
dropwise and the cultures were incubated at 37C in 5% CO2 atmosphere.  At 48 hours post-
transfection, cells were washed in phosphate buffered saline (PBS, pH 7.2) and fixed in ice cold 
2% paraformaldehyde for 5 minutes.  The cells were washed again in PBS and the cover slips 
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mounted onto microscope slides using mounting media (Slowfade Antifade, Molecular Probes).  
The cells were imaged with a Zeiss LSM 510 confocal microscope in the upright configuration.  
The objective used was a 63X 1.4n.a. Plan Apochromat.  Images were captured at 12 bit 
resolution with a pixel array of 2048 x 2048 and a zoom of 2.0X.  The EGFP was excited with 
light at 488 nm with a constant laser intensity, and the emitted light was collected after passing 
through a 505 nm long pass filter.  The amplifier offset and gain were identical for all images.  
The pinhole was set to 96 µm which at this wavelength represents one airey unit.  The optical 
section had a width of 0.7 µm. 
To confirm the presence of the Vpu fusion protein at different subcellular compartments, 
a series of co-transfection studies were performed using vectors expressing a Golgi marker fused 
to the fluorescent protein DsRed2 (DsRed2-Golgi).   293 cells were co-transfected with vectors 
expressing the various Vpu fusion proteins and a vector expressing one of the subcellular 
markers.  At 48 hours post-transfection, cells were processed for confocal microscopy as 
described above, and cells identified expressing both proteins.  Fluorescent digital images were 
obtained using a Zeiss LSM510 confocal microscope equipped with  Argon and HeNe2 lasers 
(25 mW) for the excitation (488 nm, 50% laser power) and detection (band pass 505-530 nm 
filter; BP505-530) of  EGFP and for excitation (558 nm, 100% laser power) and detection (band 
pass 583 nm filter; LP560) of DsRed2.   Images were acquired in Multitrack channel mode 
(sequential excitation/emission) with LSM510 (v 3.2) software and a Plan-Apochromat 63/1.4 
Oil DIC objective with frame size of 2048 x 2048 pixels.  Detector gain was set initially to cover 
the full range of all the samples and background corrected by setting the amplifier gain, and all 
images were then collected under the same photomultiplier detector conditions and pinhole 
diameter. 
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Construction of Viruses with the Tyrosine and Dileucine Mutations 
For the construction of a subtype C SHIV containing tyrosine and dileucine mutations, 
we used plasmid pUCvpuSC, which contains the tat and rev of HIV-1 (HXB2), the subtype C vpu 
and 5' end of the env gene.   To introduce the tyrosine and dileucine mutations, we used this 
plasmid and procedures used for site-directed mutagenesis as described above for the 
construction of the Vpu/EGFP fusion proteins.  Simian-human immunodeficiency viruses 
expressing subtype C Vpu proteins with the Y35A (SHIVSCVpuY35A), the L39G (SHIVSCVpuL39G), 
and YL35,39AG (SHIVSCVpuYL35,39AG) amino acid substitutions were constructed as previously 
described (Hill et al., 2008; Hout et al., 2006b; Hout et al., 2005; McCormick-Davis et al., 
2000a; Singh et al., 2003; Stephens et al., 2002).  Stocks were prepared, titrated in C8166 cells 
and frozen at -86C until used.  
 
Pulse-Chase Analysis of Viral Proteins 
To analyze the viral proteins synthesized and released from cells, C8166 cells were 
inoculated with 10 ng of p27 of either SHIVSCVpuY35A, SHIVSCVpuL39G,   SHIVSCVpuYL35,39AG  or 
SHIVSCVpu.  At 7 days post-inoculation, the medium was removed and infected cells were 
incubated in methionine/cysteine-free Dulbecco's modified Eagle's medium (DMEM) for 2 
hours.  The cells were then radiolabeled for 30 minutes with 1 mCi per ml of 
35
S-Translabel 
(methionine and cysteine, ICN Biomedical, Costa Mesa, CA) and the radiolabel chased for 
various periods of time in DMEM containing 100X unlabeled methionine/cysteine.  SHIV 
proteins were immunoprecipitated from the cell culture medium and infected cell lysates using 
plasma pooled from several rhesus monkeys infected previously with non-pathogenic SHIV-4.   
Briefly, the cell culture medium was clarified (16,000x g) for 2 minutes.  The supernatant was 
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transferred and made 1X with respect to cell lysis buffer (50 mM Tris-HCl, pH 7.5; 50 mM 
NaCl; 0.5% deoxycholate; 0.2% SDS; 10 mM EDTA) and SHIV proteins were 
immunoprecipitated with 10 μl of a pooled serum.  For immunoprecipitation of cell associated 
SHIV proteins, cell lysates were prepared as previously described (Hout et al., 2005; 
McCormick-Davis et al., 2000a; Stephens et al., 1995) prior to incubation with antiserum.   
Lysates were centrifuged in a microfuge to remove nuclei prior to the addition of antibody.  Cell 
lysates and culture medium were then incubated with antibody for 16 hours at 4C.  All 
immunoprecipitates were collected on protein A-Sepharose beads, the beads washed three times 
with RIPA buffer, and the samples resuspended in sample reducing buffer.  Samples were boiled 
and the SHIV specific proteins analyzed by SDS-PAGE.  Proteins were then visualized by 
standard autoradiographic techniques.   
 
Assays for Examining Cell Surface Vpu Expression 
To determine if Vpu proteins were expressed on the plasma membrane, 293 cells were 
transfected with 4.75μg of plasmid DNA expressing EGFP, VpuSCEGFP, VpuSCEGFPY35A, 
VpuSCEGFPL39G, or VpuSCEGFPYL35,39AG.   At 48 hours post-transfection, cells were 
incubated in methionine/cysteine-free media for 2 hours and then labeled with 200 μCi of 35S-
Translabel for 1 hour.  Cells were washed three times in ice-cold 1X PBS and the surface of cells 
labeled with  EZ-Link Sulfo-NHS-LC-Biotin (Pierce) at a concentration of 10 mg/ml for 1 hour 
on ice.  Cells were then washed three times in 1X PBS containing 100 mM glycine.  The cells 
were lysed in 1 ml of 1X RIPA buffer and nuclei were removed by centrifugation at 14,000 rpm 
for 15 minutes.  Cell lysates were incubated overnight at 4C with a rabbit polyclonal anti-EGFP 
antibody and protein A-Sepharose beads.  Lysate immunoprecipitates were washed three times in 
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1X RIPA, resuspended in sample reducing buffer, and boiled for 5 minutes.  Proteins were 
separated on a 10% SDS-PAGE gel and densitometry was used to quantify the total amount of 
VpuEGFP fusion expressed in each sample.   Equal amounts of fusion proteins were then 
separated on a 10% SDS-PAGE gel, the proteins were transferred to nitrocellulose and a Western 
blot was used to detect biotin-labeled proteins.  Biotin-labeled proteins were detected using a 
Vectastain-ABC-AmP chemiluminescent detection kit (Vector Laboratories).  A BioRad 
chemiluminescent imager was used to quantify the total amount of biotin-labeled VpuEGFP in 
each sample.  The experiments were conducted in triplicate and a Student’s t-test was used to 
determine statistical significance with p<0.05 considered significant. 
 
CD4 Surface Expression Analysis 
For analysis of cell surface CD4 expression in the presence of various VpuEGFP 
proteins, HeLa CD4
+ 
cells were seeded into each well of six well plates 24 hours prior to 
transfection.  Cells were transfected with plasmids expressing EGFP or various Vpu proteins 
fused to EGFP.  Cultures were monitored for 48 hours, cells removed from the six well plates 
using Ca
2+ 
/Mg
2+
-free PBS containing 1 mM EDTA and stained with PE-Cy5 conjugated anti-
CD4 (BD Bioscience).   Cells were analyzed using an LSR II flow cytometer, determining mean 
fluorescence intensity (MFI) of PE-Cy5 for transfected (EGFP positive) and untransfected 
(EGFP negative) cells within the same well.  An MFI ratio was calculated for each sample with 
the EGFP control normalized to 1.0.  Normalized ratios from at least five separate experiments 
were averaged and the standard deviation calculated.  Statisitcal significance for all groups were 
compared using a Student’s t-test, with p<0.05 considered significant. 
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Viral Replication Kinetics Analysis 
Standard p27 assays (Zeotometrix Incorporated, SIV core antigen kit) were used to assess 
release of viral particles from cells infected with SHIVSCVpu, SHIVSCVpuY35A, SHIVSCVpuL39G or 
SHIVSCVpuYL35,39AG.  Cultures of 10
6
 C8166 cells were inoculated with 10 ng of p27 (determined 
by commercial p27 antigen kits) for 4 hours.   At the end of 4 hours, the cells were centrifuged at 
400x g for 10 minutes and the pellet washed with 10 mL of medium.  This was repeated two 
additional times.   The cells were resuspended in RPMI-1640 supplemented with 10% FBS and 
antibiotics and this was considered the 0 time point of the assay.  Cultures were incubated at 37C 
and aliquots of the culture were removed at 0, 1, 3, 5, 7, and 9 days with fresh media added to 
cultures at days 3 and 6.   The culture medium was separated from the cells by centrifugation and 
assayed for p27 according to the manufacturer’s instructions.   
 
Electron Microscopy 
 To determine the site(s) of intracellular maturation, infected cells were examined by 
transmission electron microscopy.  Cultures of 10
6
 C8166 cells were inoculated with 10 ng of 
SHIVSCVpu, SHIVSCVpuY35A, SHIVSCVpuL39G or SHIVSCVpuYL35,39AG.   Cells were incubated for 5 
days at which time cells were pelleted at 400x g for 10 minutes.  Cells were washed three times 
with 10 mL of PBS (pH 7.4) and fixed in 2% glutaraldehyde overnight at 4C.  Cells were post-
fixed in 2% osmium tetroxide (OsO4) for 1 hour.  The cells were washed twice with water and 
dehydrated through a series of alcohols (30-100%) followed by embedding in Embed 812 resin.  
Thin sections were cut at 80Å, stained with uranyl acetate and lead citrate and examined under a 
JEOL 100CXII transmission electron microscope.   The number of virus particles associated with 
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50 infected cells (either at the surface or within the cell) were enumerated and data analyzed by 
planned comparisons using unpaired t-test. 
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XII.   Chapter 7: The Transmembrane Domain of Human Immunodeficiency Virus Type 1 
Vpu is the Major Influence of the Protein on the Rate of CD4
+
 T Cell Loss in Pig-tailed 
Macaques Inoculated with SHIV 
 
Abstract 
Previously, we showed that a subtype C Vpu protein from a clinical isolate of HIV-1 
displayed biological properties distinct from those exhibited by a laboratory-adapted subtype B 
Vpu (HXB2).  Inoculation of pig-tailed macaques with a simian-human immunodeficiency virus 
(SHIV) expressing a subtype C Vpu protein (SHIVSCVpu) resulted in a more gradual loss of CD4
+
 
T-cells compared to those inoculated with a SHIV expressing a subtype B Vpu (SHIVKU-1bMC33) 
(Hill et al., 2008).  In this study, we sought to determine the contributions of the N-
terminus/transmembrane domain and the cytoplasmic domain of each of these subtypes to the 
differences observed.  We constructed chimeric Vpu expressing either the subtype B or subtype 
C N-terminal region/transmembrane domain and the opposing cytoplasmic domain.  Both 
chimeric vpu genes were fused in frame with the gene for enhanced green fluorescence protein 
(EGFP).  Our results indicate that the cytoplasmic domain is responsible for localization of the 
protein and the difference in molecular weight of the fusion proteins.  Both proteins down-
modulated CD4 from the surface similar to the subtype C Vpu.  We constructed SHIV 
expressing either of the chimeric Vpu (SHIVVpuBC and SHIVVpuCB).  Both SHIV expressing the 
chimeric Vpu proteins replicated at intermediate rates compared to the two parental viruses, 
however SHIVVpuBC replicated with increased kinetics compared to SHIVVpuCB.  Inoculation of 
three pig-tailed macaques with SHIVVpuBC resulted in a rapid loss of circulating CD4
+
 T cells and 
high viral loads similar to results in macaques inoculated with SHIVKU-1bMC33.  Inoculation of 
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three pig-tailed macaques with SHIVVpuCB resulted in a more gradual loss of circulating CD4
+
 T 
cells than observed in SHIVVpuBC inoculated macaques, however, more rapid than resulted in  
macaques inoculated with SHIVSCVpu.  These results demonstrate the potential impact of the 
individual domains of the Vpu protein on biological properties, protein function and 
pathogenesis. 
 
Introduction 
 Two major functions of Vpu in HIV-1 pathogenesis have been identified.  These are the 
down-modulation of CD4 from the surface of infected cells by shunting CD4 molecules to the 
proteasome and facilitating virion release from the surface of cells.  Both the transmembrane 
domain and the cytoplasmic domain have been implicated to play a role in both of these 
functions.  However, whether these implications are due to alterations in protein interactions or 
modifications of protein structure remains in question.  The extent to which each of these 
functions and the contributions that each of the domains that mediated them contribute to disease 
progression in vivo also remains unknown. 
 During the last several years, our laboratory has generated a series of pathogenic chimeric 
simian-human immunodeficiency virus molecular clones that have greatly facilitated the study of 
the role of HIV-1 Vpu in pathogenesis.  Using SHIVKU-1bMC33, our laboratory showed that the 
Vpu protein can play a role in disease progression and that the Vpu from another subtype of 
HIV-1 affected SHIV pathogenesis differentially (Hill et al., 2008; Stephens et al., 2002).  
Additional studies from our laboratory have shown that subtype B Vpu and subtype C Vpu 
exhibit distinct structural and biological properties that could potentially affect overall HIV-1 
pathogenesis (Hill et al., 2008; Pacyniak et al., 2005; Singh et al., 2003).  Using a VpuEGFP 
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fusion system we determined that subtype B Vpu predominately localizes to the Golgi complex, 
while subtype C Vpu is efficiently transported to the plasma membrane.  The subtype B Vpu is 
more efficient at down-modulating CD4 surface expression than subtype C Vpu.  Both proteins 
associate with detergent resistant membranes, which appears to correlate with the BST-2 
associated enhancement of virion release function.  However, membrane raft association does 
not appear to impact the CD4 down-modulation function of Vpu.  Finally, a SHIV expressing a 
subtype C Vpu (SHIVSCVpu) has reduced replication kinetics and results in a decreased rate of 
CD4
+
 T cell loss and lower viral loads in infected pig-tailed macaques when compared to a SHIV 
expressing a subtype B Vpu (SHIVKU-1bMC33) (Hill et al., 2008; Pacyniak et al., 2005; Singh et 
al., 2003).  In this study, we sought to determine the contributions of the N-
terminus/transmembrane domain and the cytoplasmic domain of the subtype B and subtype C 
Vpu proteins to the structural and functional properties of each of these isolates and their impact 
on disease pathogenesis.  Our results indicate that while both domains impact both functions of 
the Vpu protein, the transmembrane domain appears to have a major influence on the rate of 
CD4
+
 T cell loss in infected pig-tailed macaques.   As the transmembrane domain is critical to 
the enhanced virion release function of Vpu, these results again question, “To what extent is the 
antagonism of BST-2 relevant in Vpu mediated enhancement of disease progression?” as pig-
tailed macaques do not express a BST-2 protein that is susceptible to HIV-1 Vpu. 
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Results 
The cytoplasmic domain of the Vpu protein dictates intracellular localization and 
molecular weight 
 The sequences of the chimeric Vpu proteins analyzed in this study are shown in Figure 
52.  293 cells were transfected with vectors expressing VpuEGFP, VpuSCEGFP1, VpuBCEGFP or 
VpuCBEGFP.  At 48 hours post-transfection, cells were analyzed by laser scanning confocal 
microscopy.  As shown in Figure 53A-D, VpuBCEGFP was predominately localized within 
intracellular compartments, similar to VpuEGFP, while the VpuCBEGFP was efficiently 
transported to the plasma membrane parallel to results observed in cells transfected with 
VpuSCEGFP1.   
 We next examined the stability of these chimeric proteins using pulse-chase analysis.  
The results shown in Figure 54, indicate that exchanging the domains of the subtypes B and C 
Vpu proteins does not modify the rate of protein turnover.  These results identify the cytoplasmic 
domain as a determinant of the differential molecular weights (Mr) of VpuEGFP and 
VpuSCEGFP1.   
 
Both domains impact the ability of Vpu to down-modulate CD4 surface expression 
 In order to examine the influence of each of the domains to the CD4 surface down-
modulation function, HeLa CD4
+
 cells were transfected with plasmids expressing VpuEGFP, 
VpuSCEGFP1, VpuBCEGFP, or VpuCBEGFP and CD4 surface expression was analyzed by flow 
cytometry.  Expression of either VpuBCEGFP or VpuCBEGFP results in CD4 surface expression 
levels similar to cells expressing VpuSCEGFP1 (Figure 55).  Statistical analysis using a Student’s 
t-test indicated that both chimeric Vpu fusion proteins were significantly less efficient at down- 
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Figure 52.  Sequence alignments of parental and chimeric Vpu proteins used in this 
study.  Base pairs similar to subtype B Vpu (B.US.HXB2) are highlighted in blue.  Base 
pairs similar to subtype C Vpu (C.BW16B01) are highlighted in yellow.     
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Figure 53.  Cellular localization of chimeric Vpu fusion proteins.  293 cells plated on 
glass coverslips were transfected with vectors expressing VpuEGFP, VpuSCEGFP1, 
VpuBCEGFP or VpuCBEGFP.  At 48 hours post transfection, cells expressing EGFP were 
identified and images collected using laser scanning confocal microscopy as described in 
the Materials and methods section.   
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Figure 54.  Protein stability of parental and chimeric Vpu fusion proteins.  293 cells 
were transfected with vectors expressing VpuEGFP, VpuSCEGFP1, VpuBCEGFP or 
VpuCBEGFP.  At 48 hours post-transfection, the cells were washed and starved in 
DMEM lacking methionine and cysteine.  Cells were radiolabeled with 
35
S-Translabel 
(MP Biomedical) for 1 hour and chased in DMEM containing 100X unlabeled 
methionine/cysteine for 6 hours.  Samples were collected at hours 0, 3, and 6 post-label.  
Cells were lysed in 1X RIPA and immunoprecipitated using a rabbit anti-EGFP serum 
and protein A-Sepharose beads.  All immune precipitates were washed, resuspended in 
reducing buffer and boiled. Proteins were separated on a 10% SDS-PAGE gel and 
visualized by standard autoradiography techniques.  Pixel density was determined using 
ImageJ software and the percent protein remaining determined.  Panel A. 
Representative autoradiographs.  Numbers above lanes represent hours post-chase.  
Panel B.  Graphical representation of the percent protein remaining at the 6-hour post-
chase period.      
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Figure 55.  CD4 surface expression in the presence of chimeric Vpu fusion proteins.  
HeLa CD4
+
 cells were transfected with plasmids expressing VpuEGFP, VpuSCEGFP1, 
VpuBCEGFP or VpuCBEGFP.  At 48 hours post-transfection the cells were removed 
from the plate and stained with PE-Cy5 conjugated to anti-CD4.  Cells were analyzed 
using a LSR II flow cytometer, determining mean fluorescence intensity (MFI) of PE-
Cy5 for transfected (EGFP positive) and untransfected (EGFP negative) cells within the 
same well.  An MFI ratio was calculated for each; EGFP was normalized to 1.  At least 
five separate experiments were performed, the normalized ratios averaged and the 
standard deviation calculated.  Groups were compared using the unpaired Student’s t-
test, with p ≤ 0.05 considered significant (*).      
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modulating CD4 surface expression compared to VpuEGFP and were similar to VpuSCEGFP1.  
These results suggest that both the N-terminal transmembrane domain and the cytoplasmic 
domain have the ability to influence Vpu mediated CD4 surface down-modulation. 
 
Exchange of subtype B and subtype C Vpu domains does not alter biosynthesis or rate of 
turnover of other SHIV proteins 
 In order to examine the processing of other viral proteins, including the Gag and Env 
proteins.  C8166 cells were inoculated with SHIVVpuBC or SHIVVpuCB and 5 days post-inoculation 
viral proteins were immunoprecipitated as described in the Materials and methods section.  The 
results in Figure 56 show that the Gag and Env proteins expressed in the chimeric Vpu SHIV 
viruses are synthesized and processed similar to the parental viruses.   
 
SHIV expressing chimeric Vpu replicate with intermediate kinetics compared to the 
parental SHIVs 
 We constructed SHIV expressing either the VpuBC (SHIVVpuBC) or the VpuCB 
(SHIVVpuCB) protein and examined the replication kinetics of these viruses in C8166 cells.  Cells 
were inoculated with 10
3
 TCID50 of SHIVKU-1bMC33, SHIVSCVpu, SHIVVpuBC, or SHIVVpuCB and 
the cultures analyzed using p27 growth curves as described in the Materials and methods section.  
Growth curve analysis was repeated in triplicate and the average p27 concentrations for each 
time point determined.  The average results of these assays are shown in Figure 57 and indicate 
that the two chimeric Vpu expressing SHIVs replicated with intermediate kinetics compared to 
SHIVKU-1bMC33 and SHIVVpuSC.  Of the two chimeric Vpu SHIVs, SHIVVpuBC replicated more  
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Figure 56.  C8166 cells were infected with 10
4
 TCID50 of SHIVVpuBC or SHIVVpuCB stock 
cultures and incubated at 37C.  After 4 hours cells were washed and resuspended in 
fresh culture media.  5 days post-infection cells were incubated in DMEM lacking 
methionine and cysteine for 2 hours.  Cells were radiolabeled with 500 µCi of 
35
S 
Translabel (MP Biomedical) for an hour.  Cells were lysed in 1X RIPA buffer and the 
nuclei removed through centrifugation.  SHIV proteins were immunoprecipitated from 
both the cell lysates using pooled serum from macaques inoculated with a non-
pathogenic SHIV and protein A-Sepharose beads.  Immune precipitates were washed 
and separated on a 10% SDS-PAGE gel and visualized using standard autoradiography 
techniques.   
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Figure 57.  C8166 cells were infected with 10
3
 TCID50 of SHIV expressing the parental 
(B or C) or chimeric (BC or CB) Vpu proteins.  4 hours post-infection the cells were 
washed, resuspended in fresh culture media and incubated at 37C.  Samples were 
collected at days 0, 1, 3, 5, 7 and 9 post-inoculation.  The amount of p27 protein present 
within the supernatant samples was quantified using a commercially available p27 
antigen capture ELISA (Zeptometrix). 
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efficiently than SHIVVpuCB, which replicated similar to SHIVSCVpu until around day 7 at which 
time the accumulation of p27 in the culture media increased through day 11. 
 
SHIVVpuCB inoculated cells exhibited an increased number of particles on the cell surface 
 We also compared the pattern of virus maturation in C8166 cells inoculated with 
SHIVKU-1bMC33, SHIVVpuSC, SHIVVpuBC or SHIVVpuCB using electron microscopy.  The results 
shown in Figure 58A-B indicate that both parental viruses (SHIVKU-1bMC33 (Panel A); SHIVSCVpu 
(Panel B)) mature at the plasma membrane as we have previously reported (Hill et al., 2008).  
SHIVs expressing either VpuBC (Panel C) or VpuCB (Panels D and E) were also found to 
mature at the plasma membrane (Figure 58C-E), however, SHIVVpuCB exhibited an increased 
number of particles associated per infected cell compared to the other three.  We determined the 
mean number of particles per cell of 50 cells at five days post-inoculation.  As shown in Figure 
59, the mean number of particles per cell for SHIVKU-1bMC33, SHIVSCVpu, and SHIVVpuBC were 35, 
21, and 34, respectively.  In contrast, SHIVVpuCB had a mean of approximately 84 particles per 
cell.  There was a clear difference in the distribution of the number of particles per cell between 
SHIVVpuCB and the other three viruses.  For the two parental viruses and SHIVVpuBC, the number 
of particles per cell was generally less than 60, while SHIVVpuCB showed a more even 
distribution.  The results for SHIVVpuCB were similar to results we reported previously for a 
SHIV expressing a Vpu with a glycine substitution at position 39 (SHIVSCVpuL39G).  However, 
SHIVSCVpuL39G was found to replicate better than SHIVVpuCB. 
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Figure 58.  Electron microscopic examination of C8166 cells inoculated with SHIVKU-
1bMC33, SHIVSCVpu, SHIVVpuBC, or SHIVVpuCB.  C8166 cells were inoculated with each 
virus for 5 days.  Cells were washed three times with PBS and processed for electron 
microscopy as described in the Materials and methods section.  Panel A.  C8166 cells 
inoculated with parental SHIVKU-1bMC33.  Panel B.  C8166 cells inoculated with parental 
SHIVSCVpu.  Panel C.  C8166 cells inoculated with SHIVVpuBC.  Panels D and E.  C8166 
cells inoculated with SHIVVpuCB.   
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Figure 59.  Enumeration of the number of viral particles associated with the infected 
C8166 cells following inoculation with SHIVKU-1bMC33 (Black), SHIVSCVpu (Blue), 
SHIVVpuBC (Green), or SHIVVpuCB (Purple).  Cells were inoculated with equivalent doses 
of infectious virus and at 5 days processed for electron microscopy as described in the 
Materials and methods section.  The number of viral particles associated with 50 cells 
per virus and mean values was calculated. 
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The rate of CD4
+
 T cell loss was decreased and plasma viral loads lower in macaques 
inoculated with SHIVVpuCB 
 In order to determine the contributions of the different domains to pathogenesis, two sets 
of three pig-tailed macaques (Set 1: W005, W018, W030 and Set 2: W004, W007, W013) were 
inoculated with 10
4 
TCID50 of either SHIVVpuBC or SHIVVpuCB, respectively, and their circulating  
CD4
+
 T cell levels and plasma viral loads monitored.  Macaques W030, W005, and W018 were 
euthanized in a moribund condition at weeks 10, 24 and 24 post-inoculation, respectively.  
Macaques W004, W007 and W013 are still being monitored and the results presented from this 
study are presented through week 24 post-inoculation.  The circulating CD4
+
 T cell levels are 
shown in Figure 60 in conjunction with results published previously for macaques inoculated 
with either SHIVKU-1bMC33 or SHIVSCVpu.  These results demonstrate a rapid and severe loss of 
CD4
+
 T cells in all three macaques inoculated with SHIVVpuBC, similar to results observed in 
SHIVKU-1bMC33 inoculated macaques.  Macaques inoculated with SHIVVpuCB exhibited a more 
gradual loss of CD4
+
 T cells, however, not to the extent observed in macaques inoculated with 
SHIVSCVpu.  We also found that early peak viral loads (weeks 1-3) in macaques inoculated with 
SHIVVpuCB were approximately 10-fold less than in macaques W018 and W030 (inoculated with 
SHIVVpuBC) (Figure 61). 
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Figure 60. Circulating CD4+ T cell levels in infected macaques.  Alterations in the levels 
of CD4
+
 T cells after experimental inoculations were monitored sequentially by FACS 
analysis (Becton Dickinson).  T cell subsets were labeled with OKT4 (CD4; Ortho 
Diagnostics Systems, Inc.), SP34 (CD3; Pharmingen) or FN18 (CD3; Biosource 
International) monoclonal antibodies.  Panel A.  The levels of circulating CD4
+
 T cells in 
three macaques (2000, CM4G and CM4K) inoculated with SHIVKU-1bMC33.  Panel B.  
The levels of circulating CD4
+
 T cells in three macaques (CX56, CX57 and PLg2) 
inoculated with SHIVSCVpu.  Panel C.  The levels of circulating CD4
+
 T cells in three 
macaques (W005, W018 and W030) inoculated with SHIVVpuBC.  Macaque W030 was 
euthanized at 10 weeks post-inoculation in a moribund condition with severe anemia (†).  
Macaques W005 and W018 were euthanized at 24 weeks post-inoculation (†).  Macaque 
W018 was diagnosed with a Candadiasis infection.  Macaque W005 did not exhibit an 
AIDS-defining illnesses aside from CD4
+
 T cell levels below 200 per µl.  Panel D.  The 
levels of circulating CD4
+
 T cells in three macaques (W004, W007 and W013) inoculated 
with SHIVVpuCB.  All three macaques inoculated with SHIVVpuCB are still being 
monitored. 
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Figure 61.  Plasma viral loads in infected macaques. Virus was pelleted from 1 mL of 
EDTA-treated plasma through ultracentrifugation (Beckman SW55Ti, 38,000rpm, 1 
hour) and viral RNA extracted using a QIAamp viral RNA kit (Qiagen).  RNA samples 
were analyzed by real-time RT-PCR using gag primers and a 5’FAM/3’TAMRA labeled 
Sigma probe that was homologous to the SIV gag gene.  Standard curves were prepared 
using a series of twelve ten-fold dilutions of T7 transcribed SIV gag mRNA of known 
concentration.  The sensitivity of this assay was 100 RNA equivalents per mL.  Samples 
were analyzed in duplicate and the number of RNA equivalents were calculated per mL 
of plasma.  Panel A.  Viral loads in three macaques (2000, CM4G and CM4K)  
inoculated with SHIVKU-1bMC33.  Panel B.  Viral loads in three macaques (CX56, CX57 
and PLg2) inoculated with SHIVSCVpu.  Panel C.  Viral loads in three macaques (W005, 
W018 and W030) inoculated with SHIVVpuBC. Macaque W030 was euthanized at 10 
weeks post-inoculation in a moribund condition with severe anemia (†). Macaques W005 
and W018 were euthanized at 24 weeks post-inoculation (†).  Macaque W018 was 
diagnosed with a Candadiasis infection.  Macaque W005 did not exhibit an AIDS-
defining illness aside from CD4
+
 T cell levels below 200 per µl. Panel D.  Viral loads in 
three macaques (W004, W007 and W013) inoculated with SHIVVpuCB.  All three 
macaques inoculated with SHIVVpuCB are still being monitored.   
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Discussion 
The biological relevance of the two separate functions of Vpu has been difficult to assess 
since alterations within either the transmembrane or cytoplasmic domain have the ability to 
modify the other region and in turn both functions.  Previously, we and other investigators 
showed that while the two domains of Vpu can influence the other, the two functions of Vpu are 
dictated by the two separable structural domains (Hout et al., 2005; Schubert et al., 1996a).  We 
have also shown that subtype B and subtype C Vpu proteins exhibit distinct biological properties 
and contain differential sorting signals that could potentially contribute to the differences in 
pathogenesis observed in macaques inoculated with SHIV expressing either of these proteins 
(Hill et al., 2008; Pacyniak et al., 2005; Ruiz et al., 2008; Singh et al., 2003).  Therefore, in this 
study we determined the impact each domain had on pathogenesis.  These studies increase our 
understanding of the role of both structural domains of Vpu and the biological significance of 
each of its functions. 
 In order to examine the role of each domain in Vpu-mediated modification of 
pathogenesis, we constructed two chimeric Vpu proteins in which we exchanged the N-
terminal/transmembrane domain regions of a subtype B and a subtype C Vpu protein (VpuBC 
and VpuCB).  Using flow cytometric analysis to determine the efficiency of each of these 
proteins to down-modulate CD4 surface expression, we found that both chimeric Vpu proteins 
were statistically less efficient at preventing cell surface expression of CD4, which is similar to 
results we previously reported for the parental subtype C Vpu protein (Hill et al., 2008).  
Previous studies examining the contributions of each domain to the ability of Vpu to degrade 
CD4 have involved mutational analysis (Hout et al., 2005; Schubert et al., 1996a).  In this study, 
we used proteins that contained unmodified transmembrane (TM) domains, and therefore these 
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results suggest that the two domains either directly influence the ability of Vpu to down-
modulate CD4 surface expression or that each subtype has evolved intricate structural features 
that allow for differential modification of this function. 
 We constructed SHIVs expressing each of these chimeric Vpu proteins and examining 
the replication kinetics.  In support of the hypothesis that both domains contribute to each 
function of Vpu, SHIV expressing either of the proteins replicated at rates intermediate of those 
observed with either the SHIVKU-1bMC33 or SHIVSCVpu parental viruses.  However, the SHIVVpuBC 
replicated more rapidly than the SHIVVpuCB, suggesting that the transmembrane domain is the 
major influence on viral propagation as was previously hypothesized.  Inoculation of pig-tailed 
macaques yielded results parallel to those observed with growth curve analysis.  Macaques 
inoculated with SHIVVpuBC displayed rapid CD4
+
 T cell loss, while macaques inoculated with 
SHIVVpuCB showed a more gradual rate of loss.  The rate of CD4
+
 T cell loss in the macaques 
inoculated with SHIVVpuCB was not as decreased as that observed in macaques inoculated with 
SHIVSCVpu.  These results provide additional support for the contribution of each domain to both 
functions of Vpu, however, the transmembrane domain appears to have a major influence on the 
rate of CD4
+
 T cell loss in infected macaques.   
Another possible factor in the rate of CD4
+
 T cell loss is the differential efficiencies of 
subtype B and subtype C Vpu proteins to down-modulate CD4 surface expression.  Even though 
both chimeric Vpu proteins were significantly less efficient at down-regulating CD4 surface 
expression, macaques inoculated with SHIV expressing either of these proteins, displayed 
differential rates of CD4
+
 T cell loss.  These results suggest that the statistical significance 
observed in vitro for these two proteins and for all four of the subtype C Vpu/EGFP fusion 
proteins analyzed previously, may not be physiologically relevant.  This also suggests that the 
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ability of the subtype B and subtype C Vpu proteins to down-modulate CD4 from the surface is 
not a major contributing factor in the differences in pathogenesis caused by these two viruses.  
These results insinuate that the major influence in the differences in pathogenesis caused by 
these two viruses is the enhanced virion release function.  Previously, we demonstrated that 
subtype B and subtype C displayed a similar ability to overcome BST-2 mediated restriction of 
virion release in HeLa cells (See Chapter 3).  Taken together, these results suggest that the 
enhanced virion release function of Vpu in vivo and the differential rates of CD4
+
 T cell loss in 
macaques inoculated with SHIV expressing different Vpu subtypes is not associated with 
overcoming BST-2 restriction or CD4 down-modulation.  This suggests that Vpu enhances 
virion release and in turn modifies disease pathogenesis in vivo, via an unknown mechanism, 
potentially associated with the ion channel function of Vpu, intra- or interprotein oligomerization 
of Vpu, or the antagonism of another yet unknown viral restriction factor.  As these results are 
based on an intravenous route of inoculation, it is possible different affects would be observed 
with mucosal transmission and additional studies are needed to fully understand the impact of 
this variable.  
 
Materials and Methods 
Plasmids, Viruses and Cell Culture 
In order to construct plasmids expressing subtype B and subtype C chimeric vpuegfp 
fusion genes an EcoRV site was inserted into each parental vpu gene expressed in a pcDNA(+) 
expression vector at the interface between the putative transmembrane domain and the 
cytoplasmic domain using site-directed mutagenesis.  The N-terminal regions were excised from 
the parental plasmids using KpnI and EcoRV restriction enzymes.  The N-terminal region 
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fragments were ligated into the opposing digested vector.  The EcoRV sites were then removed 
using site-directed mutagenesis and the resulting plasmids (pcvpuBCegfp and pcvpuCBegfp) 
sequenced to ensure validity of the genes and that no other mutations were introduced during the 
cloning process.   
For the construction of SHIVs expressing chimeric subtype B and subtype C Vpu, site-
directed mutagenesis was performed on the pGEM3zf(+) vector containing the tat, rev, vpu and 
env from either SHIVKU-1bMC33 or SHIVSCVpu, respectively to introduce an EcoRV site at the 
interface between the putative transmembrane domain and the cytoplasmic domain.  The DNA 
fragment containing the vpu cytoplasmic and env regions was isolated by digesting each 
resulting plasmid with EcoRV and KpnI restriction enzymes.  Each fragment was gel purified 
and ligated into the opposing digested vector.  The EcoRV sites were then removed using site-
directed mutagenesis and the resulting plasmids were sequenced to ensure validity of the genes 
and that no other mutations were introduced during the cloning process.  Each plasmid was then 
digested with KpnI and SphI restriction enzymes and the resulting fragments were purified and 
directly cloned into p3’SHIVKU-1bMC33 to yield p3’SHIVVpuBC and p3’SHIVVpuCB. The resulting 
plasmids were sequenced to ensure that the tat, rev, vpu and env genes were intact.  For the 
production of p3’SHIVVpuBC and p3’SHIVVpuCB each 3’SHIV plasmid was digested in 
conjunction with p5’SHIV-4 with SphI overnight, purified, ligated and used to transfect C8166 
cells as previously described (Hout et al., 2006b; Hout et al., 2005; McCormick-Davis et al., 
2000a; McCormick-Davis et al., 2000b; Singh et al., 2003; Stephens et al., 2002).  Stocks were 
prepared, titrated in C8166 and TZM-bl cells and stored at -80C until used. The 293 cell line was 
maintained DMEM supplemented with 10% fetal bovine serum, gentamicin (5 ug per mL) and 
penicillin/streptomycin (100 U per mL and 100 μg per mL, respectively).   The TZM-bl cell line 
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was obtained through the NIH AIDS Research and Reference Reagent Program, Division of 
AIDS, NIAID, NIH: TZM-bl from Dr. John C. Kappes, Dr. Xiaoyun Wu and Tranzyme Inc.  
The HeLa CD4
+
 cell line was obtained through the AIDS Research and Reference Reagent 
Program, Division of AIDS, NIAID, NIH: HeLa CD4 Clone 1022 from Dr. Bruce Chesebro.  
TZM-bl cells were maintained in Dulbecco’s minimal essential medium supplemented with 10% 
fetal bovine serum, gentamicin (5 µg per mL), and penicillin/streptomycin (100 U per mL and 
100 µg per mL, respectively).  HeLa CD4
+
 cells were maintained in Dulbecco’s minimal 
essential medium supplemented with 10% fetal bovine serum, gentamicin (5 µg per mL), 
penicillin/streptomycin (100 U per mL and 100 µg per mL, respectively) and G-418 (1 mg per 
mL).  C8166 cells were maintained in RPMI-1640, supplemented with 10mM Hepes buffer pH 
7.3, 2mM glutamine, gentamicin (5 µg per mL) and 10% fetal bovine serum (R10FBS).  
Uninfected pig-tailed PBMC were isolated as described above and activated in RPMI-1640 
supplemented with 10% FBS, penicillin/streptomycin (100 U per mL and 100 µg per mL, 
respectively), gentamicin (5 µg per mL), Concavalin A (1 mg per mL), and human recombinant 
IL-2 (100 U per mL).  Activated PBMC cultures were maintained in RPMI-1640 supplemented 
with 10% FBS, penicillin/streptomycin (100 U per mL and 100 µg per mL, respectively), 
gentamicin (5 µg per mL), and human recombinant IL-2 (100 U per mL). 
 
Laser Scanning Confocal Microscopy Analysis 
293 cells were cultured on cover slips one day prior to being transiently transfected with 
plasmids expressing either VpuBCEGFP or VpuCBEGFP using PEI (Sigma). Following 
transfection, cultures were maintained for 36-48 hours before being washed three times in PBS, 
and fixed in 2% paraformaldehyde/PBS. Cover slips were mounted in glycerol containing 
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mounting media (Slowfade Antifade solution A).  A Nikon A1 confocal microscope was used to 
collect 100X images with a 2X digital zoom, using EZ-C1 software. The pinhole was set to large 
(100 nm) for all wavelengths. EGFP was excited using an argon 488 nm laser and viewed 
through the FITC filter (525/25 nm). 
 
Pulse-Chase Analysis of Chimeric Vpu Proteins 
293 cells were transfected with vectors expressing either the VpuBCEGFP or VpuCBEGFP 
protein. At 48 hours post-transfection, the medium was removed and cells were incubated in 
methionine/cysteine-free medium for 2 hours. The cells were then radiolabeled with 200 µCi of 
35
S-Translabel (methionine and cysteine, MP Biomedical) for 1 hour. The radiolabel was chased 
in DMEM containing 100X unlabeled methionine/cysteine medium for 0 and 6 hours. Vpu 
proteins were immunoprecipitated using a rabbit anti-EGFP serum and collected on protein A-
Sepharose beads on a rotator for 18 hours.  Non-transfected 293 cells, starved, radiolabeled and 
chased for 0 hours served as a negative control. Beads were washed three times with 1X 
radioimmunoprecipitation buffer (RIPA: (50mM TrisHCl, pH 7.5; 50mM NaCl; 0.5% 
deoxycholate; 0.2% SDS; 10mM EDTA), and the samples resuspended in sample reducing 
buffer. Samples were boiled and the VpuEGFP fusion proteins separated by SDS-PAGE (12% 
gel).  Proteins were then visualized using standard autoradiographic techniques.  All conditions 
were run in duplicate, the pixel densities of each band determined using ImageJ software, 
normalized to the hour 0 sample, and the average percent protein remaining calculated. 
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CD4 Surface Expression Analysis 
For analysis of cell surface CD4 expression in the presence of each chimeric VpuEGFP 
protein, HeLa CD4
+ 
cells (2.5 x 10
5
) were seeded into each well of a six well plate 24 hours prior 
to transfection.  Cells were transfected with plasmids expressing EGFP, VpuEGFP, VpuSCEGFP, 
VpuBCEGFP, or VpuCBEGFP. Cultures were monitored for 48 hours, cells removed from the six 
well plate using Ca
2+
/Mg
2+
-free PBS containing 1mM EDTA and stained with PE-Cy5 
conjugated anti-CD4 (BD Bioscience).   Cells were analyzed using an LSR II flow cytometer, 
determining mean fluorescence intensity (MFI) of PE-Cy5 for transfected (EGFP positive) and 
untransfected (EGFP negative) cells within the same well.  An MFI ratio was calculated for each 
sample with the EGFP control normalized to 1.0.  Normalized ratios from three separate 
experiments were averaged and the standard deviation calculated.  Significance of CD4 surface 
down-regulation by each chimeric Vpu/EGFP was determined by comparing each sample to the 
EGFP only control as well as to the subtype B VpuEGFP sample, using a Student’s t-test, with 
p<0.05 considered significant. 
 
Pulse-Chase Analysis of Viral Proteins 
To analyze the viral proteins synthesized and released from cells, C8166 cells were inoculated 
with 10
4
 TCID50 of either SHIVVpuBC or SHIVVpuCB.  At 5 days post-inoculation, the medium was 
removed and infected cells were incubated in methionine/cysteine-free Dulbecco's modified 
Eagle's medium (DMEM) for 2 hours.  The cells were then radiolabeled for 1 hour with 500 µCi 
of 
35
S-Translabel (MP Biomedicals).  Cells were lysed in 1X RIPA buffer and the nuclei 
removed through centrifugation.  SHIV proteins were immunoprecipitated from the cell lysates 
302 
 
using plasma pooled from several pig-tailed macaques infected previously with a non-pathogenic 
SHIV and protein A-Sepharose beads on a rotator for 18 hours.  Immunoprecipitates were 
washed three times in 1X RIPA buffer and the samples resuspended in sample reducing buffer.  
Samples were boiled and the SHIV specific proteins analyzed by SDS-PAGE.  Proteins were 
then visualized by standard autoradiographic techniques.   
 
Viral Replication Kinetics Analysis 
Standard p27 assays (Zeotometrix Incorporated, SIV core antigen kit) were used to assess 
release of viral particles from cells infected with SHIVKU-1bMC33, SHIVSCVpu, SHIVVpuBC or 
SHIVVpuCB.  Cultures of 10
6
 C8166 cells or pig-tailed PBMC were inoculated with 10
4
 TCID50 of 
each virus stock for 4 hours.   At the end of 4 hours, the cells were centrifuged at 400x g for 10 
minutes and the pellet washed with 10 ml of medium.  This was repeated two additional times.   
The cells were resuspended in propagation medium as described above and this was considered 
the 0 time point of the assay.  Cultures were incubated at 37C and aliquots of the culture were 
removed at 0, 1, 3, 5, 7, 9, 11 and 13 days with fresh media added to cultures at days 3, 6, 9, and 
12.   The culture medium was separated from the cells by centrifugation and assayed for p27 
according to the manufacturer’s instructions.   
 
Macaques and Virus Inoculation   
Pig-tailed macaques were obtained from the Caribbean Primate Center in Puerto Rico.  
All macaques were housed in the AAALAC-approved animal facility at the University of Kansas 
Medical Center.  Six pig-tailed macaques (Set 1: W005, W018 and W030) (Set 2: W004, W007 
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and W013) were inoculated intravenously with 10
4
 TCID50 of either SHIVVpuBC or SHIVVpuCB, 
respectively.  EDTA-treated blood was collected weekly for 6 weeks, then at 3-week intervals 
for the next 6 weeks, and thereafter at monthly intervals. 
 
Processing of Blood Samples 
PBMC were prepared by centrifugation on Ficoll-Hypaque gradients as described 
previously (Joag et al., 1996; Joag et al., 1994).  Ten-fold dilutions of PBMC (10
6
 cells per ml) 
were inoculated into replicate cultures and were examined for development of cytopathic effects 
as previously described (McCormick-Davis et al., 2000a; Stephens et al., 2002).  Alterations in 
circulating levels of CD4
+
 T-lymphocytes after experimental inoculations were monitored 
sequentially by flow cytometric analysis.  T-lymphocyte subsets were labeled with OKT4 (CD4; 
Ortho Diagnostics Systems, Inc), SP34 (CD3; Pharmingen) or FN18 (CD3; Biosource 
International) monoclonal antibodies. 
 
Plasma Virus Loads 
Plasma viral RNA loads were determined on RNA extracted from EDTA-treated plasma. 
Virus was pelleted and RNA extracted using the Qiagen viral RNA kit (Qiagen).  RNA samples 
were analyzed by real-time RT-PCR using gag specific primers and a 5'FAM and 3'TAMRA 
labeled probe (Sigma) that was homologous to the SIV gag gene.  Standard curves were prepared 
using a series of six 10-fold dilutions of viral RNA of known concentration.  The sensitivity of 
the assay was 100 RNA equivalents per milliliter. Samples were analyzed in triplicate and the 
number of RNA equivalents was calculated per ml of plasma. 
304 
 
XIII. Conclusions 
Human immunodeficiency virus type 1 (HIV-1) is one of the most devastating public 
health concerns facing the world today.  While the development of highly active anti-retroviral 
therapies (HAART) has led to a global stabilization of the HIV/AIDS epidemic, the continued 
emergence of mutated strains and recombinant viruses emphasizes the need for new anti-viral 
therapeutics and vaccine development.  In addition, the responsiveness of HIV-1 to current anti-
retroviral drugs and the selection of drug resistant mutant strains has been shown to vary among 
subtypes (Champenois et al., 2008; Desai et al., 2007; Palmer et al., 1998; Poonpiriya et al., 
2008; Snoeck et al., 2006).  The first round of anti-retroviral therapy is the most important and 
therefore the predication of the potential for drug resistance as well as the general virological and 
immunological responses of patients with similar strains is essential for administering the 
optimum treatment (Martinez-Cajas et al., 2008).  Epidemiological and genotypic studies are 
necessary for detecting/identifying mutations and trends involved in drug 
resistance/responsiveness of particular HIV-1 subtypes/strains found within different populations 
(Martinez-Cajas et al., 2008; Martinez-Cajas and Wainberg, 2008).  Furthermore, 
characterization of different HIV-1 strains and their respective viral proteins is necessary in order 
to understand and develop the most favorable therapeutic regimens.  Therefore, the main 
objective of this dissertation was to identify unique and conserved domains/motifs, crucial for 
structural and/or functional characteristics of different Vpu proteins that could potentially serve 
as novel targets for anti-retroviral therapy. 
The main function of Vpu is to augment viral replication by down-modulating CD4 
surface expression and enhancing virion release (Bour and Strebel, 2003; Fujita et al., 1997; 
Hout et al., 2004; Klimkait et al., 1990; Ruiz et al., 2010a; Schubert et al., 1998; Strebel et al., 
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1989; Terwilliger et al., 1989; Willey et al., 1992a, b).  The preservation of both functions was 
not found in Vpu proteins from any group O or group N isolates examined (Sauter et al., 2009).  
Therefore, the maintenance of both functions in group M Vpu proteins contributes to the ability 
of these viruses to establish and sustain the current global pandemic.  While the mechanism by 
which HIV-1 Vpu down-modulates CD4 surface expression has been studied extensively, the 
mechanism(s) that the Vpu uses to enhance virion release is still ill-defined.  Studies examining 
the mechanism(s) by which HIV-1 Vpu enhances virion release have identified three potential 
modes of action: 1) antagonism of BST-2; 2) modification of membrane permeability with ion-
channel-like properties; or 3) inhibition of the cellular K
+
 channel, TASK-1, resulting in 
depolarization of the plasma membrane (Bour and Strebel, 2003; Coady et al., 1998; Ewart et al., 
1996; Hsu et al., 2010; Hsu et al., 2004; Neil et al., 2008; Schubert et al., 1996b; Strebel, 2004; 
Van Damme et al., 2008).  While all three mechanisms have been demonstrated in vitro, the 
physiological relevance of each remains controversial.  The majority of the studies analyzing 
these potential mechanisms have been conducted in cell lines not normally targeted by HIV-1 
Vpu.  While TASK-1 has been shown to be constitutively expressed in CD3
+
 T lymphocytes, the 
levels of expression in CD4
+
 T cells as well as macrophages remains unknown (Meuth et al., 
2008).  Additionally, BST-2 has only been shown to have high expression levels in macrophages 
(Miyagi et al., 2009; Schindler et al., 2010).  Taken together, these results suggest that HIV-1 
Vpu may use different mechanisms to enhance virion release in different cell types.  The results 
presented herein, address the physiological relevance of HIV-1 Vpu-mediated BST-2 antagonism 
using both in vitro and in vivo models. 
Our laboratory has used the SHIV/macaque model of disease extensively in order to 
provide insight into the physiological relevance of in vitro analyses of the HIV-1 Vpu protein.  In 
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light of the discovery of BST-2 as a restriction factor targeted by the HIV-1 Vpu and SIV Nef 
proteins, we sought to determine the potential of SHIV viruses as a model for studying these 
interactions and identify domains/amino acids essential to hBST-2 susceptibility to HIV-1 Vpu.  
Our results demonstrate similar susceptibilities of the hBST-2 and the ptBST-2 proteins to SHIV 
Vpu and Nef, respectively, similar to what has been reported for HIV-1 and SIV.  This 
emphasizes the suitability and value of SHIV viruses as models for studying the effects of HIV-1 
Vpu in pathogenesis.  These results also allow us to broaden our interpretation of previous in 
vivo analyses since rhesus and pig-tailed macaques do not express a BST-2 that is susceptible to 
HIV-1 Vpu.  Instead, macaque BST-2 antagonism is likely overcome by Nef.  These results do 
not, however, rule out a role for this interaction in a human HIV-1 infection and the analysis of 
the interaction between HIV-1 Vpu and hBST-2 is still warranted and provides a useful tool for 
identifying regions of the Vpu protein that represent potential targets for anti-retroviral therapy.   
Mutagenesis-based analysis of the human and ptBST-2 proteins identified the 
transmembrane domain (TMD) and a small motif (
13
DDIWK
17) in the N’terminal region as 
determinants of HIV-1 Vpu and SIV Nef susceptibility, respectively.  Results of this study also 
suggested that the length and/or topology of the BST-2 TMD are more important than the amino 
acid identity in determining sensitivity and anti-viral activity similar to results observed by other 
investigators (Perez-Caballero et al., 2009).  Together, these results provide a basis for the 
development of new Vpu targeted small molecule inhibitors designed to mimic the structural 
elements of the BST-2 protein. 
  To date, only a few studies have been conducted on the genomic contributions of 
different Vpu proteins on structure and function and even fewer have examined the impact 
different Vpu subtypes have on pathogenesis (Abraha et al., 2009; Arien et al., 2005; Ball et al., 
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2003; Hill et al., 2008; Joag et al., 1996; McCormick-Davis et al., 1998; Sauter et al., 2009).  We 
initiated our analyses by examining several biological properties associated with seven different 
HIV-1 Group M Vpu proteins.  Using an EGFP fusion reporter system we determined that 
subtypes A, A2 and C Vpu proteins were more efficiently transported to the cell surface than 
other Vpu proteins.  We did not establish a correlation of this transport with either the ability of 
each protein to down-modulate CD4 from the surface or their ability to overcome hBST-2-
mediated restriction of particle release in HeLa cells.  However, it remains to be determined 
whether the distinct localization of these proteins is physiologically relevant.  It is possible that 
the sorting signals within these proteins are distinct from those of the other Vpu proteins.  If 
these proteins lack a specific signal that retains the other Vpu proteins in the ER/Golgi 
compartments, the presence at the plasma membrane may be a default mechanism.  It is also 
possible that these proteins contain localization signals or interact with distinct cellular proteins 
that target them to the cell surface as a decoy or default mechanism.   
 Based on our identification of distinct biological properties among different Vpu proteins 
that may impact viral pathogenesis and in turn contribute to the disproportionate global 
distribution of HIV-1 subtypes, we continued our analysis by focusing on our subtype B and 
subtype C Vpu proteins.  These isolates displayed distinct localization patterns, slight variations 
in CD4 down-modulation efficiencies, which was maintained among four separate subtype C 
Vpu proteins examined, and similar abilities to overcome BST-2 restriction in HeLa cells.  The 
drawback to the majority of studies conducted to date on the role of different subtypes in HIV 
pathogenesis and their abilities to overcome cell-type specific restriction factors, is that these 
studies are generally conducted in cell lines that are not normally infected by HIV-1 and 
therefore may yield cell-type specific results.  Therefore, it is extremely important to verify these 
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results using either physiologically relevant cell types, ex vivo tissues, and/or appropriate animal 
models.  Hence, we continued our analyses of the subtype B and subtype C Vpu proteins by 
observing the affects of these proteins on SHIV replication and pathogenesis in a macaque 
model.  A SHIV expressing the subtype C Vpu protein (SHIVSCVpu) replicated with delayed 
kinetics compared to a SHIV expressing the subtype B Vpu (SHIVKU-1bMC33) and was not due to 
differential viral protein turnover or packaging within virions.  Similar results have been reported 
for studies analyzing the replication fitness of subtype B and subtype C HIV-1 isolates in human 
PBMC.  Subtype C HIV-1 isolates were found to be less replicatively fit than all other subtypes 
in PBMC, but equally efficient in Langerhans cells and ex vivo tissues (Abraha et al., 2009; 
Arien et al., 2005; Ball et al., 2003).  Inoculation of SHIVSCVpu into pig-tailed macaques resulted 
in a more gradual rate of CD4
+
 T cell lymphocytes and lower peak viral loads than observed in 
macaques inoculated with SHIVKU-1bMC33.  These results validate our hypothesis that the 
biological differences observed and/or specific differences yet undetermined between these Vpu 
proteins contribute to the modification of pathogenesis.  As these studies utilized an intravenous 
route of inoculation, it remains unknown whether similar results would be observed with 
alternate inoculation routes where transmission is more dependent on the infection and 
replication of the virus within macrophages.  Additional studies are needed to determine whether 
or not different subtypes have evolved distinct mechanisms designed to promote infection via 
specific transmission routes and whether Vpu is a determinant of this.  Several epidemiological 
studies have provided evidence in favor of this phenomenon, however, similar to other 
epidemiological studies, the minimal number of subjects analyzed invokes uncertainty in the 
validity of the trends observed (Avila et al., 2002; Buonaguro et al., 2007a; Buonaguro et al., 
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2007b; Buonaguro et al., 2004; Buonaguro et al., 2007c; Gao et al., 1996; van Harmelen et al., 
1997).   
 The spread of progeny virions is clearly augmented by the HIV-1 Vpu protein and 
therefore this protein is undoubtedly a candidate for anti-retroviral therapy.  Optimum design of 
anti-retroviral drugs requires a comprehensive understanding of the structural and functional 
features of the target protein and the specific elements that govern them.  Consequently, we 
focused our studies on identifying specific genomic constituents of the subtype B and subtype C 
Vpu proteins that influence their structural and functional properties.  Our initial examination 
concentrated on the transmembrane domain and the impact of combinatorial substitutions on 
membrane association and Vpu function.  Since the Vpu protein is membrane bound and 
interacts with known lipid raft proteins (i.e. CD4 and BST-2), we hypothesized that Vpu also 
associated with lipid rafts.  Using detergent resistant membrane (DRM) fractionation techniques, 
we determined that Vpu partially partitions into membrane rafts in a cholesterol dependent 
manner.  We also observed co-localization of VpuSCEGFP1 with a known GPI-anchor protein in 
membrane rafts using co-patched live cell imaging, thus providing additional visual confirmation 
of Vpu association with lipid rafts.  However, as these assays do not discriminate among 
different lipid compositions or distinct organelle membranes, the location where Vpu interacts 
with these membrane microdomains and the type of raft(s) Vpu favors remains unknown.  
Recent computer modeling studies suggest that Vpu does not exhibit a preference for lipid 
thickness or composition implying that Vpu may be able to adapt to different lipid environments 
and therefore may reside within multiple types of rafts (Kruger and Fischer, 2008).   
The association of Vpu with lipid rafts has potential involvement in almost every aspect 
of Vpu function as the majority of proteins Vpu has been shown to associate with lipid rafts.  In 
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order to establish a basis for this association, we examined the role of the transmembrane domain 
and the affects of combinatorial substitutions within this region on Vpu partitioning into DRM 
fractions.  The Vpu/EGFP fusion protein with a scrambled TMD (VpuTMEGFP) did not partition 
into the DRM fractions, suggesting a role for the transmembrane domain or perhaps the 
membrane proximal region of the protein (as the potential for structural alterations is greatest 
within this region) in lipid raft association.  Alanine scanning mutagenesis of the transmembrane 
domain revealed two mutants, IVV19-21AAA and W22A (or W23A), capable of abolishing Vpu 
association with lipid rafts.  Based on recent findings that the region between I17 and S23 in the 
Vpu proteins encompasses the kink region of the TMD that adjusts to the membrane 
composition, these mutants most likely alter the ability of the protein to adapt to the changing 
lipid environment and thus exclude it from these microdomains (Kruger and Fischer, 2008).  
This hypothesis was supported by the finding that the Vpu fusion mutant, W23L, retained the 
ability to partition into DRM fractions and exhibited intracellular localization and CD4 down-
modulation similar to the unmodified Vpu.   
Our analysis of the TMD alanine substitution Vpu mutants also allowed us to show a 
correlation between membrane raft association and Vpu function.  Flow cytometric analysis of 
CD4 surface expression in the presence and absence of each of these mutants revealed no direct 
correlation with the ability of Vpu to partition into lipid rafts and the ability to down-modulate 
CD4 from the cell surface.  Both mutants deficient in lipid raft association retained the ability to 
down-modulate CD4 from the cell surface, even though W22A was slightly less efficient than 
the unmodified Vpu protein (similar to VphuC).  Results from p27 and infectious unit release 
assays did suggest a direct correlation between the ability of Vpu to partition to DRM fractions 
and the enhancement of SHIV virion release.  Both the IVV19-21AAA and W22A mutants were 
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significantly reduced in the ability to enhance virion release compared to both the SHIVKU-2MC4 
empty vector control and the cells co-transfected with SHIV Vpu and the unmodified Vphu 
protein.  The Vpu TMD mutant, LVV11-13AAA, was also reduced in its capacity to enhance 
virion release.  As this mutant retained the ability to partition into DRM fractions as well as 
down-modulate CD4 from the cell surface, it may represent a region of the TMD that has the 
ability to alter the orientation/flexibility of the membrane such that it is reduced in its ability to 
interact with proteins necessary for the enhancement of virion release (such as BST-2 or perhaps 
oligomerization with other Vpu proteins).   
While these studies have identified the transmembrane domain and several specific areas 
within this domain as possible targets for anti-retroviral therapy, they do not address the specific 
mechanisms involved in Vpu-mediated enhanced virion release.  In order to fully understand the 
significance of these results, additional studies are needed to determine: 1) the cellular location 
in which Vpu associates with lipid rafts; 2) whether the correlation of lipid raft association and 
enhanced virion release function remains valid in physiologically relevant cells (i.e. 
macrophages and CD4
+
 T cells; and 3) what protein-protein interactions, if any, are involved.  
Even though the association of Vpu with lipid rafts in the ER is possible, incorporation is more 
likely in the Golgi complex and/or the plasma membrane.  It has been reported previously that 
artificial retention of the Vpu protein in the ER completely eliminates its function in the 
enhancement of virion release and that this function is only partially dependent on 
phosphorylation of the two CK-II sites in the cytoplasmic domain (Schubert and Strebel, 1994).  
Also, previous studies have provided evidence in favor of BST-2 lipid raft association occurring 
in the Golgi complex (Kupzig et al., 2003).  More recently, data has been presented that suggests 
the presence of Vpu in the trans Golgi is important for Vpu antagonism of BST-2 (Dube et al., 
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2009).  In conjunction with our results indicating that CD4 down-modulation is not dependent on 
lipid raft association, the most likely intracellular compartment for Vpu association with lipid 
rafts would be the Golgi complex.  However, as previously mentioned, Vpu has also been shown 
to interact with a background K
+
 channel, TASK-1.  TASK-1 has been shown to localize to the 
plasma membrane and this is where its interaction with Vpu is thought to occur, although the 
relevance of this interaction in macrophages and/or CD4
+
 T cells remains to be determined (Hsu 
et al., 2010; Hsu et al., 2004; Strebel, 2004).  In addition, if this is the major mechanism by 
which HIV-1 Vpu enhances virion release, Vpu subtypes that predominately localize to the 
plasma membrane would be expected to have increased enhanced virion release, which our 
results indicate is not the case.  Since HIV-1 Vpu function requires a certain level of promiscuity, 
the interactions with BST-2 and TASK-1 may represent unintentional, cell-type specific 
interactions that may or may not be physiologically relevant.  However, our identification of Vpu 
as a lipid raft associated protein, distinguishes the transmembrane domain as a target for anti-
retroviral therapy that could be utilized against all subtypes, as well as provides an additional 
means to uncovering the exact mechanisms by which Vpu promotes the spread of HIV-1 
progeny virions.  Based on the data available several potential mechanisms and sites for 
interaction of Vpu with cellular restriction factors are illustrated in Figure 62. 
The majority of HIV-1 studies have focused on the subtype B HIV-1 because it is the 
most prevalent genotype in the United States and Western Europe (Hemelaar et al., 2006; 
Oliveira et al., 2000).  However, the subtype C HIV-1 genotype currently accounts for 
approximately 50% of infections worldwide (Bjorndal et al., 1999; Essex, 1999).  It is unclear 
why this particular subtype of viruses has spread so rapidly among the human population.  It has 
been hypothesized that subtype C HIV-1 may be evolving to a less pathogenic form based on  
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Figure 62.  Possible mechanisms by which Vpu enhances virion release from cells.  (1)  
Vpu allows efficient transport of Env proteins to the site of virion assembly.  Vpu is 
synthesized on the rough endoplasmic reticulum and binds CD4 releasing gp160 for 
processing and cleavage into gp120/gp41 which may be transported to the site of 
assembly.  Vpu may function as a viroporin.  (2) Vpu resides within the rough 
endoplasmic reticulum, trans-Golgi network and at the cell surface.  It is unknown 
whether the ability of Vpu to serve as an ion channel functions to enhance virion release 
at any of these intracellular locations.  Vpu may oligomerize with TASK-1 at the cell 
surface forming non-functional ion channels which could result in the depolarization of 
the membrane and enhanced membrane scission and separation of budding virions from 
the plasma membrane.  (3) Vpu removes BST-2 from the site of virion assembly.  In the 
absence of Vpu, BST-2 is expressed at the cell surface.  Both proteins are known to 
associate with lipid rafts.  It is possible that Vpu is targeted to lipid rafts that BST-2 
normally resides within and causes an alteration in its targeting, potentially via an endo-
lysosomal, lysosomal or proteasomal degradation pathway.  Vpu may also interact with 
BST-2 and target it to different lipid rafts in order to alter the intracellular localization 
and/or turnover of BST-2 such that it cannot restrict virion release at the cell surface.   
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data indicating that subtype C viruses are less fit in PBMC competition assays than all other 
group M isolates (Abraha et al., 2009; Arien et al., 2005; Ball et al., 2003).  Analysis of 338 
HIV-1 Vpu sequences from different subtypes revealed several unique as well as conserved 
features within the cytoplasmic domain that may contribute to the effects these Vpu have on viral 
pathogenesis.  The first feature we observed was a Yxx  sequence proximal to the membrane 
present in 98% of the sequences we analyzed.  Among the subtype C Vpu proteins we analyzed, 
more than 80% contained a membrane proximal dileucine motif ([D/E]xxxL[L/I]) overlapping 
the tyrosine motif (EYRKLL).  While the dileucine motif was present in several other isolates, it 
was not as highly conserved in the other subtypes of HIV-1.  Both of these motifs include an 
upstream acidic residue, a property implicated in internalization and endosomal/lysosomal 
targeting (Bonifacino and Traub, 2003).  Based on our analysis we hypothesized that the tyrosine 
motif and/or dileucine motif within subtype C Vpu dictated the differential trafficking of the 
protein and in turn resulted in a reduction in the proteins ability to enhance virion release in 
CD4
+
 T cells.  Mutational analysis of the tyrosine residue at position 35 and the leucine residue 
at 39 demonstrated that neither residue/motif affected CD4 surface down-regulation.  A 
significant reduction in the efficiency of VpuSC to down-regulate CD4 was only observed with 
mutation of both the tyrosine and leucine residues.  This reduction was most likely due to slight 
structural alterations to either the TMD or the first cytoplasmic α-helix.  Substitution of the 
tyrosine residue at position 35 with an alanine increased the expression of the VpuSC at the 
cellular surface, while substitution of the leucine residue at position 39 with a glycine 
significantly reduced the trafficking of the VpuSC to the plasma membrane.  In contrast, 
substitution of the tyrosine residue at position 30 in the subtype B Vpu protein did not alter 
protein localization (data not shown).  Previously our laboratory reported that the signal for 
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retention of the subtype B Vpu protein in the ER/Golgi complex compartments was localized to 
the C-terminal region of the protein as deletion of the last 23 residues within a subtype B Vpu 
protein (Vpu 23EGFP) resulted in a protein that was efficiently transported to the surface 
(Pacyniak et al., 2005).  Originally, we hypothesized that the signal for this retention was a 
dileucine motif that contained the invariant leucine residue at position 63.  However, laser 
scanning confocal microscopic analysis of a Vpu protein that contained an alanine at position 63 
displayed similar intracellular localization as an unmodified VpuEGFP fusion protein (Hill et al., 
2010).  While the specific signals within each of these proteins and the mechanisms by which 
they dictate intracellular localization remains unknown, these results suggest that both proteins 
evolved to display specific localization patterns.  The potential importance of this observation is 
supported by the idea that subtype A HIV-1 represents the second major group of HIV-1 
infections worldwide and the subtype A Vpu protein we analyzed was also efficiently trafficked 
to the plasma membrane.  Additionally, a SHIV expressing a mutant VpuSC protein that was 
retained within intracellular compartments (VpuSCL39G) replicated with increased kinetics 
compared to the parental SHIVSCVpu.  While the evidence for this hypothesis is speculative at this 
point, the necessity for further analysis of other Vpu isolates that are efficiently trafficked to the 
cellular plasma membrane and the trends observed with viruses that express them is evident. 
We continued our analysis of the role of the overlapping tyrosine and dileucine motifs 
present within the VpuSC cytoplasmic domain by constructing SHIV that expressed each of the 
mutant Vpu proteins.  Our findings demonstrated a clear role for the tyrosine residue in the 
enhanced virion release function of VpuSC, while the leucine residue appeared to have an 
inhibitory role in this function.  We also analyzed the replication kinetics of a SHIV expressing 
the VpuY30A protein and found that this virus also replicated with greatly reduced kinetics 
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compared to the SHIVKU-1bMC33 parental virus (data not shown).  Based on the proximity of the 
tyrosine motif to the membrane and the existence of the acidic residue at the Y+1 position, we 
hypothesize that this motif is involved in lysosomal targeting.  Since the tyrosine motif is highly 
conserved among all HIV-1 Vpu subtypes and because the substitution of this residue did not 
alter the rate of Vpu protein turnover, it is possible this motif is involved in the targeting of 
cellular restriction factors for degradation via the lysosome.  While it is possible this targeted 
destruction applies to the BST-2 protein, the observation that in HeLa cells the subtype B and 
subtype C Vpu were equally efficient at rescuing virion release, suggests that this is not the 
mechanism utilized by these two proteins in CD4
+
 T cells (C8166 cells) or that it is not the sole 
means by which Vpu can enhance virion release.  The mechanisms by which Vpu antagonizes 
BST-2 is still controversial and differential results among separate studies suggests that the 
mechanism may be cell-type specific (Douglas et al., 2009; Goffinet et al., 2009; Gupta et al., 
2009b; Iwabu et al., 2009; Mitchell et al., 2009).  If the tyrosine motif is involved in this 
interaction, analysis of the ability of the tyrosine mutants to bind and inhibit BST-2 mediated 
virion restriction may aid in the elucidation of the mechanism(s) used in cells normally targeted 
by HIV-1.   
In contrast to SHIV expressing Vpu with disrupted tyrosine motifs, p27 growth curve 
analysis demonstrated a significant increase in the replication kinetics of SHIVSCVpuL39G as well 
as the number of particles associated with the cell surface compared to the parental SHIVSCVpu 
virus.  At this juncture, our hypothesis is that the dileucine motif may interfere with other signals 
present within the cytoplasmic domain such as the tyrosine motif.  It is possible that the tyrosine 
motif is involved in the inhibition of a cellular restriction factor, be it BST-2 or a yet unknown 
protein, and the dileucine motif may interfere with the necessary protein-protein interactions.  By 
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removing the dileucine motif and possibly the competing interactions, the tyrosine motif is able 
to function similar to that of the subtype B Vpu protein.  The explication of any protein-protein 
interactions mediated by these motifs is necessary to fully understand their role in dictating Vpu 
function and providing the necessary information for developing optimal therapeutics.   
While the results are not presented within this thesis, three pig-tailed macaques were 
inoculated with SHIVSCVpuL39G and all three selected for a Vpu protein truncated at position 28 
less than 2 weeks post-inoculation.  The virus replicated within these macaques however, the 
viral loads were relatively low and they did not exhibit a loss in circulating CD4
+
 T cell levels.  
These macaques were euthanized in a healthy condition approximately 28 weeks post-
inoculation.  While we were unable to determine the specific role of the dileucine motif in SHIV 
pathogenesis, the immediate and perpetual selection of a Vpu protein truncated prior to the 
cytoplasmic domain suggests that the dileucine motif may play a significant role in VpuSC 
function in vivo and the removal of this motif is pessimal, if not detrimental to the function of the 
protein and replication of the virus.  It is possible that all functional Vpu proteins utilize a 
dileucine motif-based trafficking signal within the cytoplasmic domain to counteract BST-2 
and/or other unknown cellular restriction factors.  Recent data has suggested a role for the 
ExxxLV-based motif in the second α-helix of the subtype B Vpu in antagonizing BST-2 
providing support for the forementioned hypothesis (Kueck et al., 2010).  The positioning of this 
dileucine motif within the cytoplasmic domain and its proximity to the transmembrane domain 
may be an evolutionary adaptation of different subtypes to either promote or subdue Vpu 
function in specific cell types.    
Although our studies have identified specific regions within the transmembrane and 
cytoplasmic domains of the subtype B and subtype C Vpu proteins, the level of impact that these 
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regions would have on Vpu enhancement of disease progression remained unknown.  Therefore, 
we analyzed the specific contributions of the transmembrane domain versus the cytoplasmic 
domain of both the subtype B and subtype C Vpu proteins by creating chimeric Vpu proteins.  
These chimeric proteins verified the role of the cytoplasmic domain in determining protein 
localization and molecular weight.  Both proteins down-modulated CD4 surface expression 
similar to the VpuSCEGFP1 fusion protein suggesting that both domains either directly influence 
the ability of Vpu to down-modulate CD4 or the membrane interface region of each protein is 
designed to allow for differential modification of this function.  However, while the ability of 
HIV-1 Vpu to down-modulate CD4 from the cell surface appears to be crucial to enhanced 
pathogenesis, the slight variability in efficiencies among the Vpu proteins analyzed in this study 
and thus different Group M proteins, does not appear to be a major determinant of the rate of 
CD4
+
 T cell loss in infected macaques.  Instead, the transmembrane domain was identified as the 
major influence on differential modification of CD4
+
 T cell loss in macaques inoculated with 
SHIV expressing either a subtype B or subtype C Vpu protein.  Macaques inoculated with either 
the SHIVSCVpu parental virus or the SHIVVpuCB virus containing the subtype C Vpu TMD 
displayed a more gradual loss in circulating CD4
+
 T cells than macaques inoculated with either 
the SHIVKU-1bMC33 parental virus or SHIVVpuBC.  Considering the impact individual mutations 
can have on the structural and functional properties of any given Vpu protein, it is tempting to 
suggest that different subtypes have evolved an intricate balance between the signals contained 
within their transmembrane and cytoplasmic domains such that Vpu function in viral 
pathogenesis is optimized for the intended targets.      
Even though these studies focused on the subtype B and subtype C Vpu proteins, our 
analyses demonstrate a clear potential for differential signaling and functional efficiency among 
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all HIV-1 Vpu subtypes with the ability to modify pathogenesis.  Additionally, our analyses 
provided evidence for Vpu association with lipid rafts and its correlation with enhancement of 
virion release, identifying a potentially significant biological property associated with Vpu 
augmentation of HIV-1 pathogenesis.  We have also provided evidence suggesting a minimal 
role for BST-2 antagonism in Vpu enhancement of pathogenesis associated via the intravenous 
route of inoculation, suggesting that additional undefined mechanisms may be involved in Vpu 
mediated enhanced virion release.  Finally, we have identified the transmembrane domain and 
membrane proximal regions as crucial components to Vpu-mediated modification of 
pathogenesis and establish these areas as focal points for anti-retroviral therapeutic development.  
Further analysis of individual Vpu proteins is necessary to identify other signaling motifs and/or 
areas critical in governing the structural and functional properties of different Vpu subtypes and 
distinct isolates.  Identification of these targeted domains and the mechanisms associated with 
their regulation of Vpu function will provide the information necessary for the development of 
novel effective anti-virals against the Vpu protein essential for combating the current HIV/AIDS 
pandemic.  
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